{"nodes":[{"data":{"id":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","class":"process","label":"","parent":"extracellular_region","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":245.8863,"y":528.5764,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89672"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89667"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89667"]]}},{"data":{"id":"Protein_84cb6c5d91a711aa1319723c8904c751","class":"macromolecule","label":"PA63","parent":"extracellular_region","clonemarker":false,"stateVariables":[{"id":"Protein_84cb6c5d91a711aa1319723c8904c751.info.1","class":"state variable","state":{"variable":"","value":"x[197 - 764]"}}],"unitsOfInformation":[],"bbox":{"x":312.58704,"y":476.72446,"w":48,"h":25},"metadata":[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]}},{"data":{"id":"Protein_e65f555bf88d9d6eeb4334997011203b","class":"macromolecule","label":"Protective Antigen (PA)","parent":"extracellular_region","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":314.4064,"y":544.9361,"w":48,"h":25},"metadata":[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]}},{"data":{"id":"Protein_113b3c0be2b4ceabd30a4319c1400208","class":"macromolecule","label":"PA20","parent":"extracellular_region","clonemarker":false,"stateVariables":[{"id":"Protein_113b3c0be2b4ceabd30a4319c1400208.info.1","class":"state variable","state":{"variable":"","value":"x[30 - 196]"}}],"unitsOfInformation":[],"bbox":{"x":302.5327,"y":422.501,"w":48,"h":25},"metadata":[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]}},{"data":{"id":"Protein_4b54a396195a7afb2d66e2623aef4725","class":"macromolecule","label":"TNF","parent":"extracellular_region","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":547.7003,"y":590.5589,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1816"]]}},{"data":{"id":"Protein_1480a71b5fcb5ed92442219cdf2c803d","class":"macromolecule","label":"VCAM1","parent":"integral_to_membrane","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":682.12683,"y":580.3422,"w":48,"h":25},"metadata":[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19320"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19320"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Complex_d99e6918542cbd099f5826a654d9b43b","class":"complex","label":"Edema toxin (unfolded)","parent":"endosome","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":594.50037,"y":85.44890000000001,"w":52,"h":94},"metadata":[["bp:displayName","Edema toxin (unfolded)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89529"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89527"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89527"]]}},{"data":{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_d99e6918542cbd099f5826a654d9b43b","class":"macromolecule","label":"PA63","parent":"Complex_d99e6918542cbd099f5826a654d9b43b","clonemarker":false,"stateVariables":[{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_d99e6918542cbd099f5826a654d9b43b.info.1","class":"state variable","state":{"variable":"","value":"x[197 - 764]"}}],"unitsOfInformation":[],"bbox":{"x":594.50037,"y":52.9489,"w":48,"h":25},"metadata":[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]}},{"data":{"id":"Protein_ef80db43845677b1e05acc7880705290_Complex_d99e6918542cbd099f5826a654d9b43b","class":"macromolecule","label":"Edema factor (3 molecules)","parent":"Complex_d99e6918542cbd099f5826a654d9b43b","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":594.50037,"y":117.9489,"w":48,"h":25},"metadata":[["bp:displayName","Edema factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P40136",[["bp:xref",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","cya"],["bp:name","BXA0141"],["bp:name","Edema factor"],["bp:name","UniProt:P40136 cya"],["bp:name","GBAA_pXO1_0142"],["bp:name","pXO1-122"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. EF is a calmodulin-dependent adenylyl cyclase that, when associated with PA, causes edema. EF is not toxic by itself and it is required for the survival of germinated spores within macrophages at the early stages of infection. Provokes dramatic elevation of intracellular cAMP levels in the host.CATALYTIC ACTIVITY ATP = 3',5'-cyclic AMP + diphosphate.ENZYME REGULATION It has an absolute requirement for host calmodulin for its activation. Inhibited by ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate.SUBUNIT Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these is toxic by itself. PA+LF forms the lethal toxin (LeTx); PA+EF forms the edema toxin (EdTx). EF probably forms oligomers as part of the translocation machinery, formed by a heterocomplex of PA63 monomers and EF subunits, and it is functional as a monomer in the host cell.DOMAIN The N-terminal region contains the residues responsible for binding to PA63. The C-terminal region contains the calmodulin-dependent activation domain and the catalytic site. This region is composed of three globular domains: CA, CB and a helical domain connected to CA by a linker. The active site lies at the interface of CA and CB. The metal ion is coordinated by residues from CA; calmodulin probably binds in a multistep fashion first to residues in CA and then to residues present in the linker and the helical domain.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS EF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the hetero-oligomeric complex by receptor-mediated endocytosis. EF requires passage through an acidic vesicle for activity. At acidic pH, the pore is inserted into the membrane, allowing translocation of EF, which probably contributes actively to its own insertion into the membrane. EF remains associated to the vesicle membrane after translocation to the cytosol, with the catalytic domains being exposed on the cytoplasmic face."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89505"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8_Complex_d99e6918542cbd099f5826a654d9b43b","class":"macromolecule","label":"PA Cellular Receptors","parent":"Complex_d99e6918542cbd099f5826a654d9b43b","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":594.50037,"y":87.9489,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","CMG2"],["bp:entityReference_http://identifiers.org/uniprot/P58335",[["bp:entityFeature",null],["bp:standardName","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:organism","Anthrax toxin receptor 2"],["bp:displayName","ANTR2_HUMAN"],["bp:name","Capillary morphogenesis gene 2 protein"],["bp:name","ANTXR2"],["bp:name","CMG-2"],["bp:name","CMG2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32476N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07452_identity"],["bp:comment","FUNCTION: Necessary for cellular interactions with laminin and theextracellular matrix. {ECO:0000269|PubMed:11683410,ECO:0000269|PubMed:12973667}.SUBUNIT: Binds laminin, and possibly also collagen type IV. Bindsto the protective antigen (PA) of Bacillus anthracis in a divalentcation-dependent manner, with the following preference: calcium >manganese > magnesium > zinc. Binding of PA leads toheptamerization of the receptor-PA complex.SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type Imembrane protein. Note=Expressed at the cell surface.SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum membrane;Single-pass type I membrane protein. Note=Expressed predominantlywithin the endoplasmic reticulum and not at the plasma membrane.SUBCELLULAR LOCATION: Isoform 3: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=P58335-1; Sequence=Displayed;Name=2;IsoId=P58335-2; Sequence=VSP_008343;Name=3;IsoId=P58335-3; Sequence=VSP_008344, VSP_008345;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=4;IsoId=P58335-4; Sequence=VSP_008346;TISSUE SPECIFICITY: Expressed in prostate, thymus, ovary, testis,pancreas, colon, heart, kidney, lung, liver, peripheral bloodleukocytes, placenta, skeletal muscle, small intestine and spleen.{ECO:0000269|PubMed:14508707}.DOMAIN: Binding to PA seems to be effected through the VWA domain.DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: Anautosomal recessive syndrome characterized by abnormal growth ofhyalinized fibrous tissue usually affecting subcutaneous regionson the scalp, ears, neck, face, hands, and feet. The lesionsappear as pearly papules or fleshy nodules. Additional featuresinclude gingival hypertrophy, progressive joint contracturesresulting in severe limitation of mobility, osteopenia, andosteoporosis. Disease severity is variable. Some individualsmanifest symptoms in infancy and have additional visceral orsystemic involvement. Hyaline deposits in multiple organs,recurrent infections and intractable diarrhea often lead to earlydeath. Surviving children may suffer from severely reducedmobility due to joint contractures. Other patients have lateronset of a milder disorder affecting only the face and digits.{ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707,ECO:0000269|PubMed:15725249}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Upon binding of the protective antigen (PA) ofBacillus anthracis the complex moves to glycosphingolipid-richlipid rafts, where it is internalized via a clathrin-dependentpathway. In the endosomal membrane, at pH under 7, the complexthen rearranges and forms a pore allowing the other components ofanthrax toxin to escape to the cytoplasm.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAY40907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};Sequence=BAB70976.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=BAD93150.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_477520"],["bp:comment","ANTR2_HUMAN Reviewed; 489 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_118429"],["bp:comment","REPLACED http://identifiers.org/uniprot/P13423"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-1"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011529889"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]}},{"data":{"id":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","class":"complex","label":"Lethal toxin (unfolded)","parent":"endosome","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":541.6336,"y":227.24829,"w":52,"h":94},"metadata":[["bp:displayName","Lethal toxin (unfolded)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:cellularLocation",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89533"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89531"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89531"]]}},{"data":{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","class":"macromolecule","label":"PA63","parent":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","clonemarker":false,"stateVariables":[{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_5c5ea046aba3d8f59f4aa35ec1f57a64.info.1","class":"state variable","state":{"variable":"","value":"x[197 - 764]"}}],"unitsOfInformation":[],"bbox":{"x":541.6336,"y":194.74829,"w":48,"h":25},"metadata":[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8_Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","class":"macromolecule","label":"PA Cellular Receptors","parent":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":541.6336,"y":259.74829,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","CMG2"],["bp:entityReference_http://identifiers.org/uniprot/P58335",[["bp:entityFeature",null],["bp:standardName","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:organism","Anthrax toxin receptor 2"],["bp:displayName","ANTR2_HUMAN"],["bp:name","Capillary morphogenesis gene 2 protein"],["bp:name","ANTXR2"],["bp:name","CMG-2"],["bp:name","CMG2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32476N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07452_identity"],["bp:comment","FUNCTION: Necessary for cellular interactions with laminin and theextracellular matrix. {ECO:0000269|PubMed:11683410,ECO:0000269|PubMed:12973667}.SUBUNIT: Binds laminin, and possibly also collagen type IV. Bindsto the protective antigen (PA) of Bacillus anthracis in a divalentcation-dependent manner, with the following preference: calcium >manganese > magnesium > zinc. Binding of PA leads toheptamerization of the receptor-PA complex.SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type Imembrane protein. Note=Expressed at the cell surface.SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum membrane;Single-pass type I membrane protein. Note=Expressed predominantlywithin the endoplasmic reticulum and not at the plasma membrane.SUBCELLULAR LOCATION: Isoform 3: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=P58335-1; Sequence=Displayed;Name=2;IsoId=P58335-2; Sequence=VSP_008343;Name=3;IsoId=P58335-3; Sequence=VSP_008344, VSP_008345;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=4;IsoId=P58335-4; Sequence=VSP_008346;TISSUE SPECIFICITY: Expressed in prostate, thymus, ovary, testis,pancreas, colon, heart, kidney, lung, liver, peripheral bloodleukocytes, placenta, skeletal muscle, small intestine and spleen.{ECO:0000269|PubMed:14508707}.DOMAIN: Binding to PA seems to be effected through the VWA domain.DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: Anautosomal recessive syndrome characterized by abnormal growth ofhyalinized fibrous tissue usually affecting subcutaneous regionson the scalp, ears, neck, face, hands, and feet. The lesionsappear as pearly papules or fleshy nodules. Additional featuresinclude gingival hypertrophy, progressive joint contracturesresulting in severe limitation of mobility, osteopenia, andosteoporosis. Disease severity is variable. Some individualsmanifest symptoms in infancy and have additional visceral orsystemic involvement. Hyaline deposits in multiple organs,recurrent infections and intractable diarrhea often lead to earlydeath. Surviving children may suffer from severely reducedmobility due to joint contractures. Other patients have lateronset of a milder disorder affecting only the face and digits.{ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707,ECO:0000269|PubMed:15725249}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Upon binding of the protective antigen (PA) ofBacillus anthracis the complex moves to glycosphingolipid-richlipid rafts, where it is internalized via a clathrin-dependentpathway. In the endosomal membrane, at pH under 7, the complexthen rearranges and forms a pore allowing the other components ofanthrax toxin to escape to the cytoplasm.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAY40907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};Sequence=BAB70976.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=BAD93150.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_477520"],["bp:comment","ANTR2_HUMAN Reviewed; 489 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_118429"],["bp:comment","REPLACED http://identifiers.org/uniprot/P13423"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-1"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011529889"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]}},{"data":{"id":"Protein_0e0ebbab4043a0bc0a123f449a5f7c29_Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","class":"macromolecule","label":"Lethal factor (3 molecules)","parent":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":541.6336,"y":229.74829,"w":48,"h":25},"metadata":[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1774533490"],["bp:id","LEF_BACAN"],["bp:db","uniprot accession"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1774533490"],["bp:id","LEF_BACAN"],["bp:db","uniprot accession"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]}},{"data":{"id":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1241.7676,"y":870.96936,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89610"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89610"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89610"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89610"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89591"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89591"]]}},{"data":{"id":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1077.7606,"y":991.1424,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89645"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89643"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89643"]]}},{"data":{"id":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1178.3289,"y":1104.4945,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89490"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89490"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89490"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89490"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89490"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89485"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89485"]]}},{"data":{"id":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":885.9191,"y":691.3758,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","VCAM1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0016021"],["bp:db","gene ontology"]]],["bp:term","integral to membrane"]]],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_39334"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89778"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89776"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89776"]]}},{"data":{"id":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1097.9723,"y":867.3104,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89588"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89588"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89588"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MKK6"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89588"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89573"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89573"]]}},{"data":{"id":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1196.567,"y":1019.75165,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89684"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89684"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89684"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89684"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation","MOD_RES 1 1 N-acetylmethionine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89684"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89683"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89683"]]}},{"data":{"id":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":791.58887,"y":527.8254,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Edema factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P40136",[["bp:xref",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","cya"],["bp:name","BXA0141"],["bp:name","Edema factor"],["bp:name","UniProt:P40136 cya"],["bp:name","GBAA_pXO1_0142"],["bp:name","pXO1-122"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. EF is a calmodulin-dependent adenylyl cyclase that, when associated with PA, causes edema. EF is not toxic by itself and it is required for the survival of germinated spores within macrophages at the early stages of infection. Provokes dramatic elevation of intracellular cAMP levels in the host.CATALYTIC ACTIVITY ATP = 3',5'-cyclic AMP + diphosphate.ENZYME REGULATION It has an absolute requirement for host calmodulin for its activation. Inhibited by ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate.SUBUNIT Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these is toxic by itself. PA+LF forms the lethal toxin (LeTx); PA+EF forms the edema toxin (EdTx). EF probably forms oligomers as part of the translocation machinery, formed by a heterocomplex of PA63 monomers and EF subunits, and it is functional as a monomer in the host cell.DOMAIN The N-terminal region contains the residues responsible for binding to PA63. The C-terminal region contains the calmodulin-dependent activation domain and the catalytic site. This region is composed of three globular domains: CA, CB and a helical domain connected to CA by a linker. The active site lies at the interface of CA and CB. The metal ion is coordinated by residues from CA; calmodulin probably binds in a multistep fashion first to residues in CA and then to residues present in the linker and the helical domain.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS EF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the hetero-oligomeric complex by receptor-mediated endocytosis. EF requires passage through an acidic vesicle for activity. At acidic pH, the pore is inserted into the membrane, allowing translocation of EF, which probably contributes actively to its own insertion into the membrane. EF remains associated to the vesicle membrane after translocation to the cytosol, with the catalytic domains being exposed on the cytoplasmic face."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89724"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89763"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation","Lethal Factor"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:xref",null],["bp:organism",null],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89764"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89760"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89760"]]}},{"data":{"id":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1290.7881,"y":1035.3281,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89479"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89475"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89475"]]}},{"data":{"id":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","class":"process","label":"","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1169.084,"y":846.16003,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:displayName","MKK7 fragments"],["bp:cellularLocation","MKK7 fragments"],["bp:feature","MKK7 fragments"],["bp:entityReference_http://identifiers.org/uniprot/O14733","MKK7 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89571"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:displayName","MKK7 fragments"],["bp:cellularLocation","MKK7 fragments"],["bp:feature","MKK7 fragments"],["bp:entityReference_http://identifiers.org/uniprot/O14733","MKK7 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89571"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:displayName","MKK7 fragments"],["bp:cellularLocation","MKK7 fragments"],["bp:feature","MKK7 fragments"],["bp:entityReference_http://identifiers.org/uniprot/O14733","MKK7 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89571"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:entityFeature",null],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:displayName","MKK7 fragments"],["bp:cellularLocation","MKK7 fragments"],["bp:feature","MKK7 fragments"],["bp:entityReference_http://identifiers.org/uniprot/O14733","MKK7 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89571"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89550"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89550"]]}},{"data":{"id":"Protein_d3215672be20c65a36ae88c23f249383","class":"macromolecule","label":"Edema factor","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":878.39716,"y":431.31912,"w":48,"h":25},"metadata":[["bp:displayName","Edema factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P40136",[["bp:xref",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","cya"],["bp:name","BXA0141"],["bp:name","Edema factor"],["bp:name","UniProt:P40136 cya"],["bp:name","GBAA_pXO1_0142"],["bp:name","pXO1-122"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. EF is a calmodulin-dependent adenylyl cyclase that, when associated with PA, causes edema. EF is not toxic by itself and it is required for the survival of germinated spores within macrophages at the early stages of infection. Provokes dramatic elevation of intracellular cAMP levels in the host.CATALYTIC ACTIVITY ATP = 3',5'-cyclic AMP + diphosphate.ENZYME REGULATION It has an absolute requirement for host calmodulin for its activation. Inhibited by ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate.SUBUNIT Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these is toxic by itself. PA+LF forms the lethal toxin (LeTx); PA+EF forms the edema toxin (EdTx). EF probably forms oligomers as part of the translocation machinery, formed by a heterocomplex of PA63 monomers and EF subunits, and it is functional as a monomer in the host cell.DOMAIN The N-terminal region contains the residues responsible for binding to PA63. The C-terminal region contains the calmodulin-dependent activation domain and the catalytic site. This region is composed of three globular domains: CA, CB and a helical domain connected to CA by a linker. The active site lies at the interface of CA and CB. The metal ion is coordinated by residues from CA; calmodulin probably binds in a multistep fashion first to residues in CA and then to residues present in the linker and the helical domain.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS EF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the hetero-oligomeric complex by receptor-mediated endocytosis. EF requires passage through an acidic vesicle for activity. At acidic pH, the pore is inserted into the membrane, allowing translocation of EF, which probably contributes actively to its own insertion into the membrane. EF remains associated to the vesicle membrane after translocation to the cytosol, with the catalytic domains being exposed on the cytoplasmic face."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89724"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_e84bfd1cc1eaa853e592d66921c21aa6","class":"macromolecule","label":"Lethal Factor","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_e84bfd1cc1eaa853e592d66921c21aa6.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1405.1064,"y":1056.4275,"w":48,"h":25},"metadata":[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89477"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89476"]]}},{"data":{"id":"Protein_10658ad17aa0266d361c96bf2a9c7d68","class":"macromolecule","label":"MAP2K3","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1289.1672,"y":1160.648,"w":48,"h":25},"metadata":[["bp:displayName","MKK3"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 15 15 Phosphoserine."],["bp:featureLocation","MOD_RES 15 15 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 15 15 Phosphoserine."],["bp:featureLocation","MOD_RES 15 15 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 15 15 Phosphoserine."],["bp:featureLocation","MOD_RES 15 15 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89486"]]}},{"data":{"id":"Protein_1046951e1eaf0edd57f635b05d7518a9","class":"macromolecule","label":"MAP2K1","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_1046951e1eaf0edd57f635b05d7518a9.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1097.052,"y":1080.1073,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK1 fragment 2"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89428"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","392"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7281"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","8"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_43537"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89429"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89427"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation","MOD_RES 222 222 Phosphoserine; by RAF."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89425"]]],["bp:displayName","MEK1 fragments"],["bp:cellularLocation","MEK1 fragments"],["bp:feature","MEK1 fragments"],["bp:entityReference_http://identifiers.org/uniprot/Q02750","MEK1 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89422"]]}},{"data":{"id":"Protein_2cd29b54b96adac86239030097504aab","class":"macromolecule","label":"MAP2K2","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_2cd29b54b96adac86239030097504aab.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1279.6443,"y":1099.7712,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","MEK2 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89635"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89636"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","10"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_4104"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89637"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89633"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89633"]]],["bp:memberPhysicalEntity",[["bp:displayName","MEK2 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89635"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89636"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","10"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_4104"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89637"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation","MOD_RES 306 306 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89633"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89633"]]],["bp:displayName","MEK2 fragments"],["bp:cellularLocation","MEK2 fragments"],["bp:feature","MEK2 fragments"],["bp:entityReference_http://identifiers.org/uniprot/P36507","MEK2 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89630"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89630"]]}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3","class":"macromolecule","label":"Lethal Factor","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":958.8542,"y":811.2378,"w":48,"h":25},"metadata":[["bp:displayName","Lethal Factor"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:name","Lethal factor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89438"]]}},{"data":{"id":"Protein_a56ed666236bbdbf9bd991c41754204f","class":"macromolecule","label":"MAP2K1","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1062.1923,"y":927.0261,"w":48,"h":25},"metadata":[["bp:displayName","MEK1"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/Q02750",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 222 222 Phosphoserine; by RAF."],["bp:featureLocation",[["bp:sequencePosition","222"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 298 298 Phosphoserine; by PAK."],["bp:featureLocation",[["bp:sequencePosition","298"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 286 286 Phosphothreonine."],["bp:featureLocation","MOD_RES 286 286 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 1"],["bp:displayName","MP2K1_HUMAN"],["bp:name","MEK 1"],["bp:name","MEK1"],["bp:name","MAPKK 1"],["bp:name","ERK activator kinase 1"],["bp:name","MAP2K1"],["bp:name","MAPK/ERK kinase 1"],["bp:name","PRKMK1"],["bp:name","MKK1"],["bp:name","MAP kinase kinase 1"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9J_see-also"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Binding of extracellular ligands such as growth factors, cytokinesand hormones to their cell-surface receptors activates RAS andthis initiates RAF1 activation. RAF1 then further activates thedual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. BothMAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERKcascade, and catalyze the concomitant phosphorylation of athreonine and a tyrosine residue in a Thr-Glu-Tyr sequence locatedin the extracellular signal-regulated kinases MAPK3/ERK1 andMAPK1/ERK2, leading to their activation and further transductionof the signal within the MAPK/ERK cascade. Depending on thecellular context, this pathway mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation, predominantly through the regulation oftranscription, metabolism and cytoskeletal rearrangements. Onetarget of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotesdifferentiation and apoptosis. MAP2K1/MEK1 has been shown toexport PPARG from the nucleus. The MAPK/ERK cascade is alsoinvolved in the regulation of endosomal dynamics, includinglysosome processing and endosome cycling through the perinuclearrecycling compartment (PNRC), as well as in the fragmentation ofthe Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,ECO:0000269|PubMed:17101779}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Ras proteins such as HRAS mediate theactivation of RAF proteins such as RAF1 or BRAF which in turnactivate extracellular signal-regulated kinases (ERK) through MAPK(mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2.These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitatingdephosphorylation of the activating residues Ser-218 and Ser-222.Inhibited by serine/threonine phosphatase 2A (By similarity). Manyinhibitors have been identified including pyrrole derivatives,TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.{ECO:0000250}.SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Formsheterodimers with KSR2 which further dimerize to form tetramers.Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (Bysimilarity). Interacts with PPARG and with isoform 1 of VRK2(PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ(PubMed:16728640). Interacts with SGK1 (PubMed:19447520).Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1(PubMed:10409742). {ECO:0000250|UniProtKB:P29678,ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome {ECO:0000269|PubMed:14737111}.Cytoplasm, cytoskeleton, microtubule organizing center, spindlepole body {ECO:0000269|PubMed:14737111}. Cytoplasm{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.Nucleus {ECO:0000269|PubMed:17101779}. Membrane{ECO:0000269|PubMed:10409742}; Peripheral membrane protein{ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomesduring prometaphase, midzone during anaphase and midbody duringtelophase/cytokinesis (PubMed:14737111). Membrane localization isprobably regulated by its interaction with KSR1 (PubMed:10409742).{ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK1a;IsoId=Q02750-1; Sequence=Displayed;Name=2; Synonyms=MKK1b;IsoId=Q02750-2; Sequence=VSP_040500;TISSUE SPECIFICITY: Widely expressed, with extremely low levels inbrain. {ECO:0000269|PubMed:1281467}.DOMAIN: The proline-rich region localized between residues 270 and307 is important for binding to RAF1 and activation ofMAP2K1/MEK1. {ECO:0000250}.PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinasekinases (RAF or MEKK1) positively regulates kinase activity. Alsophosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.MAPK1/ERK2 phosphorylation of Thr-292 occurs in response tocellular adhesion and leads to inhibition of Ser-298phosphorylation by PAK. {ECO:0000269|PubMed:16129686,ECO:0000269|PubMed:8131746}.PTM: Acetylation by Yersinia yopJ prevents phosphorylation andactivation, thus blocking the MAPK signaling pathway.{ECO:0000269|PubMed:16728640}.DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices. Distinctivefeatures of CFC3 include macrostomia and horizontal shape ofpalpebral fissures. {ECO:0000269|PubMed:16439621,ECO:0000269|PubMed:18042262}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q02750"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5604"],["bp:comment","MP2K1_HUMAN Reviewed; 393 AA."],["bp:comment","REPLACED ProteinRef_MAP2K1__40674"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01469_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002746"],["bp:comment","REPLACED ProteinRef_MAP2K1__10116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_619"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-201N_identity"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5604"],["bp:comment","REPLACED ProteinRef_MAP2K1__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18627"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_18627"]]}},{"data":{"id":"Protein_8c314e71e98ca454f68a0ba5c351e6ff","class":"macromolecule","label":"MAP2K6","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_8c314e71e98ca454f68a0ba5c351e6ff.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1113.053,"y":777.6464,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","MKK6 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89585"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89586"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","14"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13451"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89587"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89583"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89583"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK6 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89585"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89586"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","14"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13451"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89587"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89583"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89583"]]],["bp:displayName","MKK6 fragments"],["bp:cellularLocation","MKK6 fragments"],["bp:feature","MKK6 fragments"],["bp:entityReference_http://identifiers.org/uniprot/P52564","MKK6 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89575"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89575"]]}},{"data":{"id":"Protein_e2861ae7a61f3469a6509614275092e7","class":"macromolecule","label":"MAP2K2","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1269.1151,"y":970.83636,"w":48,"h":25},"metadata":[["bp:displayName","MEK2"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P36507",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 306 306 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","306"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylmethionine"],["bp:term","N-acetylmethionine"]]],["bp:comment","MOD_RES 1 1 N-acetylmethionine."],["bp:featureLocation",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 293 293 Phosphoserine."],["bp:featureLocation","MOD_RES 293 293 Phosphoserine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 2"],["bp:displayName","MP2K2_HUMAN"],["bp:name","MEK 2"],["bp:name","MEK2"],["bp:name","MAPKK 2"],["bp:name","ERK activator kinase 2"],["bp:name","MAP2K2"],["bp:name","MAPK/ERK kinase 2"],["bp:name","PRKMK2"],["bp:name","MKK2"],["bp:name","MAP kinase kinase 2"],["bp:name","2.7.12.2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_109587"],["bp:comment","REPLACED ProteinRef_MAP2K2__10090"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5605"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_719"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29119N_identity"],["bp:comment","FUNCTION: Catalyzes the concomitant phosphorylation of a threonineand a tyrosine residue in a Thr-Glu-Tyr sequence located in MAPkinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).{ECO:0000250}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:10409742}.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;Evidence={ECO:0000269|PubMed:10409742};SUBUNIT: Interacts with MORG1 (By similarity). Interacts with SGK1(PubMed:19447520). Interacts with KSR1 (PubMed:10409742).{ECO:0000250|UniProtKB:Q63932, ECO:0000269|PubMed:10409742,ECO:0000269|PubMed:19447520}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10409742}.Membrane {ECO:0000269|PubMed:10409742}; Peripheral membraneprotein {ECO:0000269|PubMed:10409742}. Note=Membrane localizationis probably regulated by its interaction with KSR1.{ECO:0000269|PubMed:10409742}.PTM: MAPKK is itself dependent on Ser/Thr phosphorylation foractivity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).Phosphorylated by MAP2K1/MEK1 (By similarity). {ECO:0000250}.PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:17116858, ECO:0000269|Ref.3}.DISEASE: Cardiofaciocutaneous syndrome 4 (CFC4) [MIM:615280]: Aform of cardiofaciocutaneous syndrome, a multiple congenitalanomaly disorder characterized by a distinctive facial appearance,heart defects and mental retardation. Heart defects includepulmonic stenosis, atrial septal defects and hypertrophiccardiomyopathy. Some affected individuals present with ectodermalabnormalities such as sparse, friable hair, hyperkeratotic skinlesions and a generalized ichthyosis-like condition. Typicalfacial features are similar to Noonan syndrome. They include highforehead with bitemporal constriction, hypoplastic supraorbitalridges, downslanting palpebral fissures, a depressed nasal bridge,and posteriorly angulated ears with prominent helices.{ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262,ECO:0000269|PubMed:20358587}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03164_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P36507"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5605"],["bp:comment","MP2K2_HUMAN Reviewed; 400 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1S9I_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5605"],["bp:comment","REPLACED ProteinRef_MAP2K2__9606"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_52364"]]}},{"data":{"id":"Protein_19dbfbf992345d3d84b48e37dfd392aa","class":"macromolecule","label":"MAP2K7","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_19dbfbf992345d3d84b48e37dfd392aa.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1222.0778,"y":766.797,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK7 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89567"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89568"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","44"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12254"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89569"]]]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation","MOD_RES 2 2 N-acetylalanine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89565"]]],["bp:displayName","MKK7 fragments"],["bp:cellularLocation","MKK7 fragments"],["bp:feature","MKK7 fragments"],["bp:entityReference_http://identifiers.org/uniprot/O14733","MKK7 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89551"]]}},{"data":{"id":"Protein_e137e9a54322e34881c467efeb070fa6","class":"macromolecule","label":"MAP2K7","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1216.9724,"y":931.4904,"w":48,"h":25},"metadata":[["bp:displayName","MKK7"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/O14733",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 275 275 Phosphothreonine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","275"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 271 271 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 271 271 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 271 271 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 271 271 Phosphoserine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 7"],["bp:displayName","MP2K7_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 2"],["bp:name","JNK-activating kinase 2"],["bp:name","MAPKK 7"],["bp:name","Stress-activated protein kinase kinase 4"],["bp:name","MEK7"],["bp:name","JNKK2"],["bp:name","SKK4"],["bp:name","MKK7"],["bp:name","MAPK/ERK kinase 7"],["bp:name","PRKMK7"],["bp:name","JNKK 2"],["bp:name","MEK 7"],["bp:name","SAPK kinase 4"],["bp:name","SAPKK-4"],["bp:name","MAP kinase kinase 7"],["bp:name","MAP2K7"],["bp:name","2.7.12.2"],["bp:name","SAPKK4"],["bp:name","JNK kinase 2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5609"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_04309_identity"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4/MKK4 shows preference forphosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thrresidue. The monophosphorylation of JNKs on the Thr residue issufficient to increase JNK activity indicating that MAP2K7/MKK7 isimportant to trigger JNK activity, while the additionalphosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimalJNK activation. Has a specific role in JNK signal transductionpathway activated by proinflammatory cytokines. The MKK/JNKsignaling pathway is also involved in mitochondrial deathsignaling pathway, including the release cytochrome c, leading toapoptosis. {ECO:0000269|PubMed:9312068,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,ECO:0000269|Ref.5}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420;ENZYME REGULATION: Activated by phosphorylation by specific MAPkinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9312068}.SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its Ddomain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3(By similarity). Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3scaffold proteins. Interacts with RASSF7, the interaction promotesphosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,ECO:0000269|PubMed:21278800}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1; Synonyms=A;IsoId=O14733-1; Sequence=Displayed;Name=2; Synonyms=B;IsoId=O14733-2; Sequence=VSP_004883;Note=May be due to intron retention.;Name=3; Synonyms=gamma1;IsoId=O14733-3; Sequence=VSP_022309;Name=4;IsoId=O14733-4; Sequence=VSP_022310;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Ubiquitous; with highest level of expressionin skeletal muscle. Isoform 3 is found at low levels in placenta,fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.DOMAIN: The DVD domain (residues 377-400) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 37-57) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000269|PubMed:15866172}.PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__9606"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/O14733-2"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_660186"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1002"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5609"],["bp:comment","REPLACED ProteinRef_MAP2K7__40674"],["bp:comment","MP2K7_HUMAN Reviewed; 419 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_10293"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_10293"]]}},{"data":{"id":"Protein_865edebf87abc1177735ccdb3359403a","class":"macromolecule","label":"MAP2K4","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_865edebf87abc1177735ccdb3359403a.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1338.8395,"y":935.78217,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","MKK4 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89607"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89608"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","45"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6472"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89609"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK4 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89607"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89608"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","45"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6472"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89609"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"]]],["bp:memberPhysicalEntity",[["bp:displayName","MKK4 fragment 1"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89607"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89608"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","45"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6472"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","1"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1091"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89609"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation","MOD_RES 257 257 Phosphoserine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89605"]]],["bp:displayName","MKK4 fragments"],["bp:cellularLocation","MKK4 fragments"],["bp:feature","MKK4 fragments"],["bp:entityReference_http://identifiers.org/uniprot/P45985","MKK4 fragments"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89592"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89592"]]}},{"data":{"id":"Protein_cbb94d6b16ea77d0d4e3333573c48654","class":"macromolecule","label":"MAP2K6","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1148.1588,"y":948.8713,"w":48,"h":25},"metadata":[["bp:displayName","MKK6"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P52564",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 211 211 Phosphothreonine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","211"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 207 207 Phosphoserine; by MAP3K; alternate."],["bp:featureLocation",[["bp:sequencePosition","207"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."],["bp:featureLocation","MOD_RES 211 211 O-acetylthreonine; by Yersinia yopJ;alternate."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 6"],["bp:displayName","MP2K6_HUMAN"],["bp:name","MEK6"],["bp:name","Stress-activated protein kinase kinase 3"],["bp:name","SKK3"],["bp:name","MKK6"],["bp:name","MAPK/ERK kinase 6"],["bp:name","PRKMK6"],["bp:name","MEK 6"],["bp:name","MAPKK 6"],["bp:name","SAPK kinase 3"],["bp:name","SAPKK-3"],["bp:name","MAP2K6"],["bp:name","MAP kinase kinase 6"],["bp:name","2.7.12.2"],["bp:name","SAPKK3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P52564-1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-31346N_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002749"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5608"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_894"],["bp:comment","MP2K6_HUMAN Reviewed; 334 AA."],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of athreonine and a tyrosine residue in the MAP kinases p38 MAPK11,MAPK12, MAPK13 and MAPK14 and plays an important role in theregulation of cellular responses to cytokines and all kinds ofstresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are bothessential for the activation of MAPK11 and MAPK13 induced byenvironmental stress, whereas MAP2K6/MKK6 is the major MAPK11activator in response to TNF. MAP2K6/MKK6 also phosphorylates andactivates PAK6. The p38 MAP kinase signal transduction pathwayleads to direct activation of transcription factors. Nucleartargets of p38 MAP kinase include the transcription factors ATF2and ELK1. Within the p38 MAPK signal transduction pathway,MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14activation, and is therefore required for STAT4 activation andSTAT4-regulated gene expression in response to IL-12 stimulation.The pathway is also crucial for IL-6-induced SOCS3 expression anddown-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclastdifferentiation through NF-kappa-B transactivation by TNFSF11, andin endochondral ossification and since SOX9 is another likelydownstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediatesapoptotic cell death in thymocytes. Acts also as a regulator formelanocytes dendricity, through the modulation of Rho familyGTPases. {ECO:0000269|PubMed:10961885,ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393,ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669,ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074,ECO:0000269|PubMed:9218798}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated by dual phosphorylation on Ser-207and Thr-211 in response to a variety of cellular stresses,including UV radiation, osmotic shock, hypoxia, inflammatorycytokines, interferon gamma (IFNG), and less often by growthfactors. MAP2K6/MKK6 is activated by the majority of M3Ks, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2.{ECO:0000269|PubMed:20364819, ECO:0000269|PubMed:8626699,ECO:0000269|PubMed:8663074}.SUBUNIT: Dimer. Interacts with Yersinia yopJ. Interacts (via its Ddomain) with its substrates MAPK11, MAPK12, MAPK13 and MAPK14 (Bysimilarity). Interacts (via its DVD domain) with MAP3Ks activatorslike MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK3,MAP3K4/MEKK4, MAP3K7/TAK1, MAP3K11/MLK3 and MAP3K17/TAOK2 (Bysimilarity). Interacts with DCTN1. Interacts with EIF2AK2/PKR.{ECO:0000250, ECO:0000269|PubMed:10497253,ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15375157,ECO:0000269|PubMed:19141286}.SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9768359}.Cytoplasm {ECO:0000269|PubMed:9768359}. Cytoplasm, cytoskeleton{ECO:0000269|PubMed:9768359}. Note=Binds to microtubules.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1; Synonyms=MKK6b;IsoId=P52564-1; Sequence=Displayed;Name=2; Synonyms=MKK6;IsoId=P52564-2; Sequence=VSP_004882;TISSUE SPECIFICITY: Isoform 2 is only expressed in skeletalmuscle. Isoform 1 is expressed in skeletal muscle, heart, and inlesser extent in liver or pancreas. {ECO:0000269|PubMed:8621675}.INDUCTION: Strongly activated by UV, anisomycin, and osmotic shockbut not by phorbol esters, NGF or EGF.DOMAIN: The DVD domain (residues 311-334) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.{ECO:0000269|PubMed:15866172}.DOMAIN: The D domain (residues 4-19) contains a conserved dockingsite and is required for the binding to MAPK substrates.{ECO:0000250}.PTM: Weakly autophosphorylated. Phosphorylated at Ser-207 and Thr-211 by the majority of M3Ks, such as MAP3K5/ASK1, MAP3K1/MEKK1,MAP3K2/MEKK2, MAP3K3/MEKK3, MAP3K4/MEKK4, MAP3K7/TAK1,MAP3K11/MLK3 and MAP3K17/TAOK2. {ECO:0000269|PubMed:16728640}.PTM: Acetylation of Ser-207 and Thr-211 by Yersinia yopJ preventsphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5608_gene_product"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5608"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03155_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89574"]]}},{"data":{"id":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","class":"macromolecule","label":"MAP2K3","parent":"cytoplasm","clonemarker":false,"stateVariables":[{"id":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":1193.9633,"y":1229.1096,"w":48,"h":25},"metadata":[["bp:displayName","MKK3 fragments"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89489"]]],["bp:entityReference_http://identifiers.org/uniprot/P46734",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 218 218 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","218"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 222 222 Phosphothreonine."],["bp:featureLocation","MOD_RES 222 222 Phosphothreonine."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 3"],["bp:displayName","MP2K3_HUMAN"],["bp:name","SAPKK2"],["bp:name","MEK3"],["bp:name","SKK2"],["bp:name","Stress-activated protein kinase kinase 2"],["bp:name","MAP2K3"],["bp:name","MAPK/ERK kinase 3"],["bp:name","PRKMK3"],["bp:name","MEK 3"],["bp:name","MAPKK 3"],["bp:name","MKK3"],["bp:name","SAPK kinase 2"],["bp:name","SAPKK-2"],["bp:name","MAP kinase kinase 3"],["bp:name","2.7.12.2"],["bp:comment","MP2K3_HUMAN Reviewed; 347 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-34242N_identity"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_621"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_659731"],["bp:comment","FUNCTION: Dual specificity kinase. Is activated by cytokines andenvironmental stress in vivo. Catalyzes the concomitantphosphorylation of a threonine and a tyrosine residue in the MAPkinase p38. Part of a signaling cascade that begins with theactivation of the adrenergic receptor ADRA1B and leads to theactivation of MAPK14. {ECO:0000269|PubMed:21224381,ECO:0000269|PubMed:8622669}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.{ECO:0000269|PubMed:8622669}.ENZYME REGULATION: Activated by dual phosphorylation on Ser-218and Thr-222. {ECO:0000269|PubMed:8622669}.SUBUNIT: Component of a signaling complex containing at leastAKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13interacts directly with PKN1, which in turn recruits MAPK14,MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK andincreases its kinase activity (PubMed:11980910). Part of a complexwith MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1(PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).{ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,ECO:0000269|PubMed:21224381}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Name=3; Synonyms=3b;IsoId=P46734-1; Sequence=Displayed;Name=1;IsoId=P46734-2; Sequence=VSP_004878;Name=2; Synonyms=3c;IsoId=P46734-3; Sequence=VSP_004877;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 byMAP kinase kinase kinases regulates positively the kinase activity(PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).{ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventingphosphorylation and activation, thus blocking the MAPK signalingpathway. {ECO:0000269|PubMed:16728640}.DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/5606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002747"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P46734-3"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_016880347"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_entrez_gene_locuslink_28424"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5606"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03816_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89487"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89487"]]}},{"data":{"id":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","class":"macromolecule","label":"MAP2K4","parent":"cytoplasm","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1319.4633,"y":814.9436,"w":48,"h":25},"metadata":[["bp:displayName","MKK4"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005737"],["bp:db","gene ontology"]]],["bp:term","cytoplasm"],["bp:term","Cytoplasm"]]],["bp:entityReference_http://identifiers.org/uniprot/P45985",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 257 257 Phosphoserine; by MAP3K."],["bp:featureLocation",[["bp:sequencePosition","257"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES N-acetylalanine"],["bp:term","N-acetylalanine"]]],["bp:comment","MOD_RES 2 2 N-acetylalanine."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 261 261 Phosphothreonine; by MAP3K."],["bp:featureLocation","MOD_RES 261 261 Phosphothreonine; by MAP3K."]]],["bp:standardName","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:xref","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:organism","Dual specificity mitogen-activated protein kinase kinase 4"],["bp:displayName","MP2K4_HUMAN"],["bp:name","c-Jun N-terminal kinase kinase 1"],["bp:name","SAPKK1"],["bp:name","MEK4"],["bp:name","JNKK"],["bp:name","Stress-activated protein kinase kinase 1"],["bp:name","SAPK/ERK kinase 1"],["bp:name","JNKK1"],["bp:name","SEK1"],["bp:name","SERK1"],["bp:name","MAP2K4"],["bp:name","MAPK/ERK kinase 4"],["bp:name","PRKMK4"],["bp:name","JNK-activating kinase 1"],["bp:name","MEK 4"],["bp:name","SAPKK-1"],["bp:name","MAPKK 4"],["bp:name","MKK4"],["bp:name","SKK1"],["bp:name","SAPK kinase 1"],["bp:name","MAP kinase kinase 4"],["bp:name","2.7.12.2"],["bp:comment","MP2K4_HUMAN Reviewed; 399 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_03213_identity"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_6416"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_659"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__9606"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_003001"],["bp:comment","FUNCTION: Dual specificity protein kinase which acts as anessential component of the MAP kinase signal transduction pathway.Essential component of the stress-activated protein kinase/c-JunN-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,is the one of the only known kinase to directly activate thestress-activated protein kinase/c-Jun N-terminal kinasesMAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 andMAP2K7/MKK7 both activate the JNKs by phosphorylation, but theydiffer in their preference for the phosphorylation site in theThr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation ofthe Tyr residue and MAP2K7/MKK7 for the Thr residue. Thephosphorylation of the Thr residue by MAP2K7/MKK7 seems to be theprerequisite for JNK activation at least in response toproinflammatory cytokines, while other stimuli activate bothMAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylateJNKs. MAP2K4 is required for maintaining peripheral lymphoidhomeostasis. The MKK/JNK signaling pathway is also involved inmitochondrial death signaling pathway, including the releasecytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7exclusively activates JNKs, MAP2K4/MKK4 additionally activates thep38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.{ECO:0000269|PubMed:7716521}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.ENZYME REGULATION: Activated in response to a variety of cellularstresses, including UV and gamma-irradiation, heat shock,hyperosmolarity, T-cell receptor stimulation, peroxide andinflammatory cytokines. Also activated by developmental cues.MAP2K4/MKK4 is activated by the majority of MKKKs, such asMAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.{ECO:0000269|PubMed:9003778}.SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via itsD domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ksactivators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts withARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,ECO:0000269|PubMed:9003778}.SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P45985-1; Sequence=Displayed;Name=2;IsoId=P45985-2; Sequence=VSP_038838;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Abundant expression is seen in the skeletalmuscle. It is also widely expressed in other tissues.DOMAIN: The DVD domain (residues 364-387) contains a conserveddocking site and is found in the mammalian MAP kinase kinases(MAP2Ks). The DVD sites bind to their specific upstream MAP kinasekinase kinases (MAP3Ks) and are essential for activation.DOMAIN: The D domain (residues 34-52) contains a conserved dockingsite and is required for the binding to MAPK substrates.PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAPkinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thrprotein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/map2k4/\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/ncbigene/6416"],["bp:comment","REPLACED ProteinRef_MAP2K4__40674"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_19959"]]}},{"data":{"id":"extracellular_region","class":"compartment","label":"extracellular region","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":405.043315,"y":506.529945,"w":337.31403,"h":197.05789},"metadata":null}},{"data":{"id":"integral_to_membrane","class":"compartment","label":"integral to membrane","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":682.12683,"y":580.3422,"w":52,"h":29},"metadata":null}},{"data":{"id":"endosome","class":"compartment","label":"endosome","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":568.0669800000001,"y":156.3486,"w":108.86676,"h":239.7994},"metadata":null}},{"data":{"id":"cytoplasm","class":"compartment","label":"cytoplasm","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1106.59767,"y":830.2143699999999,"w":649.0176,"h":826.7905},"metadata":null}},{"data":{"id":"SmallMolecule_bccee74407d2f7a76e0e86b318622e2b_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","class":"simple chemical","label":"ATP","parent":"","clonemarker":true,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":764.2502,"y":208.40535,"w":45,"h":15},"metadata":[["bp:displayName","ATP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:15422",[["bp:standardName","adenosine 5'-(tetrahydrogen triphosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:22249"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:78675"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:10789"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:40938"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:27027"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37096"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:57299"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:13236"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37045"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37045"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37045"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37045"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:37045"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H16N5O13P3"],["bp:displayName","ATP"],["bp:name","H4atp"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O"],["bp:name","C10H16N5O13P3"],["bp:name","Adenosine triphosphate"],["bp:name","Adenosine 5'-triphosphate"],["bp:name","ADENOSINE-5'-TRIPHOSPHATE"],["bp:name","CHEBI:15422"],["bp:molecularWeight","507.181"],["bp:comment","is_conjugate_acid_of CHEBI:57299"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00538"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0001351_ATP"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bind_13_identity"],["bp:comment","REPLACED http://identifiers.org/kegg.compound/C00002"],["bp:comment","has_role CHEBI:27027"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00002.eref"],["bp:comment","has_role CHEBI:50733"],["bp:comment","is_a CHEBI:37096"],["bp:comment","has_role CHEBI:78675"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2127"],["bp:comment","An adenosine 5'-phosphate in which the 5'-phosphate is a triphosphate group. It is involved in the transportation of chemical energy during metabolic pathways."],["bp:comment","is_a CHEBI:37045"],["bp:structure","is_a CHEBI:37045"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2126"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2126"]]}},{"data":{"id":"Protein_8c42f97fd80a86c01161722db974a062","class":"macromolecule","label":"CASP1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":639.1545,"y":652.6526,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 1"],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","302"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref",[["bp:id","P29466"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CASP1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","CASP1"],["bp:db","hgnc symbol"]]],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72758"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72758"]]}},{"data":{"id":"Complex_d9db3aaef19689040cd2291a442db6a4","class":"complex","label":"PA/Cellular Receptors","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":54.812559,"y":376.99716,"w":52.000004,"h":59},"metadata":[["bp:displayName","PA/Cellular Receptors"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89696"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89696"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89696"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89696"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89694"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89694"]]}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8_Complex_d9db3aaef19689040cd2291a442db6a4","class":"macromolecule","label":"PA Cellular Receptors","parent":"Complex_d9db3aaef19689040cd2291a442db6a4","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":54.812557,"y":391.99716,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","CMG2"],["bp:entityReference_http://identifiers.org/uniprot/P58335",[["bp:entityFeature",null],["bp:standardName","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:organism","Anthrax toxin receptor 2"],["bp:displayName","ANTR2_HUMAN"],["bp:name","Capillary morphogenesis gene 2 protein"],["bp:name","ANTXR2"],["bp:name","CMG-2"],["bp:name","CMG2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32476N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07452_identity"],["bp:comment","FUNCTION: Necessary for cellular interactions with laminin and theextracellular matrix. {ECO:0000269|PubMed:11683410,ECO:0000269|PubMed:12973667}.SUBUNIT: Binds laminin, and possibly also collagen type IV. Bindsto the protective antigen (PA) of Bacillus anthracis in a divalentcation-dependent manner, with the following preference: calcium >manganese > magnesium > zinc. Binding of PA leads toheptamerization of the receptor-PA complex.SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type Imembrane protein. Note=Expressed at the cell surface.SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum membrane;Single-pass type I membrane protein. Note=Expressed predominantlywithin the endoplasmic reticulum and not at the plasma membrane.SUBCELLULAR LOCATION: Isoform 3: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=P58335-1; Sequence=Displayed;Name=2;IsoId=P58335-2; Sequence=VSP_008343;Name=3;IsoId=P58335-3; Sequence=VSP_008344, VSP_008345;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=4;IsoId=P58335-4; Sequence=VSP_008346;TISSUE SPECIFICITY: Expressed in prostate, thymus, ovary, testis,pancreas, colon, heart, kidney, lung, liver, peripheral bloodleukocytes, placenta, skeletal muscle, small intestine and spleen.{ECO:0000269|PubMed:14508707}.DOMAIN: Binding to PA seems to be effected through the VWA domain.DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: Anautosomal recessive syndrome characterized by abnormal growth ofhyalinized fibrous tissue usually affecting subcutaneous regionson the scalp, ears, neck, face, hands, and feet. The lesionsappear as pearly papules or fleshy nodules. Additional featuresinclude gingival hypertrophy, progressive joint contracturesresulting in severe limitation of mobility, osteopenia, andosteoporosis. Disease severity is variable. Some individualsmanifest symptoms in infancy and have additional visceral orsystemic involvement. Hyaline deposits in multiple organs,recurrent infections and intractable diarrhea often lead to earlydeath. Surviving children may suffer from severely reducedmobility due to joint contractures. Other patients have lateronset of a milder disorder affecting only the face and digits.{ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707,ECO:0000269|PubMed:15725249}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Upon binding of the protective antigen (PA) ofBacillus anthracis the complex moves to glycosphingolipid-richlipid rafts, where it is internalized via a clathrin-dependentpathway. In the endosomal membrane, at pH under 7, the complexthen rearranges and forms a pore allowing the other components ofanthrax toxin to escape to the cytoplasm.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAY40907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};Sequence=BAB70976.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=BAD93150.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_477520"],["bp:comment","ANTR2_HUMAN Reviewed; 489 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_118429"],["bp:comment","REPLACED http://identifiers.org/uniprot/P13423"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-1"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011529889"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]}},{"data":{"id":"Protein_d6e07b06c20eda94bf7f9c32e13105bb_Complex_d9db3aaef19689040cd2291a442db6a4","class":"macromolecule","label":"Protective Antigen (PA)","parent":"Complex_d9db3aaef19689040cd2291a442db6a4","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":54.812557,"y":361.99716,"w":48,"h":25},"metadata":[["bp:displayName","Protective Antigen (PA)"],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1377343867"],["bp:id","PAG_BACAN"],["bp:db","uniprot accession"]]],["bp:xref",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89695"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":453.97162,"y":913.32916,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89619"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89617"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89617"]]}},{"data":{"id":"Protein_f1a4eab3c776c0a7d0ff066569d2dbca","class":"macromolecule","label":"ESR1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":812.977,"y":329.9498,"w":48,"h":25},"metadata":[["bp:displayName","Estrogen receptor alpha"],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."],["bp:featureLocation","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."],["bp:featureLocation","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."],["bp:featureLocation","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."],["bp:featureLocation","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."],["bp:featureLocation","MOD_RES 537 537 Phosphotyrosine; by Tyr-kinases."]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:name","ER alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"]]}},{"data":{"id":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","class":"complex","label":"Caspase 1 (tetramer)","parent":"","clonemarker":false,"stateVariables":[{"id":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":482.039,"y":752.3875,"w":52,"h":64},"metadata":[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation","MOD_RES 302 302 Phosphoserine."]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]}},{"data":{"id":"Protein_4ebf51e90945926fb21480b6e3d327ed_Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","class":"macromolecule","label":"CASP1","parent":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","clonemarker":false,"stateVariables":[{"id":"Protein_4ebf51e90945926fb21480b6e3d327ed_Complex_b1ae6006620d93cbf0ccb97c7be5f9ac.info.1","class":"state variable","state":{"variable":"","value":"x[317 - 404]"}}],"unitsOfInformation":[],"bbox":{"x":482.039,"y":769.8875,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 1 p10"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63571"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","404"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16686"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","317"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_12860"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63572"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","302"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","302"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72690"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72690"]]}},{"data":{"id":"Protein_46ccc358e2dd3cba614099d36e9ac94a_Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","class":"macromolecule","label":"CASP1","parent":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","clonemarker":false,"stateVariables":[{"id":"Protein_46ccc358e2dd3cba614099d36e9ac94a_Complex_b1ae6006620d93cbf0ccb97c7be5f9ac.info.1","class":"state variable","state":{"variable":"","value":"x[120 - 297]"}}],"unitsOfInformation":[],"bbox":{"x":482.039,"y":734.8875,"w":48,"h":25},"metadata":[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","302"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 302 302 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","302"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8","class":"macromolecule","label":"PA Cellular Receptors","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":76.755436,"y":457.5399,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","CMG2"],["bp:entityReference_http://identifiers.org/uniprot/P58335",[["bp:entityFeature",null],["bp:standardName","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:organism","Anthrax toxin receptor 2"],["bp:displayName","ANTR2_HUMAN"],["bp:name","Capillary morphogenesis gene 2 protein"],["bp:name","ANTXR2"],["bp:name","CMG-2"],["bp:name","CMG2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32476N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07452_identity"],["bp:comment","FUNCTION: Necessary for cellular interactions with laminin and theextracellular matrix. {ECO:0000269|PubMed:11683410,ECO:0000269|PubMed:12973667}.SUBUNIT: Binds laminin, and possibly also collagen type IV. Bindsto the protective antigen (PA) of Bacillus anthracis in a divalentcation-dependent manner, with the following preference: calcium >manganese > magnesium > zinc. Binding of PA leads toheptamerization of the receptor-PA complex.SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type Imembrane protein. Note=Expressed at the cell surface.SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum membrane;Single-pass type I membrane protein. Note=Expressed predominantlywithin the endoplasmic reticulum and not at the plasma membrane.SUBCELLULAR LOCATION: Isoform 3: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=P58335-1; Sequence=Displayed;Name=2;IsoId=P58335-2; Sequence=VSP_008343;Name=3;IsoId=P58335-3; Sequence=VSP_008344, VSP_008345;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=4;IsoId=P58335-4; Sequence=VSP_008346;TISSUE SPECIFICITY: Expressed in prostate, thymus, ovary, testis,pancreas, colon, heart, kidney, lung, liver, peripheral bloodleukocytes, placenta, skeletal muscle, small intestine and spleen.{ECO:0000269|PubMed:14508707}.DOMAIN: Binding to PA seems to be effected through the VWA domain.DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: Anautosomal recessive syndrome characterized by abnormal growth ofhyalinized fibrous tissue usually affecting subcutaneous regionson the scalp, ears, neck, face, hands, and feet. The lesionsappear as pearly papules or fleshy nodules. Additional featuresinclude gingival hypertrophy, progressive joint contracturesresulting in severe limitation of mobility, osteopenia, andosteoporosis. Disease severity is variable. Some individualsmanifest symptoms in infancy and have additional visceral orsystemic involvement. Hyaline deposits in multiple organs,recurrent infections and intractable diarrhea often lead to earlydeath. Surviving children may suffer from severely reducedmobility due to joint contractures. Other patients have lateronset of a milder disorder affecting only the face and digits.{ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707,ECO:0000269|PubMed:15725249}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Upon binding of the protective antigen (PA) ofBacillus anthracis the complex moves to glycosphingolipid-richlipid rafts, where it is internalized via a clathrin-dependentpathway. In the endosomal membrane, at pH under 7, the complexthen rearranges and forms a pore allowing the other components ofanthrax toxin to escape to the cytoplasm.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAY40907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};Sequence=BAB70976.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=BAD93150.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_477520"],["bp:comment","ANTR2_HUMAN Reviewed; 489 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_118429"],["bp:comment","REPLACED http://identifiers.org/uniprot/P13423"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-1"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011529889"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]}},{"data":{"id":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":205.26656,"y":323.3856,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","PA20"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89665"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","196"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7275"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","30"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_34001"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89666"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89663"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89711"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89709"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89709"]]}},{"data":{"id":"Protein_3de48755180a4a3529a499c370317030","class":"macromolecule","label":"IL1B","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":434.76825,"y":995.8611,"w":48,"h":25},"metadata":[["bp:displayName","IL1 beta"],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref",[["bp:relationshipType",null],["bp:id","IL1B"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P01584"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P01584"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8721"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":149.67386,"y":375.68887,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PA63"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:xref",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:organism",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89624"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89626"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89623"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89623"]]}},{"data":{"id":"SmallMolecule_e251e68f3321c5cb807aa97132bcfba7","class":"simple chemical","label":"cAMP","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":957.5422,"y":232.15994,"w":48,"h":20},"metadata":[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:75771"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:1325"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:1325"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:1325"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]}},{"data":{"id":"Protein_a3645b1d8f86749ea253214e3ae4efc3","class":"macromolecule","label":"FURIN","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":146.38942,"y":430.98468,"w":48,"h":25},"metadata":[["bp:displayName","Furin or Furin like Endopeptidase"],["bp:entityReference_http://identifiers.org/uniprot/P09958",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 775 775 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","775"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 773 773 Phosphoserine; by CK2."],["bp:featureLocation",[["bp:sequencePosition","773"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P09958"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P09958"]]],["bp:standardName","Furin"],["bp:xref","Furin"],["bp:xref","Furin"],["bp:organism","Furin"],["bp:displayName","FURIN_HUMAN"],["bp:name","FUR"],["bp:name","PCSK3"],["bp:name","3.4.21.75"],["bp:name","Paired basic amino acid residue-cleaving enzyme"],["bp:name","Dibasic-processing enzyme"],["bp:name","FURIN"],["bp:name","PACE"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_16685"],["bp:comment","FUNCTION: Furin is likely to represent the ubiquitous endoproteaseactivity within constitutive secretory pathways and capable ofcleavage at the RX(K/R)R consensus motif.{ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:1629222,ECO:0000269|PubMed:1713771, ECO:0000269|PubMed:2251280,ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,ECO:0000269|PubMed:7592877, ECO:0000269|PubMed:7690548,ECO:0000269|PubMed:9130696}.FUNCTION: (Microbial infection) Probably cleaves and activatesanthrax and diphtheria toxins. Required for H7N1 and H5N1influenza virus infection probably by cleaving hemagglutinin.{ECO:0000269|PubMed:25974265}.CATALYTIC ACTIVITY: Release of mature proteins from theirproproteins by cleavage of -Arg-Xaa-Yaa-Arg-|-Zaa- bonds, whereXaa can be any amino acid and Yaa is Arg or Lys. Releases albumin,complement component C3 and von Willebrand factor from theirrespective precursors. {ECO:0000269|PubMed:11799113,ECO:0000269|PubMed:1629222, ECO:0000269|PubMed:1713771,ECO:0000269|PubMed:2251280, ECO:0000269|PubMed:24666235,ECO:0000269|PubMed:25974265, ECO:0000269|PubMed:7592877,ECO:0000269|PubMed:7690548, ECO:0000269|PubMed:9130696}.COFACTOR:Name=Ca(2+); Xref=ChEBI:CHEBI:29108;Evidence={ECO:0000269|PubMed:24666235,ECO:0000269|PubMed:25974265, ECO:0000269|PubMed:9130696};Note=Binds 3 calcium ions per subunit.{ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,ECO:0000269|PubMed:9130696};ENZYME REGULATION: Inhibited by the not secondly cleavedpropeptide (PubMed:9130696, PubMed:11799113). Inhibited by m-guanidinomethyl-phenylacetyl-Arg-Val-Arg-(amidomethyl)-benzamidine(m-guanidinomethyl-Phac-RVR-Amb) and 4-guanidinomethyl-phenylacteyl-Arg-Tle-Arg-4-amidinobenzylamide (MI-1148)(PubMed:24666235, PubMed:25974265). {ECO:0000269|PubMed:11799113,ECO:0000269|PubMed:24666235, ECO:0000269|PubMed:25974265,ECO:0000269|PubMed:9130696}.BIOPHYSICOCHEMICAL PROPERTIES:pH dependence:Optimum pH is 6.0. {ECO:0000269|PubMed:9130696};SUBUNIT: Interacts with FLNA (By similarity). Binds to PACS1 whichmediates TGN localization and connection to clathrin adapters(PubMed:11331585). {ECO:0000250|UniProtKB:P23188,ECO:0000269|PubMed:11331585}.SUBCELLULAR LOCATION: Golgi apparatus, trans-Golgi networkmembrane {ECO:0000269|PubMed:11331585,ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:8846780,ECO:0000269|PubMed:9130696, ECO:0000269|PubMed:9412467}; Single-pass type I membrane protein {ECO:0000305}. Cell membrane{ECO:0000269|PubMed:11799113, ECO:0000269|PubMed:9130696,ECO:0000269|PubMed:9412467}; Single-pass type I membrane protein{ECO:0000305}. Secreted {ECO:0000305|PubMed:11799113}. Endosomemembrane {ECO:0000269|PubMed:9412467}; Single-pass type I membraneprotein {ECO:0000305}. Note=Shuttles between the trans-Golginetwork and the cell surface (PubMed:9412467, PubMed:11799113).Propeptide cleavage is a prerequisite for exit of furin moleculesout of the endoplasmic reticulum (ER). A second cleavage withinthe propeptide occurs in the trans Golgi network (TGN), followedby the release of the propeptide and the activation of furin(PubMed:11799113). {ECO:0000269|PubMed:11799113,ECO:0000269|PubMed:9412467}.TISSUE SPECIFICITY: Seems to be expressed ubiquitously.{ECO:0000269|PubMed:1713771}.DOMAIN: Contains a cytoplasmic domain responsible for its TGNlocalization and recycling from the cell surface.{ECO:0000269|PubMed:8846780}.PTM: The inhibition peptide, which plays the role of anintramolecular chaperone, is autocatalytically removed in theendoplasmic reticulum (ER) and remains non-covalently bound tofurin as a potent autoinhibitor. Following transport to the transGolgi, a second cleavage within the inhibition propeptide resultsin propeptide dissociation and furin activation.{ECO:0000269|PubMed:1629222, ECO:0000269|PubMed:9130696}.PTM: Phosphorylation is required for TGN localization of theendoprotease. In vivo, exists as di-, mono- and non-phosphorylatedforms. {ECO:0000269|PubMed:8846780}.SIMILARITY: Belongs to the peptidase S8 family. Furin subfamily.{ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/FURINID40646ch15q26.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00653_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-29904N_identity"],["bp:comment","FURIN_HUMAN Reviewed; 794 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002560"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5045"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5045"]]],["bp:name","FURIN"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_48219"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_48219"]]}},{"data":{"id":"Protein_df684cdcf919e347d3ad85620a83c969","class":"macromolecule","label":"ESR1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_df684cdcf919e347d3ad85620a83c969.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":633.7944,"y":363.78177,"w":48,"h":25},"metadata":[["bp:displayName","Estrogen receptor alpha"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89462"]]],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89461"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89461"]]}},{"data":{"id":"Protein_e47df6e9143abd56f0359798973ea35e","class":"macromolecule","label":"VCAM1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":702.8143,"y":470.12637,"w":48,"h":25},"metadata":[["bp:displayName","VCAM1"],["bp:entityReference_http://identifiers.org/uniprot/P19320",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P19320"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P19320"]]],["bp:standardName","Vascular cell adhesion protein 1"],["bp:xref",[["bp:relationshipType",null],["bp:id","VCAM1"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P19320"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P19320"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","VCAM1_HUMAN"],["bp:name","CD106"],["bp:name","V-CAM 1"],["bp:name","INCAM-100"],["bp:name","VCAM-1"],["bp:name","VCAM1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7412"],["bp:comment","FUNCTION: Important in cell-cell recognition. Appears to functionin leukocyte-endothelial cell adhesion. Interacts with integrinalpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates bothadhesion and signal transduction. The VCAM1/ITGA4/ITGB1interaction may play a pathophysiologic role both in immuneresponses and in leukocyte emigration to sites of inflammation.SUBUNIT: Binds to ECMV-D capsid proteins and acts as a receptorfor this virus. {ECO:0000250}.SUBCELLULAR LOCATION: Membrane; Single-pass type I membraneprotein.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=3;Comment=Additional isoforms seem to exist.;Name=1; Synonyms=Long, VCAM-7D;IsoId=P19320-1; Sequence=Displayed;Note=Major isoform.;Name=2; Synonyms=Short, VCAM-6D;IsoId=P19320-2; Sequence=VSP_002580;Name=3;IsoId=P19320-3; Sequence=VSP_044636;Note=No experimental confirmation available.;TISSUE SPECIFICITY: Expressed on inflammed vascular endothelium,as well as on macrophage-like and dendritic cell types in bothnormal and inflammed tissue.INDUCTION: By cytokines (e.g. IL-1, TNF-alpha).DOMAIN: Either the first or the fourth Ig-like C2-type domain isrequired for VLA4-dependent cell adhesion.PTM: Sialoglycoprotein.WEB RESOURCE: Name=Wikipedia; Note=VCAM1 entry;URL=\"https://en.wikipedia.org/wiki/VCAM1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/vcam1/\";WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;Note=VCAM-1;URL=\"http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Itlect_266\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001069"],["bp:comment","VCAM1_HUMAN Reviewed; 739 AA."],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7412"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01888_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_7412_gene_product"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_542413"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_4177"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":382.61462,"y":214.65924,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89537"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89504"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89504"]]}},{"data":{"id":"Protein_0e1cdb16881e89a3a864b018959a0b1b","class":"macromolecule","label":"CALM2","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":777.8657,"y":252.85332,"w":48,"h":25},"metadata":[["bp:displayName","CaM"],["bp:entityReference_http://identifiers.org/uniprot/P62158",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P62158"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P62158"]]],["bp:xref",[["bp:id","GO:0008440"],["bp:db","gene ontology"]]],["bp:xref",[["bp:id","R-HSA-5627123"],["bp:db","reactome"]]],["bp:xref",[["bp:id","GO:0031982"],["bp:db","gene ontology"]]],["bp:xref",[["bp:id","2N6A"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:xref",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:organism",[["bp:id","1YRU"],["bp:db","protein data bank"]]],["bp:displayName","CAM"],["bp:name","HEL-S-72"],["bp:name","CAMII"],["bp:name","PHKD"],["bp:name","Phosphorylase kinase, delta"],["bp:name","CALML2"],["bp:name","calm_human"],["bp:name","Calmodulin"],["bp:name","CAMI"],["bp:name","CaM"],["bp:name","CAMC"],["bp:name","CAMB"],["bp:name","CAMIII"],["bp:name","UniProt:P62158 CALM1"],["bp:name","P62158"],["bp:name","CAM3"],["bp:name","CAM2"],["bp:name","CAM1"],["bp:name","CALM"],["bp:name","CALM3"],["bp:name","CALM2"],["bp:name","CALM1"],["bp:name","PHKD3"],["bp:name","PHKD2"],["bp:comment","MISCELLANEOUS This protein has four functional calcium-binding sites."],["bp:comment","REPLACED generic http://www.pantherdb.org/pathways/biopax/P06959#_CaM_PROTEIN"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9159"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_9159"]]}},{"data":{"id":"Protein_ef80db43845677b1e05acc7880705290","class":"macromolecule","label":"Edema factor (3 molecules)","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":437.48343,"y":264.4547,"w":48,"h":25},"metadata":[["bp:displayName","Edema factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P40136",[["bp:xref",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P40136"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","cya"],["bp:name","BXA0141"],["bp:name","Edema factor"],["bp:name","UniProt:P40136 cya"],["bp:name","GBAA_pXO1_0142"],["bp:name","pXO1-122"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. EF is a calmodulin-dependent adenylyl cyclase that, when associated with PA, causes edema. EF is not toxic by itself and it is required for the survival of germinated spores within macrophages at the early stages of infection. Provokes dramatic elevation of intracellular cAMP levels in the host.CATALYTIC ACTIVITY ATP = 3',5'-cyclic AMP + diphosphate.ENZYME REGULATION It has an absolute requirement for host calmodulin for its activation. Inhibited by ethyl 5-aminopyrazolo[1,5-a]quinazoline-3-carboxylate.SUBUNIT Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these is toxic by itself. PA+LF forms the lethal toxin (LeTx); PA+EF forms the edema toxin (EdTx). EF probably forms oligomers as part of the translocation machinery, formed by a heterocomplex of PA63 monomers and EF subunits, and it is functional as a monomer in the host cell.DOMAIN The N-terminal region contains the residues responsible for binding to PA63. The C-terminal region contains the calmodulin-dependent activation domain and the catalytic site. This region is composed of three globular domains: CA, CB and a helical domain connected to CA by a linker. The active site lies at the interface of CA and CB. The metal ion is coordinated by residues from CA; calmodulin probably binds in a multistep fashion first to residues in CA and then to residues present in the linker and the helical domain.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS EF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the hetero-oligomeric complex by receptor-mediated endocytosis. EF requires passage through an acidic vesicle for activity. At acidic pH, the pore is inserted into the membrane, allowing translocation of EF, which probably contributes actively to its own insertion into the membrane. EF remains associated to the vesicle membrane after translocation to the cytosol, with the catalytic domains being exposed on the cytoplasmic face."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89505"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":651.21967,"y":901.42084,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89471"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89471"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89471"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89471"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89471"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89466"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89466"]]}},{"data":{"id":"Protein_bf52215c50aa3837652ce37f0f7a1963","class":"macromolecule","label":"DEFA1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1494.2594,"y":1290.2595,"w":48,"h":25},"metadata":[["bp:displayName","Defensin alpha 1"],["bp:entityReference_http://identifiers.org/uniprot/P59665",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES ADP-ribosylarginine"],["bp:term","ADP-ribosylarginine"]]],["bp:comment","MOD_RES 78 78 ADP-ribosylarginine; by ART1."],["bp:featureLocation",[["bp:sequencePosition","78"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 85 85 Phosphotyrosine."],["bp:featureLocation",[["bp:sequencePosition","85"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 88 88 ADP-ribosylarginine; by ART1."],["bp:featureLocation",[["bp:sequencePosition","88"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Neutrophil defensin 1"],["bp:xref",[["bp:id","P59665"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","P59665"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","P59665"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P59665"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","DEF1_HUMAN"],["bp:name","DEFA2"],["bp:name","DEFA1"],["bp:name","DEF1"],["bp:name","Neutrophil defensin 2"],["bp:name","Defensin, alpha 1"],["bp:name","HP-2"],["bp:name","HP-1"],["bp:name","HP 1-56"],["bp:name","HNP-2"],["bp:name","HNP-1"],["bp:name","MRS"],["bp:name","HP1"],["bp:name","DEFA1B"],["bp:name","HP2"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_1667"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_1667"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_004075"],["bp:comment","DEF1_HUMAN Reviewed; 94 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00499_identity"],["bp:comment","FUNCTION: Defensin 1 and defensin 2 have antibacterial, fungicideand antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to killmicrobes by permeabilizing their plasma membrane.{ECO:0000269|PubMed:15616305, ECO:0000269|PubMed:17452329}.SUBUNIT: Dimer (PubMed:17452329). Interacts with RETN(PubMed:15064728). {ECO:0000269|PubMed:15064728,ECO:0000269|PubMed:17452329}.SUBCELLULAR LOCATION: Secreted.PTM: ADP-ribosylation drastically reduces cytotoxic andantibacterial activities, and enhances IL8 production.PTM: Phosphorylation at Tyr-85 has been found in some cancer celllines, and interferes with ADP-ribosylation.{ECO:0000269|PubMed:21904558}.SIMILARITY: Belongs to the alpha-defensin family. {ECO:0000305}. COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89656"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89656"]]}},{"data":{"id":"SmallMolecule_9b22836354cdf8aea3eff63fd02770a2","class":"simple chemical","label":"Ca2+","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":911.8999,"y":295.1566,"w":48,"h":20},"metadata":[["bp:displayName","Ca2+"],["bp:entityReference_#SmallMoleculeReference_872fa74c97864800541ad5fffd0ef1b0",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1122"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":261.29994,"y":257.09067,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Channel"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:name","PA63/Cellular Receptors"],["bp:name","PA63/Cellular Receptors (Heptamer)"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89661"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Channel"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:name","PA63/Cellular Receptors"],["bp:name","PA63/Cellular Receptors (Heptamer)"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89661"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89660"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89660"]]}},{"data":{"id":"Complex_0cc29c9365910b581e2d7970e350a3f4","class":"complex","label":"Channel","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":345.61804,"y":327.89038,"w":52,"h":64},"metadata":[["bp:displayName","Channel"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:component",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89525"],["bp:stoichiometricCoefficient","1.0"]]],["bp:name","PA63/Cellular Receptors"],["bp:name","PA63/Cellular Receptors (Heptamer)"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89510"]]}},{"data":{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_0cc29c9365910b581e2d7970e350a3f4","class":"macromolecule","label":"PA63","parent":"Complex_0cc29c9365910b581e2d7970e350a3f4","clonemarker":false,"stateVariables":[{"id":"Protein_c3127a3cfa59fcfbd7d8cccc67d15ace_Complex_0cc29c9365910b581e2d7970e350a3f4.info.1","class":"state variable","state":{"variable":"","value":"x[197 - 764]"}}],"unitsOfInformation":[],"bbox":{"x":345.61804,"y":310.39038,"w":48,"h":25},"metadata":[["bp:displayName","PA63"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89514"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","764"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89516"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","197"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_9639"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89515"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89511"]]}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8_Complex_0cc29c9365910b581e2d7970e350a3f4","class":"macromolecule","label":"PA Cellular Receptors","parent":"Complex_0cc29c9365910b581e2d7970e350a3f4","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":345.61804,"y":345.39038,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","TEM8"],["bp:entityReference_http://identifiers.org/uniprot/Q9H6X2",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 362 362 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","362"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Anthrax toxin receptor 1"],["bp:xref",[["bp:id","Q9H6X2"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","ANTXR1"],["bp:db","hgnc symbol"]]],["bp:displayName","ANTR1_HUMAN"],["bp:name","ATR"],["bp:name","Tumor endothelial marker 8"],["bp:name","ANTXR1"],["bp:name","TEM8"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_84168"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_05913_identity"],["bp:comment","FUNCTION: Plays a role in cell attachment and migration. Interactswith extracellular matrix proteins and with the actincytoskeleton. Mediates adhesion of cells to type 1 collagen andgelatin, reorganization of the actin cytoskeleton and promotescell spreading. Plays a role in the angiogenic response ofcultured umbilical vein endothelial cells.{ECO:0000269|PubMed:15777794, ECO:0000269|PubMed:16762926}.SUBUNIT: Interacts with gelatin and type 1 collagen. Interactswith the actin cytoskeleton. Binds to the protective antigen (PA)of Bacillus anthracis. Binding does not occur in the presence ofcalcium. {ECO:0000269|PubMed:11700562,ECO:0000269|PubMed:12700348, ECO:0000269|PubMed:15777794,ECO:0000269|PubMed:16762926, ECO:0000269|PubMed:20585457}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16762926};Single-pass type I membrane protein {ECO:0000269|PubMed:16762926}.Cell projection, lamellipodium membrane{ECO:0000269|PubMed:16762926}; Single-pass type I membrane protein{ECO:0000269|PubMed:16762926}. Cell projection, filopodiummembrane {ECO:0000269|PubMed:16762926}; Single-pass type Imembrane protein {ECO:0000269|PubMed:16762926}. Note=At themembrane of lamellipodia and at the tip of actin-enrichedfilopodia. Colocalizes with actin at the base of lamellipodia.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=6;Comment=Experimental confirmation may be lacking for someisoforms.;Name=1;IsoId=Q9H6X2-1; Sequence=Displayed;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=2;IsoId=Q9H6X2-2; Sequence=VSP_000444, VSP_000445;Name=3;IsoId=Q9H6X2-3; Sequence=VSP_000446, VSP_000447;Note=No experimental confirmation available.;Name=4;IsoId=Q9H6X2-4; Sequence=VSP_000448, VSP_000449;Name=5; Synonyms=V4;IsoId=Q9H6X2-5; Sequence=VSP_047865;Name=6; Synonyms=V5;IsoId=Q9H6X2-6; Sequence=VSP_047863, VSP_047864;Note=Prostate-specific.;TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells(at protein level). Highly expressed in tumor endothelial cells.{ECO:0000269|PubMed:15777794}.INDUCTION: Up-regulated in cultured angiogenic umbilical veinendothelial cells. {ECO:0000269|PubMed:15777794}.DOMAIN: Binding to PA occurs through the VWA domain.DISEASE: Hemangioma, capillary infantile (HCI) [MIM:602089]: Acondition characterized by dull red, firm, dome-shapedhemangiomas, sharply demarcated from surrounding skin, usuallypresenting at birth or occurring within the first two or threemonths of life. They result from highly proliferative, localizedgrowth of capillary endothelium and generally undergo regressionand involution without scarring. {ECO:0000269|PubMed:18931684}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: GAPO syndrome (GAPO) [MIM:230740]: A diseasecharacterized by growth retardation, alopecia, failure of tootheruption, and progressive optic atrophy in some patients.{ECO:0000269|PubMed:23602711}. Note=The disease is caused bymutations affecting the gene represented in this entry.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA91707.1; Type=Miscellaneous discrepancy; Note=Erroneous initiation (Translation N-terminally extended) due to a conflict with the genome, including a frameshift.; Evidence={ECO:0000305};Sequence=BAB15128.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/Q9H6X2-1"],["bp:comment","ANTR1_HUMAN Reviewed; 564 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89524"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:memberPhysicalEntity",[["bp:displayName","CMG2"],["bp:entityReference_http://identifiers.org/uniprot/P58335",[["bp:entityFeature",null],["bp:standardName","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:xref","Anthrax toxin receptor 2"],["bp:organism","Anthrax toxin receptor 2"],["bp:displayName","ANTR2_HUMAN"],["bp:name","Capillary morphogenesis gene 2 protein"],["bp:name","ANTXR2"],["bp:name","CMG-2"],["bp:name","CMG2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-32476N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07452_identity"],["bp:comment","FUNCTION: Necessary for cellular interactions with laminin and theextracellular matrix. {ECO:0000269|PubMed:11683410,ECO:0000269|PubMed:12973667}.SUBUNIT: Binds laminin, and possibly also collagen type IV. Bindsto the protective antigen (PA) of Bacillus anthracis in a divalentcation-dependent manner, with the following preference: calcium >manganese > magnesium > zinc. Binding of PA leads toheptamerization of the receptor-PA complex.SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type Imembrane protein. Note=Expressed at the cell surface.SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum membrane;Single-pass type I membrane protein. Note=Expressed predominantlywithin the endoplasmic reticulum and not at the plasma membrane.SUBCELLULAR LOCATION: Isoform 3: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=4;Name=1;IsoId=P58335-1; Sequence=Displayed;Name=2;IsoId=P58335-2; Sequence=VSP_008343;Name=3;IsoId=P58335-3; Sequence=VSP_008344, VSP_008345;Note=May be produced at very low levels due to a premature stopcodon in the mRNA, leading to nonsense-mediated mRNA decay.;Name=4;IsoId=P58335-4; Sequence=VSP_008346;TISSUE SPECIFICITY: Expressed in prostate, thymus, ovary, testis,pancreas, colon, heart, kidney, lung, liver, peripheral bloodleukocytes, placenta, skeletal muscle, small intestine and spleen.{ECO:0000269|PubMed:14508707}.DOMAIN: Binding to PA seems to be effected through the VWA domain.DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: Anautosomal recessive syndrome characterized by abnormal growth ofhyalinized fibrous tissue usually affecting subcutaneous regionson the scalp, ears, neck, face, hands, and feet. The lesionsappear as pearly papules or fleshy nodules. Additional featuresinclude gingival hypertrophy, progressive joint contracturesresulting in severe limitation of mobility, osteopenia, andosteoporosis. Disease severity is variable. Some individualsmanifest symptoms in infancy and have additional visceral orsystemic involvement. Hyaline deposits in multiple organs,recurrent infections and intractable diarrhea often lead to earlydeath. Surviving children may suffer from severely reducedmobility due to joint contractures. Other patients have lateronset of a milder disorder affecting only the face and digits.{ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707,ECO:0000269|PubMed:15725249}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Upon binding of the protective antigen (PA) ofBacillus anthracis the complex moves to glycosphingolipid-richlipid rafts, where it is internalized via a clathrin-dependentpathway. In the endosomal membrane, at pH under 7, the complexthen rearranges and forms a pore allowing the other components ofanthrax toxin to escape to the cytoplasm.SIMILARITY: Belongs to the ATR family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAY40907.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};Sequence=BAB70976.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=BAD93150.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_477520"],["bp:comment","ANTR2_HUMAN Reviewed; 489 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_118429"],["bp:comment","REPLACED http://identifiers.org/uniprot/P13423"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P58335-1"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011529889"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89523"]]],["bp:displayName","PA Cellular Receptors"],["bp:entityReference_#ProteinReference_12785bb23c81307cf5226e3374f5d004","PA Cellular Receptors"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89625"]]}},{"data":{"id":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":867.46387,"y":214.76712,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","cAMP"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:17489",[["bp:standardName","adenosine 3',5'-(hydrogen phosphate)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:61296"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19834"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:19827"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:58165"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:17489"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76971"],["bp:db","chebi"]]],["bp:chemicalFormula","C10H12N5O6P"],["bp:displayName","3',5'-cyclic AMP"],["bp:name","CHEBI:17489"],["bp:name","3',5'-Cyclic AMP"],["bp:name","ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE"],["bp:name","cAMP"],["bp:name","Adenosine 3',5'-phosphate"],["bp:name","Adenosine 3',5'-cyclic phosphate"],["bp:name","C10H12N5O6P"],["bp:name","adenosine 3',5'-cyclic monophosphate"],["bp:name","Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1O"],["bp:name","Cyclic adenylic acid"],["bp:name","Cyclic AMP"],["bp:molecularWeight","329.053"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:19834"],["bp:comment","A 3',5'-cyclic purine nucleotide having having adenine as the nucleobase."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_bf56be77e64db9fb2269a064c22ba4c3"],["bp:comment","REPLACED http://identifiers.org/hmdb/HMDB00058"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1924"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB02527"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5b8a75aeda504bac462d3b44c1796e67"],["bp:comment","is_a CHEBI:61296"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d000242"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00575.eref"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/SmallMoleculeReference_5a93a42a9dc980130aa64519d09e62c4"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100024_cAMP"],["bp:comment","is_conjugate_acid_of CHEBI:58165"],["bp:comment","has_role CHEBI:77746"],["bp:comment","REPLACED http://identifiers.org/cas/60-92-4"],["bp:structure","REPLACED http://identifiers.org/cas/60-92-4"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1923"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89722"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89720"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89720"]]}},{"data":{"id":"Protein_0d32fa56842fc6735647a989fc43bd18","class":"macromolecule","label":"IL1B","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_0d32fa56842fc6735647a989fc43bd18.info.1","class":"state variable","state":{"variable":"","value":"Act"}},{"id":"Protein_0d32fa56842fc6735647a989fc43bd18.state.2","class":"state variable","state":{"variable":"","value":"x[117 - 269]"}}],"unitsOfInformation":[],"bbox":{"x":420.0129,"y":840.3432,"w":48,"h":25},"metadata":[["bp:displayName","IL1 beta fragment"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63549"]]],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63271"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","269"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_22309"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","117"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_18758"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63272"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P01584",[["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01584"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01584"]]],["bp:standardName","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:xref","Interleukin-1 beta"],["bp:organism","Interleukin-1 beta"],["bp:displayName","IL1B_HUMAN"],["bp:name","IL-1 beta"],["bp:name","IL1B"],["bp:name","Catabolin"],["bp:name","IL1F2"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01584"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3553"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00985_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-474N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/3553"],["bp:comment","IL1B_HUMAN Reviewed; 269 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000567"],["bp:comment","FUNCTION: Potent proinflammatory cytokine. Initially discovered asthe major endogenous pyrogen, induces prostaglandin synthesis,neutrophil influx and activation, T-cell activation and cytokineproduction, B-cell activation and antibody production, andfibroblast proliferation and collagen production. Promotes Th17differentiation of T-cells. {ECO:0000269|PubMed:3920526}.SUBUNIT: Monomer. In its precursor form, weakly interacts withfull-length MEFV; the mature cytokine does not interact at all(PubMed:17431422). {ECO:0000269|PubMed:17431422,ECO:0000269|PubMed:20802483}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:15192144}. Lysosome{ECO:0000269|PubMed:15192144}. Secreted, exosome{ECO:0000250|UniProtKB:P10749}. Secreted{ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144}.Note=The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome orbacterial flagellin for NLRC4 inflammasome, cleaved and secreted.IL1B lacks any known signal sequence and the pathway(s) of itssecretion is(are) not yet fully understood (PubMed:24201029). Onthe basis of experimental results, several unconventionalsecretion mechanisms have been proposed. 1. Secretion viasecretory lysosomes: a fraction of CASP1 and IL1B precursor may beincorporated, by a yet undefined mechanism, into secretorylysosomes that undergo Ca(2+)-dependent exocytosis with release ofmature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes ormultivesicular bodies (MVBs) and then merge with the plasmamembrane releasing soluble IL1B or IL1B-containing exosomes(PubMed:24201029). However, autophagy impacts IL1B production atseveral levels and its role in secretion is still controversial.3. Secretion via exosomes: ATP-activation of P2RX7 leads to theformation of MVBs containing exosomes with entrapped IL1B, CASP1and other inflammasome components. These MVBs undergo exocytosiswith the release of exosomes. The release of soluble IL1B occursafter the lysis of exosome membranes (By similarity). 4. Secretionby microvesicle shedding: activation of the ATP receptor P2RX7 mayinduce an immediate shedding of membrane-derived microvesiclescontaining IL1B and possibly inflammasome components. The cytokineis then released in the extracellular compartment aftermicrovesicle lysis (PubMed:11728343). 5. Release by translocationthrough permeabilized plasma membrane. This may occur in cellsundergoing pyroptosis due to sustained activation of theinflammasome (By similarity). These mechanisms may not be notmutually exclusive. {ECO:0000250|UniProtKB:P10749,ECO:0000269|PubMed:11728343, ECO:0000269|PubMed:15192144,ECO:0000305|PubMed:24201029}.TISSUE SPECIFICITY: Expressed in activated monocytes/macrophages(at protein level). {ECO:0000269|PubMed:15192144}.INDUCTION: By LPS (PubMed:15192144). Transcription and translationinduced by M.tuberculosis and a number of different M.tuberculosiscomponents in macrophages; EsxA is the most potent activatortested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:15192144, ECO:0000269|PubMed:20148899}.PTM: Activation of the IL1B precursor involves a CASP1-catalyzedproteolytic cleavage. Processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.MISCELLANEOUS: The IL1B production occurs in 2 steps, each beingcontrolled by different stimuli. First, inflammatory signals, suchas LPS, stimulate the synthesis and promote the accumulation ofcytosolic stores of pro-IL1B (priming). Then additional signalsare required for inflammasome assembly, leading to CASP1activation, pro-IL1B processing and eventually secretion of theactive cytokine. IL1B processing and secretion are temporarilyassociated. {ECO:0000269|PubMed:15192144}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/IL1BID40950ch2q13.html\";WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/il1b/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL1B\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3553"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_63548"]]}},{"data":{"id":"Protein_80b38565780a9a6cbd4b39d8b614b11e","class":"macromolecule","label":"NLRP1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_80b38565780a9a6cbd4b39d8b614b11e.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":554.57745,"y":813.6401,"w":48,"h":25},"metadata":[["bp:displayName","Nalp 1b"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89448"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9C000",[["bp:standardName","NACHT, LRR and PYD domains-containing protein 1"],["bp:xref",[["bp:id","Q9C000"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:displayName","NLRP1_HUMAN"],["bp:name","NLRP1"],["bp:name","Death effector filament-forming ced-4-like apoptosis protein"],["bp:name","KIAA0926"],["bp:name","NAC"],["bp:name","CARD7"],["bp:name","Caspase recruitment domain-containing protein 7"],["bp:name","Nucleotide-binding domain and caspase recruitment domain"],["bp:name","NALP1"],["bp:name","DEFCAP"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_22861"],["bp:comment","FUNCTION: As the sensor component of the NLRP1 inflammasome, playsa crucial role in innate immunity and inflammation. In response topathogens and other damage-associated signals, initiates theformation of the inflammasome polymeric complex, made of NLRP1,CASP1, and possibly PYCARD. Recruitment of proCASP1 to theinflammasome promotes its activation and CASP1-catalyzed IL1B andIL18 maturation and secretion in the extracellular milieu.Activation of NLRP1 inflammasome is also required for HMGB1secretion. The active cytokines and HMGB1 stimulate inflammatoryresponses. Inflammasomes can also induce pyroptosis, aninflammatory form of programmed cell death (PubMed:22665479,PubMed:17418785). May be activated by muramyl dipeptide (MDP), afragment of bacterial peptidoglycan, in a NOD2-dependent manner(PubMed:18511561). Contrary to its mouse ortholog, not activatedby Bacillus anthracis lethal toxin (PubMed:19651869). It isunclear whether isoform 2 is involved in inflammasome formation.It is not cleaved within the FIIND domain, does not assemble intospecks, nor promote IL1B release (PubMed:22665479). However, in anvitro cell-free system, it has been shown to be activated by MDP(PubMed:17349957). Binds ATP (PubMed:11113115, PubMed:15212762).{ECO:0000250|UniProtKB:A1Z198, ECO:0000269|PubMed:11113115,ECO:0000269|PubMed:15212762, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:19651869, ECO:0000269|PubMed:22665479}.SUBUNIT: Sensor component of NLRP1 inflammasomes. Inflammasomesare supramolecular complexes that assemble in the cytosol inresponse to pathogens and other damage-associated signals and playcritical roles in innate immunity and inflammation. Classicalinflammasomes consist of a signal sensor component, an adapter(ASC/PYCARD), which recruits an effector proinflammatory caspase(CASP1 and CASP5). This interaction initiates speck formation(nucleation) which greatly enhances further addition of solublePYCARD molecules to the speck in a prion-like polymerizationprocess. CASP1 filament formation increases local enzymeconcentration, resulting in trans-autocleavage and activation.Active CASP1 then processes IL1B and IL18 precursors, leading tothe release of mature cytokines in the extracellular milieu andinflammatory response. In NLRP1 inflammasome, the role of PYCARDis not clear. Following activation, NLRP1 can directly interactwith CASP1 (possibly through CARD domain) to form a functionalinflammasome, although the presence of PYCARD increases CASP1activity (PubMed:17418785, PubMed:17349957). In a differentexperimental system, neither CASP1-binding, NLRP1 inflammasomespeck formation, nor IL1B release were observed in the absence ofPYCARD (PubMed:22665479, PubMed:12191486). Hence PYCARD may not benecessary for NLRP1 and CASP1 interaction, but is required forspeck formation and full inflammasome activity (By similarity).Homomer (PubMed:17349957). Interacts (via LRR repeats) with BCL2and BCL2L1 (via the loop between motifs BH4 and BH3); theseinteractions reduce NLRP1 inflammasome-induced CASP1 activationand IL1B release, possibly by impairing NLRP1 interaction withPYCARD (PubMed:17418785). Interacts with NOD2; this interaction isenhanced in the presence of muramyl dipeptide (MDP) and increasesIL1B release (PubMed:18511561). Interacts with EIF2AK2/PKR; thisinteraction requires EIF2AK2 activity, is accompanied by EIF2AK2autophosphorylation and promotes inflammasome assembly in responseto danger-associated signals (By similarity). Interacts with MEFV;this interaction targets NLRP1 to degradation by autophagy, hencepreventing excessive IL1B- and IL18-mediated inflammation(PubMed:17431422, PubMed:26347139). {ECO:0000250|UniProtKB:A1Z198,ECO:0000250|UniProtKB:Q2LKW6, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:17431422, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:22665479, ECO:0000269|PubMed:26347139}.SUBUNIT: (Microbial infection) Interacts with vaccinia virusprotein F1 (PubMed:16439990). {ECO:0000269|PubMed:16439990}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:17418785}. Cytoplasm{ECO:0000269|PubMed:17164409}. Inflammasome{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:22665479}.Nucleus {ECO:0000269|PubMed:17164409}. Note=Nucleocytoplasmicdistribution in lymphoid organs (probably in T-cells) and inneurons. In epithelial cells, predominantly cytoplasmic.{ECO:0000269|PubMed:17164409}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=7;Name=1; Synonyms=NAC beta, DEFCAP-L, NALP1-L{ECO:0000303|PubMed:15285719};IsoId=Q9C000-1; Sequence=Displayed;Name=2; Synonyms=NAC alpha, DEFCAP-S, NALP1-S{ECO:0000303|PubMed:15285719}, NLRP1deltaEx14;IsoId=Q9C000-2; Sequence=VSP_004327;Name=3; Synonyms=NAC gamma;IsoId=Q9C000-3; Sequence=VSP_004326, VSP_004327;Name=4; Synonyms=NAC delta;IsoId=Q9C000-4; Sequence=VSP_004326;Name=5;IsoId=Q9C000-5; Sequence=VSP_053803, VSP_053804, VSP_053805;Name=6;IsoId=Q9C000-6; Sequence=VSP_053802;Name=7;IsoId=Q9C000-7; Sequence=VSP_053801, VSP_053803, VSP_053804,VSP_053805;TISSUE SPECIFICITY: Widely expressed (PubMed:11113115,PubMed:17164409). Abundantly expressed in primary immune cells(isoform 1 and isoform 2), including in neutrophils,monocytes/macrophages, dendritic cells (mostly Langerhans cells),and B- and T-lymphocytes (at protein level) (PubMed:15285719,PubMed:17164409). Strongly expressed in epithelial cells liningthe glandular epithelium, such as that of the gastrointestinaltract (stomach, small intestine, colon), the respiratory tract(trachea and bronchi), and the endometrial and endocervicalglands, gallbladder, prostate, and breast (at protein level). Intestis, expressed in spermatogonia and primary spermatocytes, butnot in Sertoli cells (at protein level). In the brain, expressedin neurons, in particular in pyramidal ones and inoligodendrocytes, but not detected in microglia (at protein level)(PubMed:17164409). Expressed in adult and fetal ocular tissues,including in adult and 24-week old fetal choroid, sclera, cornea,and optic nerve, as well as in adult retina and fetalretina/retinal pigment epithelium (PubMed:23349227).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409, ECO:0000269|PubMed:23349227}.DEVELOPMENTAL STAGE: Associated with differentiation in stratifiedepithelia of the skin, esophagus, intestine, and cervix, as wellas in the prostate gland. Undetectable in undifferentiated basalcells, but expressed in differentiated luminal secretory cells(PubMed:11113115). Expressed in differentiated macrophages andgranulocytes, but not their precursors (at protein level)(PubMed:11113115, PubMed:15285719). In testis, also associatedwith cell differentiation, with conflicting results. Expressed inspermatogonia and primary spermatocytes, but not in cells fromlater differentiation stages, including secondary spermatocytes,spermatids, and spermatozoa (at protein level) (PubMed:17164409).Not detected in spermatocytes, nor spermatids, and stronglyexpressed in spermatozoa (at protein level) (PubMed:11113115).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409}.INDUCTION: Up-regulated by ATF4 during endoplasmic reticulum (ER)stress response (PubMed:26086088). Up-regulated in arterialendothelial cells exposed to plasma from patients with peripheralarterial disease, but not to plasma from healthy controls(PubMed:24439873). {ECO:0000269|PubMed:24439873,ECO:0000269|PubMed:26086088}.DOMAIN: The CARD domain, rather than the pyrin domain, is involvedin the interaction with PYCARD, CASP1 and CASP5.{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:22665479}.DOMAIN: The leucine-rich repeat (LRR) domain may be involved inautoinhibition in the absence of activating signal, possiblythrough intramolecular interaction with the NACHT domain.{ECO:0000250|UniProtKB:Q9EPB4, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957}.DOMAIN: The FIIND (domain with function to find) region isinvolved in homomerization, but not in CASP1-binding (Bysimilarity). Autocatalytic cleavage in this region occursconstitutively, prior to activation signals, and is required forinflammasome activity (IL1B release), possibly by facilitatingCASP1 binding. Both N- and C-terminal fragments remain associated(PubMed:22665479, PubMed:22087307). {ECO:0000250|UniProtKB:Q2LKW6,ECO:0000269|PubMed:22087307, ECO:0000269|PubMed:22665479}.DISEASE: Vitiligo-associated multiple autoimmune disease 1(VAMAS1) [MIM:606579]: A disorder characterized by the associationof vitiligo with several autoimmune and autoinflammatory diseasesincluding autoimmune thyroid disease, rheumatoid arthritis andsystemic lupus erythematosus. {ECO:0000269|PubMed:17377159}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Palmoplantar carcinoma, multiple self-healing (MSPC)[MIM:615225]: An autosomal dominant disease characterized bykeratopathy with neovascularization, bilateral cornealopacification, palmoplantar hyperkeratosis, dyshidrosis,dystrophic nails, and recurrent keratoacanthomas in palmoplantarskin as well as in conjunctival and corneal epithelia. Inaddition, patients experience a high susceptibility to malignantsquamous cell carcinoma. {ECO:0000269|PubMed:23349227}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.MISCELLANEOUS: In macrophages and dendritic cells, NLRP1inflammasome activation of CASP1 and IL1B maturation can bedampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, suchas CD40LG. {ECO:0000250|UniProtKB:Q2LKW6}.SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA76770.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};Sequence=BAB15469.1; Type=Frameshift; Positions=1241; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-38407N_identity"],["bp:comment","NLRP1_HUMAN Reviewed; 1473 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_127497"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07364_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89447"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_ae18bb0c7fb20e92441b843d6a51f500","class":"macromolecule","label":"PGR","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_ae18bb0c7fb20e92441b843d6a51f500.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":633.30853,"y":1103.9963,"w":48,"h":25},"metadata":[["bp:displayName","Progesterone Receptor"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89735"]]],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89734"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89734"]]}},{"data":{"id":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7","class":"simple chemical","label":"LPS","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1131.8145,"y":1473.5272,"w":48,"h":20},"metadata":[["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:89981"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:52603"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:16412"],["bp:db","chebi"]]],["bp:displayName","LPS"],["bp:entityReference_#SmallMoleculeReference_1cab2055c77aed5a2121cdb3f9cb7656",[]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_46267"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","class":"simple chemical","label":"Epigallocatechin-3-gallate (EGCG)","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1383.2452,"y":1259.4712,"w":48,"h":20},"metadata":[["bp:displayName","Epigallocatechin-3-gallate (EGCG)"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:4806",[["bp:standardName","(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:42255"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63962"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35610"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:26195"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:23053"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:63726"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:4806"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:76924"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:22586"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:22586"],["bp:db","chebi"]]],["bp:chemicalFormula","C22H18O11"],["bp:displayName","(-)-epigallocatechin 3-gallate"],["bp:name","EGCG"],["bp:name","(-)-epigallocatechin-3-O-gallate"],["bp:name","Epigallocatechin 3-gallate"],["bp:name","C22H18O11"],["bp:name","Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1"],["bp:name","[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate"],["bp:name","CHEBI:4806"],["bp:molecularWeight","458.3717"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89482"],["bp:comment","has_role CHEBI:76924"],["bp:comment","has_functional_parent CHEBI:42255"],["bp:comment","is_a CHEBI:26195"],["bp:comment","is_a CHEBI:23053"],["bp:comment","has_role CHEBI:63726"],["bp:comment","has_role CHEBI:22586"],["bp:comment","has_role CHEBI:35610"],["bp:comment","has_role CHEBI:63962"],["bp:comment","A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin."],["bp:comment","is_a CHEBI:37576"],["bp:structure","is_a CHEBI:37576"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89481"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89481"]]}},{"data":{"id":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":663.2355,"y":1021.5031,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PGRB"],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:name","PGRA"],["bp:name","Progesterone Receptor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","PGRB"],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:name","PGRA"],["bp:name","Progesterone Receptor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","PGRB"],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:name","PGRA"],["bp:name","Progesterone Receptor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","PGRB"],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:name","PGRA"],["bp:name","Progesterone Receptor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89736"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89730"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89730"]]}},{"data":{"id":"Protein_7b5bedaf1d5cfe7f0ada582e5773c6b1","class":"macromolecule","label":"IL18","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":260.62604,"y":727.9205,"w":48,"h":25},"metadata":[["bp:displayName","IL18"],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","IL18"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","IL18"],["bp:db","hgnc symbol"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_8813"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":627.31683,"y":815.51355,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89448"]]],["bp:entityReference_http://identifiers.org/uniprot/Q9C000",[["bp:standardName","NACHT, LRR and PYD domains-containing protein 1"],["bp:xref",[["bp:id","Q9C000"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:displayName","NLRP1_HUMAN"],["bp:name","NLRP1"],["bp:name","Death effector filament-forming ced-4-like apoptosis protein"],["bp:name","KIAA0926"],["bp:name","NAC"],["bp:name","CARD7"],["bp:name","Caspase recruitment domain-containing protein 7"],["bp:name","Nucleotide-binding domain and caspase recruitment domain"],["bp:name","NALP1"],["bp:name","DEFCAP"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_22861"],["bp:comment","FUNCTION: As the sensor component of the NLRP1 inflammasome, playsa crucial role in innate immunity and inflammation. In response topathogens and other damage-associated signals, initiates theformation of the inflammasome polymeric complex, made of NLRP1,CASP1, and possibly PYCARD. Recruitment of proCASP1 to theinflammasome promotes its activation and CASP1-catalyzed IL1B andIL18 maturation and secretion in the extracellular milieu.Activation of NLRP1 inflammasome is also required for HMGB1secretion. The active cytokines and HMGB1 stimulate inflammatoryresponses. Inflammasomes can also induce pyroptosis, aninflammatory form of programmed cell death (PubMed:22665479,PubMed:17418785). May be activated by muramyl dipeptide (MDP), afragment of bacterial peptidoglycan, in a NOD2-dependent manner(PubMed:18511561). Contrary to its mouse ortholog, not activatedby Bacillus anthracis lethal toxin (PubMed:19651869). It isunclear whether isoform 2 is involved in inflammasome formation.It is not cleaved within the FIIND domain, does not assemble intospecks, nor promote IL1B release (PubMed:22665479). However, in anvitro cell-free system, it has been shown to be activated by MDP(PubMed:17349957). Binds ATP (PubMed:11113115, PubMed:15212762).{ECO:0000250|UniProtKB:A1Z198, ECO:0000269|PubMed:11113115,ECO:0000269|PubMed:15212762, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:19651869, ECO:0000269|PubMed:22665479}.SUBUNIT: Sensor component of NLRP1 inflammasomes. Inflammasomesare supramolecular complexes that assemble in the cytosol inresponse to pathogens and other damage-associated signals and playcritical roles in innate immunity and inflammation. Classicalinflammasomes consist of a signal sensor component, an adapter(ASC/PYCARD), which recruits an effector proinflammatory caspase(CASP1 and CASP5). This interaction initiates speck formation(nucleation) which greatly enhances further addition of solublePYCARD molecules to the speck in a prion-like polymerizationprocess. CASP1 filament formation increases local enzymeconcentration, resulting in trans-autocleavage and activation.Active CASP1 then processes IL1B and IL18 precursors, leading tothe release of mature cytokines in the extracellular milieu andinflammatory response. In NLRP1 inflammasome, the role of PYCARDis not clear. Following activation, NLRP1 can directly interactwith CASP1 (possibly through CARD domain) to form a functionalinflammasome, although the presence of PYCARD increases CASP1activity (PubMed:17418785, PubMed:17349957). In a differentexperimental system, neither CASP1-binding, NLRP1 inflammasomespeck formation, nor IL1B release were observed in the absence ofPYCARD (PubMed:22665479, PubMed:12191486). Hence PYCARD may not benecessary for NLRP1 and CASP1 interaction, but is required forspeck formation and full inflammasome activity (By similarity).Homomer (PubMed:17349957). Interacts (via LRR repeats) with BCL2and BCL2L1 (via the loop between motifs BH4 and BH3); theseinteractions reduce NLRP1 inflammasome-induced CASP1 activationand IL1B release, possibly by impairing NLRP1 interaction withPYCARD (PubMed:17418785). Interacts with NOD2; this interaction isenhanced in the presence of muramyl dipeptide (MDP) and increasesIL1B release (PubMed:18511561). Interacts with EIF2AK2/PKR; thisinteraction requires EIF2AK2 activity, is accompanied by EIF2AK2autophosphorylation and promotes inflammasome assembly in responseto danger-associated signals (By similarity). Interacts with MEFV;this interaction targets NLRP1 to degradation by autophagy, hencepreventing excessive IL1B- and IL18-mediated inflammation(PubMed:17431422, PubMed:26347139). {ECO:0000250|UniProtKB:A1Z198,ECO:0000250|UniProtKB:Q2LKW6, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:17431422, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:22665479, ECO:0000269|PubMed:26347139}.SUBUNIT: (Microbial infection) Interacts with vaccinia virusprotein F1 (PubMed:16439990). {ECO:0000269|PubMed:16439990}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:17418785}. Cytoplasm{ECO:0000269|PubMed:17164409}. Inflammasome{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:22665479}.Nucleus {ECO:0000269|PubMed:17164409}. Note=Nucleocytoplasmicdistribution in lymphoid organs (probably in T-cells) and inneurons. In epithelial cells, predominantly cytoplasmic.{ECO:0000269|PubMed:17164409}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=7;Name=1; Synonyms=NAC beta, DEFCAP-L, NALP1-L{ECO:0000303|PubMed:15285719};IsoId=Q9C000-1; Sequence=Displayed;Name=2; Synonyms=NAC alpha, DEFCAP-S, NALP1-S{ECO:0000303|PubMed:15285719}, NLRP1deltaEx14;IsoId=Q9C000-2; Sequence=VSP_004327;Name=3; Synonyms=NAC gamma;IsoId=Q9C000-3; Sequence=VSP_004326, VSP_004327;Name=4; Synonyms=NAC delta;IsoId=Q9C000-4; Sequence=VSP_004326;Name=5;IsoId=Q9C000-5; Sequence=VSP_053803, VSP_053804, VSP_053805;Name=6;IsoId=Q9C000-6; Sequence=VSP_053802;Name=7;IsoId=Q9C000-7; Sequence=VSP_053801, VSP_053803, VSP_053804,VSP_053805;TISSUE SPECIFICITY: Widely expressed (PubMed:11113115,PubMed:17164409). Abundantly expressed in primary immune cells(isoform 1 and isoform 2), including in neutrophils,monocytes/macrophages, dendritic cells (mostly Langerhans cells),and B- and T-lymphocytes (at protein level) (PubMed:15285719,PubMed:17164409). Strongly expressed in epithelial cells liningthe glandular epithelium, such as that of the gastrointestinaltract (stomach, small intestine, colon), the respiratory tract(trachea and bronchi), and the endometrial and endocervicalglands, gallbladder, prostate, and breast (at protein level). Intestis, expressed in spermatogonia and primary spermatocytes, butnot in Sertoli cells (at protein level). In the brain, expressedin neurons, in particular in pyramidal ones and inoligodendrocytes, but not detected in microglia (at protein level)(PubMed:17164409). Expressed in adult and fetal ocular tissues,including in adult and 24-week old fetal choroid, sclera, cornea,and optic nerve, as well as in adult retina and fetalretina/retinal pigment epithelium (PubMed:23349227).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409, ECO:0000269|PubMed:23349227}.DEVELOPMENTAL STAGE: Associated with differentiation in stratifiedepithelia of the skin, esophagus, intestine, and cervix, as wellas in the prostate gland. Undetectable in undifferentiated basalcells, but expressed in differentiated luminal secretory cells(PubMed:11113115). Expressed in differentiated macrophages andgranulocytes, but not their precursors (at protein level)(PubMed:11113115, PubMed:15285719). In testis, also associatedwith cell differentiation, with conflicting results. Expressed inspermatogonia and primary spermatocytes, but not in cells fromlater differentiation stages, including secondary spermatocytes,spermatids, and spermatozoa (at protein level) (PubMed:17164409).Not detected in spermatocytes, nor spermatids, and stronglyexpressed in spermatozoa (at protein level) (PubMed:11113115).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409}.INDUCTION: Up-regulated by ATF4 during endoplasmic reticulum (ER)stress response (PubMed:26086088). Up-regulated in arterialendothelial cells exposed to plasma from patients with peripheralarterial disease, but not to plasma from healthy controls(PubMed:24439873). {ECO:0000269|PubMed:24439873,ECO:0000269|PubMed:26086088}.DOMAIN: The CARD domain, rather than the pyrin domain, is involvedin the interaction with PYCARD, CASP1 and CASP5.{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:22665479}.DOMAIN: The leucine-rich repeat (LRR) domain may be involved inautoinhibition in the absence of activating signal, possiblythrough intramolecular interaction with the NACHT domain.{ECO:0000250|UniProtKB:Q9EPB4, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957}.DOMAIN: The FIIND (domain with function to find) region isinvolved in homomerization, but not in CASP1-binding (Bysimilarity). Autocatalytic cleavage in this region occursconstitutively, prior to activation signals, and is required forinflammasome activity (IL1B release), possibly by facilitatingCASP1 binding. Both N- and C-terminal fragments remain associated(PubMed:22665479, PubMed:22087307). {ECO:0000250|UniProtKB:Q2LKW6,ECO:0000269|PubMed:22087307, ECO:0000269|PubMed:22665479}.DISEASE: Vitiligo-associated multiple autoimmune disease 1(VAMAS1) [MIM:606579]: A disorder characterized by the associationof vitiligo with several autoimmune and autoinflammatory diseasesincluding autoimmune thyroid disease, rheumatoid arthritis andsystemic lupus erythematosus. {ECO:0000269|PubMed:17377159}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Palmoplantar carcinoma, multiple self-healing (MSPC)[MIM:615225]: An autosomal dominant disease characterized bykeratopathy with neovascularization, bilateral cornealopacification, palmoplantar hyperkeratosis, dyshidrosis,dystrophic nails, and recurrent keratoacanthomas in palmoplantarskin as well as in conjunctival and corneal epithelia. Inaddition, patients experience a high susceptibility to malignantsquamous cell carcinoma. {ECO:0000269|PubMed:23349227}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.MISCELLANEOUS: In macrophages and dendritic cells, NLRP1inflammasome activation of CASP1 and IL1B maturation can bedampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, suchas CD40LG. {ECO:0000250|UniProtKB:Q2LKW6}.SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA76770.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};Sequence=BAB15469.1; Type=Frameshift; Positions=1241; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-38407N_identity"],["bp:comment","NLRP1_HUMAN Reviewed; 1473 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_127497"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07364_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89447"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89450"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000","Nalp 1b"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89449"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89443"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89443"]]}},{"data":{"id":"Protein_12ce91dd41f0737ffb0898c71af2f854","class":"macromolecule","label":"TNF","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1220.2275,"y":1494.0182,"w":48,"h":25},"metadata":[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref",[["bp:relationshipType",null],["bp:id","TNF"],["bp:db","hgnc symbol"]]],["bp:xref",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","P01375"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]}},{"data":{"id":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":343.90964,"y":771.91315,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IL18 fragment"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89753"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","37"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6505"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89754"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89752"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89756"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","IL18 fragment"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89753"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","37"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6505"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89754"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89752"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89756"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","IL18 fragment"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89753"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","37"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6505"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89754"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89752"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89756"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","IL18 fragment"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89753"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","37"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6505"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89754"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89752"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89756"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89749"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89749"]]}},{"data":{"id":"Protein_9ad1fe91c68525293ccc9fa8cd5986e0","class":"macromolecule","label":"PGR","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":567.6443,"y":954.4583,"w":48,"h":25},"metadata":[["bp:displayName","PGRB"],["bp:entityReference_http://identifiers.org/uniprot/P06401",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 294 294 Phosphoserine; by MAPK1."],["bp:featureLocation",[["bp:sequencePosition","294"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 213 213 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","213"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 162 162 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","162"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 400 400 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","400"],["bp:positionStatus","EQUAL"]]]]],["bp:standardName","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:xref","Progesterone receptor"],["bp:organism","Progesterone receptor"],["bp:displayName","PRGR_HUMAN"],["bp:name","PGR"],["bp:name","Nuclear receptor subfamily 3 group C member 3"],["bp:name","PR"],["bp:name","NR3C3"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SQN_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5241"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_5241"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_5241_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5967N_identity"],["bp:comment","FUNCTION: The steroid hormones and their receptors are involved inthe regulation of eukaryotic gene expression and affect cellularproliferation and differentiation in target tissues. Depending onthe isoform, progesterone receptor functions as transcriptionalactivator or repressor. {ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:1587864, ECO:0000269|PubMed:9407067,ECO:0000305}.FUNCTION: Isoform A: Ligand-dependent transdominant repressor ofsteroid hormone receptor transcriptional activity includingrepression of its isoform B, MR and ER. Transrepressional activitymay involve recruitment of corepressor NCOR2.{ECO:0000269|PubMed:7969170, ECO:0000269|PubMed:8180103,ECO:0000269|PubMed:8264658, ECO:0000305,ECO:0000305|PubMed:10757795}.FUNCTION: Isoform B: Transcriptional activator of severalprogesteron-dependent promoters in a variety of cell types.Involved in activation of SRC-dependent MAPK signaling on hormonestimulation. {ECO:0000269|PubMed:7969170}.FUNCTION: Isoform 4: Increases mitochondrial membrane potentialand cellular respiration upon stimulation by progesterone.SUBUNIT: Interacts with SMARD1 and UNC45A. Interacts with CUEDC2;the interaction promotes ubiquitination, decreases sumoylation,and repesses transcriptional activity. Interacts with PIAS3; theinteraction promotes sumoylation of PR in a hormone-dependentmanner, inhibits DNA-binding, and alters nuclear export. Interactswith SP1; the interaction requires ligand-induced phosphorylationon Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform Ainteracts with NCOR2. Isoform B (but not isoform A) interacts withNCOA2 and NCOA1. Isoform B (but not isoform A) interacts withKLF9. {ECO:0000250|UniProtKB:Q00175, ECO:0000269|PubMed:10757795,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12917342,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:18202149}.SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nucleoplasmicshuttling is both homone- and cell cycle-dependent. On hormonestimulation, retained in the cytoplasm in the G(1) and G(2)/Mphases.SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainlynuclear.SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane{ECO:0000269|PubMed:23518922}.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;Name=B; Synonyms=PRB, PR-B;IsoId=P06401-1; Sequence=Displayed;Note=Produced by alternative promoter usage.;Name=A; Synonyms=PRA, PR-A;IsoId=P06401-2; Sequence=VSP_003706;Note=Produced by alternative promoter usage.;Name=3;IsoId=P06401-3; Sequence=VSP_046942;Note=Produced by alternative splicing of isoform B.;Name=4; Synonyms=PR-M;IsoId=P06401-4; Sequence=VSP_047454, VSP_047455;Note=Produced by alternative promoter usage.;Name=5; Synonyms=delta4;IsoId=P06401-5; Sequence=VSP_053543;Note=Produced by alternative splicing of isoform B.;TISSUE SPECIFICITY: In reproductive tissues the expression ofisoform A and isoform B varies as a consequence of developmentaland hormonal status. Isoform A and isoform B are expressed incomparable levels in uterine glandular epithelium during theproliferative phase of the menstrual cycle. Expression of isoformB but not of isoform A persists in the glands during mid-secretoryphase. In the stroma, isoform A is the predominant form throughoutthe cycle. Heterogeneous isoform expression between the glands ofthe endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.{ECO:0000269|PubMed:11041221}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain.PTM: Phosphorylated on multiple serine sites. Several of thesesites are hormone-dependent. Phosphorylation on Ser-294 occurspreferentially on isoform B, is highly hormone-dependent andmodulates ubiquitination and sumoylation on Lys-388.Phosphorylation on Ser-102 and Ser-345 also requires induction byhormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 andSer-400 is increased in response to progesterone and can bephosphorylated in vitro by the CDK2-A1 complex. Increased levelsof phosphorylation on Ser-400 also in the presence of EGF,heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2is ligand-independent, and increases nuclear translocation andtranscriptional activity. Phosphorylation at Ser-162 and Ser-294,but not at Ser-190, is impaired during the G(2)/M phase of thecell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is requiredfor interaction with SP1. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:11110801,ECO:0000269|PubMed:15572662, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17020914, ECO:0000269|PubMed:17173941,ECO:0000269|PubMed:17347654, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:7476977,ECO:0000269|PubMed:8702648, ECO:0000269|PubMed:9171245}.PTM: Sumoylation is hormone-dependent and repressestranscriptional activity. Sumoylation on all three sites isenhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388,the main site of sumoylation, is repressed by ubiquitination onthe same site, and modulated by phosphorylation at Ser-294.{ECO:0000269|PubMed:10628747, ECO:0000269|PubMed:10655479,ECO:0000269|PubMed:15798179, ECO:0000269|PubMed:17020914,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17717077, ECO:0000269|PubMed:18202149,ECO:0000269|PubMed:8702648}.PTM: Ubiquitination is hormone-dependent and represses sumoylationon the same site. Promoted by MAPK-mediated phosphorylation onSer-294. {ECO:0000269|PubMed:10628747,ECO:0000269|PubMed:10655479, ECO:0000269|PubMed:15798179,ECO:0000269|PubMed:17173941, ECO:0000269|PubMed:17717077,ECO:0000269|PubMed:18202149, ECO:0000269|PubMed:8702648}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation.{ECO:0000269|PubMed:22031296}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/pgr/\";WEB RESOURCE: Name=Wikipedia; Note=Progesterone receptor entry;URL=\"https://en.wikipedia.org/wiki/Progesterone_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1A28_see-also"],["bp:comment","PRGR_HUMAN Reviewed; 933 AA."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5241"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000917"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-2"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1033"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_22720800"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P06401-1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SR7_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07077_identity"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q8NG45"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1ZUC_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1E3K_see-also"]]],["bp:name","PGRA"],["bp:name","Progesterone Receptor"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89731"]]}},{"data":{"id":"Protein_f770be719c3769a43a5ae41343066e13","class":"macromolecule","label":"MAPK3","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":681.9814,"y":325.84827,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 187 187 Phosphotyrosine; by MAP2K1 and MAP2K2."],["bp:featureLocation",[["bp:sequencePosition","187"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 29 29 Phosphoserine; by SGK1."],["bp:featureLocation",[["bp:sequencePosition","29"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:organism","Mitogen-activated protein kinase 1"],["bp:displayName","MK01_HUMAN"],["bp:name","ERT1"],["bp:name","PRKM2"],["bp:name","PRKM1"],["bp:name","p42-MAPK"],["bp:name","2.7.11.24"],["bp:name","MAPK 2"],["bp:name","ERK-2"],["bp:name","ERK2"],["bp:name","Mitogen-activated protein kinase 2"],["bp:name","MAPK 1"],["bp:name","MAP kinase 2"],["bp:name","Extracellular signal-regulated kinase 2"],["bp:name","MAP kinase isoform p42"],["bp:name","MAPK1"],["bp:name","MAP kinase 1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P28482_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002736"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5594"],["bp:comment","REPLACED ProteinRef_MAPK1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620407"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-519N_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P28482"],["bp:comment","REPLACED ProteinRef_MAPK1__40674"],["bp:comment","REPLACED ProteinRef_MAPK1__9606"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_832"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1WZY_see-also"],["bp:comment","MK01_HUMAN Reviewed; 360 AA."],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway.MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an importantrole in the MAPK/ERK cascade. They participate also in a signalingcascade initiated by activated KIT and KITLG/SCF. Depending on thecellular context, the MAPK/ERK cascade mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation through the regulation of transcription,translation, cytoskeletal rearrangements. The MAPK/ERK cascadeplays also a role in initiation and regulation of meiosis,mitosis, and postmitotic functions in differentiated cells byphosphorylating a number of transcription factors. About 160substrates have already been discovered for ERKs. Many of thesesubstrates are localized in the nucleus, and seem to participatein the regulation of transcription upon stimulation. However,other substrates are found in the cytosol as well as in othercellular organelles, and those are responsible for processes suchas translation, mitosis and apoptosis. Moreover, the MAPK/ERKcascade is also involved in the regulation of the endosomaldynamics, including lysosome processing and endosome cyclingthrough the perinuclear recycling compartment (PNRC); as well asin the fragmentation of the Golgi apparatus during mitosis. Thesubstrates include transcription factors (such as ATF2, BCL6,ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such asCANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators ofapoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG),regulators of translation (such as EIF4EBP1) and a variety ofother signaling-related molecules (like ARHGEF2, DCC, FRS2 orGRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2,RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2,RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases(such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates whichenable the propagation the MAPK/ERK signal to additional cytosolicand nuclear targets, thereby extending the specificity of thecascade. Mediates phosphorylation of TPR in respons to EGFstimulation. May play a role in the spindle assembly checkpoint.Phosphorylates PML and promotes its interaction with PIN1, leadingto PML degradation. Phosphorylates CDK2AP2 (By similarity).{ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:10617468,ECO:0000269|PubMed:10637505, ECO:0000269|PubMed:11154262,ECO:0000269|PubMed:12110590, ECO:0000269|PubMed:12356731,ECO:0000269|PubMed:12792650, ECO:0000269|PubMed:12794087,ECO:0000269|PubMed:12974390, ECO:0000269|PubMed:15184391,ECO:0000269|PubMed:15241487, ECO:0000269|PubMed:15616583,ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:15788397,ECO:0000269|PubMed:15952796, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19879846, ECO:0000269|PubMed:22033920,ECO:0000269|PubMed:7588608, ECO:0000269|PubMed:8622688,ECO:0000269|PubMed:9480836, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9649500, ECO:0000269|PubMed:9687510,ECO:0000303|PubMed:15526160, ECO:0000303|PubMed:16393692,ECO:0000303|PubMed:19565474, ECO:0000303|PubMed:21779493}.FUNCTION: Acts as a transcriptional repressor. Binds to a[GC]AAA[GC] consensus sequence. Repress the expression ofinterferon gamma-induced genes. Seems to bind to the promoter ofCCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 andSTAT1. Transcriptional activity is independent of kinase activity.{ECO:0000269|PubMed:19879846}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2on Thr-185 and Tyr-187 in response to external stimuli likeinsulin or NGF. Both phosphorylations are required for activity.This phosphorylation causes dramatic conformational changes, whichenable full activation and interaction of MAPK1/ERK2 with itssubstrates. Phosphorylation on Ser-29 by SGK1 results in itsactivation by enhancing its interaction with MAP2K1/MEK1 andMAP2K2/MEK2. Dephosphorylated and inactivated by DUSP3, DUSP6 andDUSP9. Inactivated by pyrimidylpyrrole inhibitors.{ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes. Binds to HIV-1 Nef through its SH3domain. This interaction inhibits its tyrosine-kinase activity.Interacts with ADAM15, ARHGEF2, ARRB2, DAPK1 (via death domain),HSF4, IER3, IPO7, DUSP6, NISCH, SGK1, and isoform 1 of NEK2.Interacts (phosphorylated form) with CAV2 ('Tyr-19'-phosphorylatedform); the interaction, promoted by insulin, leads to nuclearlocation and MAPK1 activation. Interacts with MORG1, PEA15 andMKNK2 (By similarity). MKNK2 isoform 1 binding prevents fromdephosphorylation and inactivation (By similarity). Interacts withDCC (By similarity). The phosphorylated form interacts with PML(isoform PML-4). Interacts with STYX. Interacts with CDK2AP2 (Bysimilarity). {ECO:0000250|UniProtKB:P63085,ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:11912194,ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:15358203,ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16139248,ECO:0000269|PubMed:16242327, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:17194451, ECO:0000269|PubMed:17300186,ECO:0000269|PubMed:18211802, ECO:0000269|PubMed:18296648,ECO:0000269|PubMed:18435604, ECO:0000269|PubMed:18760948,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19827834,ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:23847209,ECO:0000269|PubMed:8794306, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9827991}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle{ECO:0000250}. Nucleus. Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome. Cytoplasm. Note=Associated with thespindle during prometaphase and metaphase (By similarity). PEA15-binding and phosphorylated DAPK1 promote its cytoplasmicretention. Phosphorylation at Ser- 246 and Ser-248 as well asautophosphorylation at Thr-190 promote nuclear localization.{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P28482-1; Sequence=Displayed;Name=2;IsoId=P28482-2; Sequence=VSP_047815;DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity).Dually phosphorylated on Thr-185 and Tyr-187, which activates theenzyme. Undergoes regulatory phosphorylation on additionalresidues such as Ser-246 and Ser-248 in the kinase insert domain(KID) These phosphorylations, which are probably mediated by morethan one kinase, are important for binding of MAPK1/ERK2 toimportin-7 (IPO7) and its nuclear translocation. In addition,autophosphorylation of Thr-190 was shown to affect the subcellularlocalization of MAPK1/ERK2 as well. Ligand-activated ALK inducestyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-187.Phosphorylation on Ser-29 by SGK1 results in its activation byenhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. DUSP3and DUSP6 dephosphorylate specifically MAPK1/ERK2 and MAPK3/ERK1whereas DUSP9 dephosphorylates a broader range of MAPKs.{ECO:0000250, ECO:0000269|PubMed:17274988,ECO:0000269|PubMed:18760948, ECO:0000269|PubMed:19053285,ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19494114}.PTM: ISGylated. {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA77753.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Extracellular signal-regulatedkinase entry;URL=\"https://en.wikipedia.org/wiki/Extracellular_signal-regulated_kinase\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK1ID41288ch22q11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_MAPK1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01496_identity"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2361"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2361"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphotyrosine"],["bp:term","MOD_RES Phosphotyrosine"]]],["bp:comment","MOD_RES 187 187 Phosphotyrosine; by MAP2K1 and MAP2K2."],["bp:featureLocation",[["bp:sequencePosition","187"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 29 29 Phosphoserine; by SGK1."],["bp:featureLocation",[["bp:sequencePosition","29"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Phosphothreonine"],["bp:term","Phosphothreonine"]]],["bp:comment","MOD_RES 190 190 Phosphothreonine; by autocatalysis."],["bp:featureLocation","MOD_RES 190 190 Phosphothreonine; by autocatalysis."]]],["bp:standardName","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:xref","Mitogen-activated protein kinase 1"],["bp:organism","Mitogen-activated protein kinase 1"],["bp:displayName","MK01_HUMAN"],["bp:name","ERT1"],["bp:name","PRKM2"],["bp:name","PRKM1"],["bp:name","p42-MAPK"],["bp:name","2.7.11.24"],["bp:name","MAPK 2"],["bp:name","ERK-2"],["bp:name","ERK2"],["bp:name","Mitogen-activated protein kinase 2"],["bp:name","MAPK 1"],["bp:name","MAP kinase 2"],["bp:name","Extracellular signal-regulated kinase 2"],["bp:name","MAP kinase isoform p42"],["bp:name","MAPK1"],["bp:name","MAP kinase 1"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P28482_identity"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_002736"],["bp:comment","REPLACED http://identifiers.org/ncbigene/5594"],["bp:comment","REPLACED ProteinRef_MAPK1__10090"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_620407"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-519N_identity"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P28482"],["bp:comment","REPLACED ProteinRef_MAPK1__40674"],["bp:comment","REPLACED ProteinRef_MAPK1__9606"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_832"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_5594"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1WZY_see-also"],["bp:comment","MK01_HUMAN Reviewed; 360 AA."],["bp:comment","FUNCTION: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway.MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an importantrole in the MAPK/ERK cascade. They participate also in a signalingcascade initiated by activated KIT and KITLG/SCF. Depending on thecellular context, the MAPK/ERK cascade mediates diverse biologicalfunctions such as cell growth, adhesion, survival anddifferentiation through the regulation of transcription,translation, cytoskeletal rearrangements. The MAPK/ERK cascadeplays also a role in initiation and regulation of meiosis,mitosis, and postmitotic functions in differentiated cells byphosphorylating a number of transcription factors. About 160substrates have already been discovered for ERKs. Many of thesesubstrates are localized in the nucleus, and seem to participatein the regulation of transcription upon stimulation. However,other substrates are found in the cytosol as well as in othercellular organelles, and those are responsible for processes suchas translation, mitosis and apoptosis. Moreover, the MAPK/ERKcascade is also involved in the regulation of the endosomaldynamics, including lysosome processing and endosome cyclingthrough the perinuclear recycling compartment (PNRC); as well asin the fragmentation of the Golgi apparatus during mitosis. Thesubstrates include transcription factors (such as ATF2, BCL6,ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such asCANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators ofapoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG),regulators of translation (such as EIF4EBP1) and a variety ofother signaling-related molecules (like ARHGEF2, DCC, FRS2 orGRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2,RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2,RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases(such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates whichenable the propagation the MAPK/ERK signal to additional cytosolicand nuclear targets, thereby extending the specificity of thecascade. Mediates phosphorylation of TPR in respons to EGFstimulation. May play a role in the spindle assembly checkpoint.Phosphorylates PML and promotes its interaction with PIN1, leadingto PML degradation. Phosphorylates CDK2AP2 (By similarity).{ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:10617468,ECO:0000269|PubMed:10637505, ECO:0000269|PubMed:11154262,ECO:0000269|PubMed:12110590, ECO:0000269|PubMed:12356731,ECO:0000269|PubMed:12792650, ECO:0000269|PubMed:12794087,ECO:0000269|PubMed:12974390, ECO:0000269|PubMed:15184391,ECO:0000269|PubMed:15241487, ECO:0000269|PubMed:15616583,ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:15788397,ECO:0000269|PubMed:15952796, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19879846, ECO:0000269|PubMed:22033920,ECO:0000269|PubMed:7588608, ECO:0000269|PubMed:8622688,ECO:0000269|PubMed:9480836, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9649500, ECO:0000269|PubMed:9687510,ECO:0000303|PubMed:15526160, ECO:0000303|PubMed:16393692,ECO:0000303|PubMed:19565474, ECO:0000303|PubMed:21779493}.FUNCTION: Acts as a transcriptional repressor. Binds to a[GC]AAA[GC] consensus sequence. Repress the expression ofinterferon gamma-induced genes. Seems to bind to the promoter ofCCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 andSTAT1. Transcriptional activity is independent of kinase activity.{ECO:0000269|PubMed:19879846}.CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.COFACTOR:Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};ENZYME REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2on Thr-185 and Tyr-187 in response to external stimuli likeinsulin or NGF. Both phosphorylations are required for activity.This phosphorylation causes dramatic conformational changes, whichenable full activation and interaction of MAPK1/ERK2 with itssubstrates. Phosphorylation on Ser-29 by SGK1 results in itsactivation by enhancing its interaction with MAP2K1/MEK1 andMAP2K2/MEK2. Dephosphorylated and inactivated by DUSP3, DUSP6 andDUSP9. Inactivated by pyrimidylpyrrole inhibitors.{ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.SUBUNIT: Binds both upstream activators and downstream substratesin multimolecular complexes. Binds to HIV-1 Nef through its SH3domain. This interaction inhibits its tyrosine-kinase activity.Interacts with ADAM15, ARHGEF2, ARRB2, DAPK1 (via death domain),HSF4, IER3, IPO7, DUSP6, NISCH, SGK1, and isoform 1 of NEK2.Interacts (phosphorylated form) with CAV2 ('Tyr-19'-phosphorylatedform); the interaction, promoted by insulin, leads to nuclearlocation and MAPK1 activation. Interacts with MORG1, PEA15 andMKNK2 (By similarity). MKNK2 isoform 1 binding prevents fromdephosphorylation and inactivation (By similarity). Interacts withDCC (By similarity). The phosphorylated form interacts with PML(isoform PML-4). Interacts with STYX. Interacts with CDK2AP2 (Bysimilarity). {ECO:0000250|UniProtKB:P63085,ECO:0000250|UniProtKB:P63086, ECO:0000269|PubMed:11912194,ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:15358203,ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16139248,ECO:0000269|PubMed:16242327, ECO:0000269|PubMed:16581800,ECO:0000269|PubMed:17194451, ECO:0000269|PubMed:17300186,ECO:0000269|PubMed:18211802, ECO:0000269|PubMed:18296648,ECO:0000269|PubMed:18435604, ECO:0000269|PubMed:18760948,ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19827834,ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:23847209,ECO:0000269|PubMed:8794306, ECO:0000269|PubMed:9596579,ECO:0000269|PubMed:9827991}.SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle{ECO:0000250}. Nucleus. Cytoplasm, cytoskeleton, microtubuleorganizing center, centrosome. Cytoplasm. Note=Associated with thespindle during prometaphase and metaphase (By similarity). PEA15-binding and phosphorylated DAPK1 promote its cytoplasmicretention. Phosphorylation at Ser- 246 and Ser-248 as well asautophosphorylation at Thr-190 promote nuclear localization.{ECO:0000250}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=P28482-1; Sequence=Displayed;Name=2;IsoId=P28482-2; Sequence=VSP_047815;DOMAIN: The TXY motif contains the threonine and tyrosine residueswhose phosphorylation activates the MAP kinases.PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity).Dually phosphorylated on Thr-185 and Tyr-187, which activates theenzyme. Undergoes regulatory phosphorylation on additionalresidues such as Ser-246 and Ser-248 in the kinase insert domain(KID) These phosphorylations, which are probably mediated by morethan one kinase, are important for binding of MAPK1/ERK2 toimportin-7 (IPO7) and its nuclear translocation. In addition,autophosphorylation of Thr-190 was shown to affect the subcellularlocalization of MAPK1/ERK2 as well. Ligand-activated ALK inducestyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-187.Phosphorylation on Ser-29 by SGK1 results in its activation byenhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. DUSP3and DUSP6 dephosphorylate specifically MAPK1/ERK2 and MAPK3/ERK1whereas DUSP9 dephosphorylates a broader range of MAPKs.{ECO:0000250, ECO:0000269|PubMed:17274988,ECO:0000269|PubMed:18760948, ECO:0000269|PubMed:19053285,ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19265199,ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:19494114}.PTM: ISGylated. {ECO:0000250}.SIMILARITY: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily.{ECO:0000305}.SEQUENCE CAUTION:Sequence=CAA77753.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Extracellular signal-regulatedkinase entry;URL=\"https://en.wikipedia.org/wiki/Extracellular_signal-regulated_kinase\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/MAPK1ID41288ch22q11.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED ProteinRef_MAPK1__10116"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01496_identity"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2361"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2361"]]],["bp:displayName","ERK1-2"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2"],["bp:name","Erk1-2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2358"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2358"]]}},{"data":{"id":"Protein_3dae87e8b2d131ac77af80ab21758406","class":"macromolecule","label":"MAPK3","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_3dae87e8b2d131ac77af80ab21758406.info.1","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":841.7682,"y":287.7538,"w":48,"h":25},"metadata":[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00047"],["bp:db","protein modification ontology"]]],["bp:term","opthr"],["bp:term","O-phospho-L-threonine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]}},{"data":{"id":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":751.4615,"y":338.84732,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:evidence",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:memberPhysicalEntity",[["bp:displayName","Erk2"],["bp:feature",[["bp:modificationType",[["bp:xref",[["bp:id","MOD:00048"],["bp:db","protein modification ontology"]]],["bp:term","optyr"],["bp:term","O4'-phospho-L-tyrosine"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2049"],["bp:featureLocation",[["bp:sequencePosition","184"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2050"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2046"]]],["bp:feature",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:entityReference_http://identifiers.org/uniprot/P28482",[["bp:modificationType",null],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"],["bp:featureLocation","REPLACED http://pid.nci.nih.gov/biopax#pid_2047"]]],["bp:name","ERK2"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_2043"]]],["bp:displayName","ERK1-2-active"],["bp:feature","ERK1-2-active"],["bp:entityReference_http://identifiers.org/uniprot/P27361","ERK1-2-active"],["bp:name","Erk1-2-active"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_66283"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11387"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_11385"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_11385"]]}},{"data":{"id":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1210.6726,"y":1409.3763,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89614"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","TNF-alpha"],["bp:entityReference_http://identifiers.org/uniprot/P01375",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P01375"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 2 2 Phosphoserine; by CK1."],["bp:featureLocation",[["bp:sequencePosition","2"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P01375"]]],["bp:standardName","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:xref","Tumor necrosis factor"],["bp:organism","Tumor necrosis factor"],["bp:displayName","TNFA_HUMAN"],["bp:name","ICD2"],["bp:name","ICD1"],["bp:name","Intracellular domain 2"],["bp:name","Intracellular domain 1"],["bp:name","Cachectin"],["bp:name","NTF"],["bp:name","N-terminal fragment"],["bp:name","Tumor necrosis factor ligand superfamily member 2"],["bp:name","TNFSF2"],["bp:name","TNF-a"],["bp:name","TNF"],["bp:name","Tumor necrosis factor, soluble form"],["bp:name","TNFA"],["bp:name","Tumor necrosis factor, membrane form"],["bp:name","C-domain 2"],["bp:name","TNF-alpha"],["bp:name","C-domain 1"],["bp:comment","FUNCTION: Cytokine that binds to TNFRSF1A/TNFR1 andTNFRSF1B/TNFBR. It is mainly secreted by macrophages and caninduce cell death of certain tumor cell lines. It is potentpyrogen causing fever by direct action or by stimulation ofinterleukin-1 secretion and is implicated in the induction ofcachexia, Under certain conditions it can stimulate cellproliferation and induce cell differentiation. Impairs regulatoryT-cells (Treg) function in individuals with rheumatoid arthritisvia FOXP3 dephosphorylation. Upregulates the expression of proteinphosphatase 1 (PP1), which dephosphorylates the key 'Ser-418'residue of FOXP3, thereby inactivating FOXP3 and rendering Tregcells functionally defective (PubMed:23396208). Key mediator ofcell death in the anticancer action of BCG-stimulated neutrophilsin combination with DIABLO/SMAC mimetic in the RT4v6 bladdercancer cell line (PubMed:22517918). {ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.FUNCTION: The TNF intracellular domain (ICD) form induces IL12production in dendritic cells. {ECO:0000269|PubMed:16829952}.SUBUNIT: Homotrimer. Interacts with SPPL2B.{ECO:0000269|PubMed:16829951}.SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16829952};Single-pass type II membrane protein{ECO:0000269|PubMed:16829952}.SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form:Membrane; Single-pass type II membrane protein.SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form:Secreted.SUBCELLULAR LOCATION: C-domain 1: Secreted.SUBCELLULAR LOCATION: C-domain 2: Secreted.PTM: The soluble form derives from the membrane form byproteolytic processing. The membrane-bound form is furtherproteolytically processed by SPPL2A or SPPL2B through regulatedintramembrane proteolysis producing TNF intracellular domains(ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space.{ECO:0000269|PubMed:16829951, ECO:0000269|PubMed:16829952,ECO:0000269|PubMed:9034191}.PTM: The membrane form, but not the soluble form, isphosphorylated on serine residues. Dephosphorylation of themembrane form occurs by binding to soluble TNFRSF1A/TNFR1.{ECO:0000269|PubMed:10205166, ECO:0000269|PubMed:8597870}.PTM: O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.{ECO:0000269|PubMed:8631363}.POLYMORPHISM: Genetic variations in TNF influence susceptibilityto hepatitis B virus (HBV) infection [MIM:610424].POLYMORPHISM: Genetic variations in TNF are involved insusceptibility to malaria [MIM:611162].DISEASE: Psoriatic arthritis (PSORAS) [MIM:607507]: Aninflammatory, seronegative arthritis associated with psoriasis. Itis a heterogeneous disorder ranging from a mild, non-destructivedisease to a severe, progressive, erosive arthropathy. Five typesof psoriatic arthritis have been defined: asymmetricaloligoarthritis characterized by primary involvement of the smalljoints of the fingers or toes; asymmetrical arthritis whichinvolves the joints of the extremities; symmetrical polyarthritischaracterized by a rheumatoid like pattern that can involve hands,wrists, ankles, and feet; arthritis mutilans, which is a rare butdeforming and destructive condition; arthritis of the sacroiliacjoints and spine (psoriatic spondylitis).{ECO:0000269|PubMed:12746914}. Note=Disease susceptibility isassociated with variations affecting the gene represented in thisentry.SIMILARITY: Belongs to the tumor necrosis factor family.{ECO:0000305}.SEQUENCE CAUTION:Sequence=AAF71992.1; Type=Frameshift; Positions=91, 157; Evidence={ECO:0000305};Sequence=CAA75070.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};WEB RESOURCE: Name=Wikipedia; Note=Tumor necrosis factor alphaentry;URL=\"https://en.wikipedia.org/wiki/Tumor_necrosis_factor-alpha\";WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/TNFaID319.html\";WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SeattleSNPs;URL=\"http://pga.gs.washington.edu/data/tnf/\";WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation andpolymorphism database;URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TNF\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000585"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_7124"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_01855_identity"],["bp:comment","TNFA_HUMAN Reviewed; 233 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-2895N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1TNF_see-also"],["bp:comment","REPLACED http://identifiers.org/ncbigene/7124"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_P01375"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_7124"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_1571"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89614"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89613"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89613"]]}},{"data":{"id":"Protein_67c8de75d5dc723dda616b98126413cb","class":"macromolecule","label":"NLRP1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":678.85114,"y":771.6829,"w":48,"h":25},"metadata":[["bp:displayName","Nalp 1b"],["bp:entityReference_http://identifiers.org/uniprot/Q9C000",[["bp:standardName","NACHT, LRR and PYD domains-containing protein 1"],["bp:xref",[["bp:id","Q9C000"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","NLRP1"],["bp:db","hgnc symbol"]]],["bp:displayName","NLRP1_HUMAN"],["bp:name","NLRP1"],["bp:name","Death effector filament-forming ced-4-like apoptosis protein"],["bp:name","KIAA0926"],["bp:name","NAC"],["bp:name","CARD7"],["bp:name","Caspase recruitment domain-containing protein 7"],["bp:name","Nucleotide-binding domain and caspase recruitment domain"],["bp:name","NALP1"],["bp:name","DEFCAP"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_22861"],["bp:comment","FUNCTION: As the sensor component of the NLRP1 inflammasome, playsa crucial role in innate immunity and inflammation. In response topathogens and other damage-associated signals, initiates theformation of the inflammasome polymeric complex, made of NLRP1,CASP1, and possibly PYCARD. Recruitment of proCASP1 to theinflammasome promotes its activation and CASP1-catalyzed IL1B andIL18 maturation and secretion in the extracellular milieu.Activation of NLRP1 inflammasome is also required for HMGB1secretion. The active cytokines and HMGB1 stimulate inflammatoryresponses. Inflammasomes can also induce pyroptosis, aninflammatory form of programmed cell death (PubMed:22665479,PubMed:17418785). May be activated by muramyl dipeptide (MDP), afragment of bacterial peptidoglycan, in a NOD2-dependent manner(PubMed:18511561). Contrary to its mouse ortholog, not activatedby Bacillus anthracis lethal toxin (PubMed:19651869). It isunclear whether isoform 2 is involved in inflammasome formation.It is not cleaved within the FIIND domain, does not assemble intospecks, nor promote IL1B release (PubMed:22665479). However, in anvitro cell-free system, it has been shown to be activated by MDP(PubMed:17349957). Binds ATP (PubMed:11113115, PubMed:15212762).{ECO:0000250|UniProtKB:A1Z198, ECO:0000269|PubMed:11113115,ECO:0000269|PubMed:15212762, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:17418785, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:19651869, ECO:0000269|PubMed:22665479}.SUBUNIT: Sensor component of NLRP1 inflammasomes. Inflammasomesare supramolecular complexes that assemble in the cytosol inresponse to pathogens and other damage-associated signals and playcritical roles in innate immunity and inflammation. Classicalinflammasomes consist of a signal sensor component, an adapter(ASC/PYCARD), which recruits an effector proinflammatory caspase(CASP1 and CASP5). This interaction initiates speck formation(nucleation) which greatly enhances further addition of solublePYCARD molecules to the speck in a prion-like polymerizationprocess. CASP1 filament formation increases local enzymeconcentration, resulting in trans-autocleavage and activation.Active CASP1 then processes IL1B and IL18 precursors, leading tothe release of mature cytokines in the extracellular milieu andinflammatory response. In NLRP1 inflammasome, the role of PYCARDis not clear. Following activation, NLRP1 can directly interactwith CASP1 (possibly through CARD domain) to form a functionalinflammasome, although the presence of PYCARD increases CASP1activity (PubMed:17418785, PubMed:17349957). In a differentexperimental system, neither CASP1-binding, NLRP1 inflammasomespeck formation, nor IL1B release were observed in the absence ofPYCARD (PubMed:22665479, PubMed:12191486). Hence PYCARD may not benecessary for NLRP1 and CASP1 interaction, but is required forspeck formation and full inflammasome activity (By similarity).Homomer (PubMed:17349957). Interacts (via LRR repeats) with BCL2and BCL2L1 (via the loop between motifs BH4 and BH3); theseinteractions reduce NLRP1 inflammasome-induced CASP1 activationand IL1B release, possibly by impairing NLRP1 interaction withPYCARD (PubMed:17418785). Interacts with NOD2; this interaction isenhanced in the presence of muramyl dipeptide (MDP) and increasesIL1B release (PubMed:18511561). Interacts with EIF2AK2/PKR; thisinteraction requires EIF2AK2 activity, is accompanied by EIF2AK2autophosphorylation and promotes inflammasome assembly in responseto danger-associated signals (By similarity). Interacts with MEFV;this interaction targets NLRP1 to degradation by autophagy, hencepreventing excessive IL1B- and IL18-mediated inflammation(PubMed:17431422, PubMed:26347139). {ECO:0000250|UniProtKB:A1Z198,ECO:0000250|UniProtKB:Q2LKW6, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957, ECO:0000269|PubMed:17418785,ECO:0000269|PubMed:17431422, ECO:0000269|PubMed:18511561,ECO:0000269|PubMed:22665479, ECO:0000269|PubMed:26347139}.SUBUNIT: (Microbial infection) Interacts with vaccinia virusprotein F1 (PubMed:16439990). {ECO:0000269|PubMed:16439990}.SUBCELLULAR LOCATION: Cytoplasm, cytosol{ECO:0000269|PubMed:17418785}. Cytoplasm{ECO:0000269|PubMed:17164409}. Inflammasome{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:22665479}.Nucleus {ECO:0000269|PubMed:17164409}. Note=Nucleocytoplasmicdistribution in lymphoid organs (probably in T-cells) and inneurons. In epithelial cells, predominantly cytoplasmic.{ECO:0000269|PubMed:17164409}.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=7;Name=1; Synonyms=NAC beta, DEFCAP-L, NALP1-L{ECO:0000303|PubMed:15285719};IsoId=Q9C000-1; Sequence=Displayed;Name=2; Synonyms=NAC alpha, DEFCAP-S, NALP1-S{ECO:0000303|PubMed:15285719}, NLRP1deltaEx14;IsoId=Q9C000-2; Sequence=VSP_004327;Name=3; Synonyms=NAC gamma;IsoId=Q9C000-3; Sequence=VSP_004326, VSP_004327;Name=4; Synonyms=NAC delta;IsoId=Q9C000-4; Sequence=VSP_004326;Name=5;IsoId=Q9C000-5; Sequence=VSP_053803, VSP_053804, VSP_053805;Name=6;IsoId=Q9C000-6; Sequence=VSP_053802;Name=7;IsoId=Q9C000-7; Sequence=VSP_053801, VSP_053803, VSP_053804,VSP_053805;TISSUE SPECIFICITY: Widely expressed (PubMed:11113115,PubMed:17164409). Abundantly expressed in primary immune cells(isoform 1 and isoform 2), including in neutrophils,monocytes/macrophages, dendritic cells (mostly Langerhans cells),and B- and T-lymphocytes (at protein level) (PubMed:15285719,PubMed:17164409). Strongly expressed in epithelial cells liningthe glandular epithelium, such as that of the gastrointestinaltract (stomach, small intestine, colon), the respiratory tract(trachea and bronchi), and the endometrial and endocervicalglands, gallbladder, prostate, and breast (at protein level). Intestis, expressed in spermatogonia and primary spermatocytes, butnot in Sertoli cells (at protein level). In the brain, expressedin neurons, in particular in pyramidal ones and inoligodendrocytes, but not detected in microglia (at protein level)(PubMed:17164409). Expressed in adult and fetal ocular tissues,including in adult and 24-week old fetal choroid, sclera, cornea,and optic nerve, as well as in adult retina and fetalretina/retinal pigment epithelium (PubMed:23349227).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409, ECO:0000269|PubMed:23349227}.DEVELOPMENTAL STAGE: Associated with differentiation in stratifiedepithelia of the skin, esophagus, intestine, and cervix, as wellas in the prostate gland. Undetectable in undifferentiated basalcells, but expressed in differentiated luminal secretory cells(PubMed:11113115). Expressed in differentiated macrophages andgranulocytes, but not their precursors (at protein level)(PubMed:11113115, PubMed:15285719). In testis, also associatedwith cell differentiation, with conflicting results. Expressed inspermatogonia and primary spermatocytes, but not in cells fromlater differentiation stages, including secondary spermatocytes,spermatids, and spermatozoa (at protein level) (PubMed:17164409).Not detected in spermatocytes, nor spermatids, and stronglyexpressed in spermatozoa (at protein level) (PubMed:11113115).{ECO:0000269|PubMed:11113115, ECO:0000269|PubMed:15285719,ECO:0000269|PubMed:17164409}.INDUCTION: Up-regulated by ATF4 during endoplasmic reticulum (ER)stress response (PubMed:26086088). Up-regulated in arterialendothelial cells exposed to plasma from patients with peripheralarterial disease, but not to plasma from healthy controls(PubMed:24439873). {ECO:0000269|PubMed:24439873,ECO:0000269|PubMed:26086088}.DOMAIN: The CARD domain, rather than the pyrin domain, is involvedin the interaction with PYCARD, CASP1 and CASP5.{ECO:0000269|PubMed:12191486, ECO:0000269|PubMed:17349957,ECO:0000269|PubMed:22665479}.DOMAIN: The leucine-rich repeat (LRR) domain may be involved inautoinhibition in the absence of activating signal, possiblythrough intramolecular interaction with the NACHT domain.{ECO:0000250|UniProtKB:Q9EPB4, ECO:0000269|PubMed:12191486,ECO:0000269|PubMed:17349957}.DOMAIN: The FIIND (domain with function to find) region isinvolved in homomerization, but not in CASP1-binding (Bysimilarity). Autocatalytic cleavage in this region occursconstitutively, prior to activation signals, and is required forinflammasome activity (IL1B release), possibly by facilitatingCASP1 binding. Both N- and C-terminal fragments remain associated(PubMed:22665479, PubMed:22087307). {ECO:0000250|UniProtKB:Q2LKW6,ECO:0000269|PubMed:22087307, ECO:0000269|PubMed:22665479}.DISEASE: Vitiligo-associated multiple autoimmune disease 1(VAMAS1) [MIM:606579]: A disorder characterized by the associationof vitiligo with several autoimmune and autoinflammatory diseasesincluding autoimmune thyroid disease, rheumatoid arthritis andsystemic lupus erythematosus. {ECO:0000269|PubMed:17377159}.Note=Disease susceptibility is associated with variationsaffecting the gene represented in this entry.DISEASE: Palmoplantar carcinoma, multiple self-healing (MSPC)[MIM:615225]: An autosomal dominant disease characterized bykeratopathy with neovascularization, bilateral cornealopacification, palmoplantar hyperkeratosis, dyshidrosis,dystrophic nails, and recurrent keratoacanthomas in palmoplantarskin as well as in conjunctival and corneal epithelia. Inaddition, patients experience a high susceptibility to malignantsquamous cell carcinoma. {ECO:0000269|PubMed:23349227}. Note=Thedisease is caused by mutations affecting the gene represented inthis entry.MISCELLANEOUS: In macrophages and dendritic cells, NLRP1inflammasome activation of CASP1 and IL1B maturation can bedampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, suchas CD40LG. {ECO:0000250|UniProtKB:Q2LKW6}.SIMILARITY: Belongs to the NLRP family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=BAA76770.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};Sequence=BAB15469.1; Type=Frameshift; Positions=1241; Evidence={ECO:0000305}; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-38407N_identity"],["bp:comment","NLRP1_HUMAN Reviewed; 1473 AA."],["bp:comment","REPLACED http://identifiers.org/refseq/NP_127497"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_07364_identity"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89444"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":704.783,"y":399.96838,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Estrogen receptor alpha"],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:name","ER alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89463"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Estrogen receptor alpha"],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:name","ER alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89463"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Estrogen receptor alpha"],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:name","ER alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89463"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Estrogen receptor alpha"],["bp:entityReference_http://identifiers.org/uniprot/P03372",[["bp:entityFeature",[["bp:modificationType",[["bp:term","MOD_RES Asymmetric dimethylarginine"],["bp:term","Asymmetric dimethylarginine"]]],["bp:comment","MOD_RES 260 260 Asymmetric dimethylarginine; by PRMT1."],["bp:featureLocation",[["bp:sequencePosition","260"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 106 106 Phosphoserine; by CDK2."],["bp:featureLocation",[["bp:sequencePosition","106"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P03372"]]],["bp:standardName","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:xref","Estrogen receptor"],["bp:organism","Estrogen receptor"],["bp:displayName","ESR1_HUMAN"],["bp:name","ER"],["bp:name","ESR1"],["bp:name","ESR"],["bp:name","Nuclear receptor subfamily 3 group A member 1"],["bp:name","ER-alpha"],["bp:name","Estradiol receptor"],["bp:name","NR3A1"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7E_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1L2I_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SJ0_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1R5K_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_3ERT_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_uniprotkb_P03372_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIM_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1QKU_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q9H2M2"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2BJ4_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2099"],["bp:comment","ESR1_HUMAN Reviewed; 595 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XPC_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000116"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_968"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XQC_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P03372-4"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1X7R_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1G50_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1YIN_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP6_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1PCG_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-5965N_identity"],["bp:comment","REPLACED http://identifiers.org/ncbigene/2099"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2099"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1XP9_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00589_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1UOM_see-also"],["bp:comment","FUNCTION: Nuclear hormone receptor. The steroid hormones and theirreceptors are involved in the regulation of eukaryotic geneexpression and affect cellular proliferation and differentiationin target tissues. Ligand-dependent nuclear transactivationinvolves either direct homodimer binding to a palindromic estrogenresponse element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,Sp1 and Sp3, to mediate ERE-independent signaling. Ligand bindinginduces a conformational change allowing subsequent orcombinatorial association with multiprotein coactivator complexesthrough LXXLL motifs of their respective components. Mutualtransrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcriptionfrom the IL6 promoter and displace RELA/p65 and associatedcoregulators from the promoter. Recruited to the NF-kappa-Bresponse element of the CCL2 and IL8 promoters and can displaceCREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50on ERE sequences. Can also act synergistically with NF-kappa-B toactivate transcription involving respective recruitment adjacentresponse elements; the function involves CREBBP. Can activate thetranscriptional activity of TFF1. Also mediates membrane-initiatedestrogen signaling involving various kinase cascades. Isoform 3 isinvolved in activation of NOS3 and endothelial nitric oxideproduction. Isoforms lacking one or several functional domains arethought to modulate transcriptional activity by competitive ligandor DNA binding and/or heterodimerization with the full lengthreceptor. Essential for MTA1-mediated transcriptional regulationof BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer withESR2. Isoform 3 can probably homodimerize or heterodimerize withisoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1Cand NCOA3 coactivator (By similarity). Interacts with EP300; theinteraction is estrogen-dependent and enhanced by CITED1.Interacts with CITED1; the interaction is estrogen-dependent.Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;the interaction is a ligand-inducible. Interacts with PHB2, PELP1and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interactswith KDM5A. Interacts with SMARD1. Interacts with HEXIM1.Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7beta-estradiol (E2) and enhances ERS1-mediated transcription.Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 andthis interaction is enhanced by estradiol. Interacts with KIF18Aand LDB1. Interacts with RLIM (via C-terminus). Interacts withMACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4Ablocks binding to PLCG and inhibits estrogen-induced cellproliferation. Interacts with DYNLL1. Interacts with CCDC62 in thepresence of estradiol/E2; this interaction seems to enhance thetranscription of target genes. Interacts with NR2C1; theinteraction prevents homodimerization of ESR1 and suppresses itstranscriptional activity and cell growth. Interacts with DNAAF4.Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC andPTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only inthe presence of SAV1 and vice-versa. Binds to CSNK1D. Interactswith NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domainssimultaneously and mediate their transcriptional synergy.Interacts with DDX5. Interacts with NCOA1; the interaction seemsto require a self-association of N-terminal and C-terminalregions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.Interacts with NRIP1 (By similarity). Interacts with GPER1; theinteraction occurs in an estrogen-dependent manner. Interacts withCLOCK and the interaction is stimulated by estrogen. Interactswith BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.Interacts with LMTK3; the interaction phosphorylates ESR1 (invitro) and protects it against proteasomal degradation. Interactswith CCAR2 (via N-terminus) in a ligand-independent manner.Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependentand -independent manner (PubMed:23874500). Interacts with DCAF13,LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts (viaDNA-binding domain) with POU4F2 (C-terminus); this interactionincreases the estrogen receptor ESR1 transcriptional activity in aDNA- and ligand 17-beta-estradiol-independent manner (Bysimilarity). Interacts with ESRRB isoform 1 (PubMed:19755138).{ECO:0000250, ECO:0000250|UniProtKB:P19785,ECO:0000269|PubMed:10359819, ECO:0000269|PubMed:10409727,ECO:0000269|PubMed:10567404, ECO:0000269|PubMed:10681512,ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:10970861,ECO:0000269|PubMed:11113208, ECO:0000269|PubMed:11265755,ECO:0000269|PubMed:11358960, ECO:0000269|PubMed:11477071,ECO:0000269|PubMed:11581164, ECO:0000269|PubMed:11682626,ECO:0000269|PubMed:11875103, ECO:0000269|PubMed:11971969,ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:12093804,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12554772,ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:15047147,ECO:0000269|PubMed:15199063, ECO:0000269|PubMed:15891768,ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:16427018,ECO:0000269|PubMed:16603732, ECO:0000269|PubMed:17006958,ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, ECO:0000269|PubMed:12682286,ECO:0000269|PubMed:20074560}. Cytoplasm{ECO:0000269|PubMed:12682286}. Cell membrane{ECO:0000269|PubMed:12682286}; Peripheral membrane protein{ECO:0000269|PubMed:12682286}; Cytoplasmic side{ECO:0000269|PubMed:12682286}. Note=A minor fraction is associatedwith the inner membrane.SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cellmembrane; Peripheral membrane protein; Cytoplasmic side. Cellmembrane; Single-pass type I membrane protein. Note=Associatedwith the inner membrane via palmitoylation (Probable). At least asubset exists as a transmembrane protein with a N-terminalextracellular domain. {ECO:0000305}.SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatuswhere most probably palmitoylation occurs. Associated with theplasma membrane when palmitoylated.ALTERNATIVE PRODUCTS:Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;Name=1; Synonyms=Long, hER-alpha66, ER66;IsoId=P03372-1; Sequence=Displayed;Name=2; Synonyms=Short;IsoId=P03372-2; Sequence=VSP_003680;Note=No experimental confirmation available.;Name=3; Synonyms=hER-alpha46, ER46;IsoId=P03372-3; Sequence=VSP_042460;Note=Produced by alternative promoter usage.;Name=4; Synonyms=hER-alpha36, ER36;IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;Note=Produced by alternative splicing of isoform 3.;TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressedin the pituitary gland. {ECO:0000269|PubMed:10970861}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain. Themodulating domain, also known as A/B or AF-1 domain has a ligand-independent transactivation function. The C-terminus contains aligand-dependent transactivation domain, also known as E/F or AF-2domain which overlaps with the ligand binding domain. AF-1 and AF-2 activate transcription independently and synergistically and actin a promoter- and cell-specific manner. AF-1 seems to provide themajor transactivation function in differentiated cells.PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylationprobably enhances transcriptional activity. Self-associationinduces phosphorylation. Dephosphorylation at Ser-118 by PPP5Cinhibits its transactivation activity. Phosphorylated by LMTK3 invitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,ECO:0000269|PubMed:7838153}.PTM: Glycosylated; contains N-acetylglucosamine, probably O-linked. {ECO:0000269|PubMed:8999954}.PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1proteasomal degradation (PubMed:21602804, PubMed:28068668).Deubiquitinated by OTUB1 (PubMed:19383985).{ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,ECO:0000269|PubMed:28068668}.PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favorcytoplasmic localization. {ECO:0000269|PubMed:18657504}.PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).{ECO:0000269|PubMed:22031296}.PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation isrequired for plasma membrane targeting and for rapid intracellularsignaling via ERK and AKT kinases and cAMP generation, but not forsignaling mediated by the nuclear hormone receptor.{ECO:0000269|PubMed:22031296}.POLYMORPHISM: Genetic variations in ESR1 are correlated with bonemineral density (BMD). Low BMD is a risk factor for osteoporoticfracture. Osteoporosis is characterized by reduced bone mineraldensity, disruption of bone microarchitecture, and the alterationof the amount and variety of non-collagenous proteins in bone.Osteoporotic bones are more at risk of fracture.{ECO:0000269|PubMed:10942433}.DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disordercharacterized by partial or complete resistance to estrogens, inthe presence of elevated estrogen serum levels. Clinical featuresinclude absence of the pubertal growth spurt, delayed bonematuration, unfused epiphyses, reduced bone mineral density,osteoporosis, continued growth into adulthood and very tall adultstature. Glucose intolerance, hyperinsulinemia and lipidabnormalities may also be present. {ECO:0000269|PubMed:23841731,ECO:0000269|PubMed:27754803}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),such as tamoxifen, raloxifene, toremifene, lasofoxifene,clomifene, femarelle and ormeloxifene, have tissue selectiveagonistic and antagonistic effects on the estrogen receptor (ER).They interfere with the ER association with coactivators orcorepressors, mainly involving the AF-2 domain.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/esr1/\";WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;URL=\"https://en.wikipedia.org/wiki/Estrogen_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."]]],["bp:name","ER alpha"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_13940"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89463"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89458"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89458"]]}},{"data":{"id":"Protein_611f13ead06fd476d39022ff0937dff1","class":"macromolecule","label":"NR3C1","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":632.5273,"y":965.65485,"w":48,"h":25},"metadata":[["bp:displayName","Glucocorticoid Receptor"],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","45"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 113 113 Phosphoserine."],["bp:featureLocation","MOD_RES 113 113 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:name","GR alpha"],["bp:name","GR beta"],["bp:name","GR"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_16850"]]}},{"data":{"id":"ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":121.720345,"y":516.3618200000001,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Protective Antigen (PA)"],["bp:cellularLocation",[["bp:xref",[["bp:id","GO:0005576"],["bp:db","gene ontology"]]],["bp:term","extracellular region"],["bp:term","extracellular"],["bp:term","Extracellular"]]],["bp:entityReference_http://identifiers.org/uniprot/P13423",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P13423"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P13423"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1764184489"],["bp:id","P13423"],["bp:db","uniprot knowledgebase"]]],["bp:displayName","pag"],["bp:name","pagA"],["bp:name","GBAA_pXO1_0164"],["bp:name","Protective Antigen (PA)"],["bp:name","Protective antigen"],["bp:name","PA83"],["bp:name","Anthrax toxins translocating protein"],["bp:name","UniProt:P13423 pagA"],["bp:name","BXA0164"],["bp:name","PA"],["bp:name","PA-83"],["bp:name","pXO1-110"],["bp:comment","FUNCTION One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.PTM Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.MISCELLANEOUS In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89668"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89699"],["bp:stoichiometricCoefficient","1.0"]]],["bp:spontaneous","true"],["bp:left","true"],["bp:left","true"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89693"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89693"]]}},{"data":{"id":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":639.9902,"y":726.1302,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:xref",[["bp:physicalEntity",[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:left",[["bp:physicalEntity",[["bp:displayName","Caspase 1 (tetramer)"],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:componentStoichiometry",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:component",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:feature",[["bp:physicalEntity",[["bp:displayName","Caspase 1 p20"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63566"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","297"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_62345"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","120"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_475"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_63567"]]]]],["bp:entityReference_http://identifiers.org/uniprot/P29466",[["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P29466"]]],["bp:standardName","Caspase-1"],["bp:xref","Caspase-1"],["bp:xref","Caspase-1"],["bp:organism","Caspase-1"],["bp:displayName","CASP1_HUMAN"],["bp:name","Interleukin-1 beta-converting enzyme"],["bp:name","IL-1 beta-converting enzyme"],["bp:name","CASP1"],["bp:name","IL-1BC"],["bp:name","Caspase-1 subunit p10"],["bp:name","3.4.22.36"],["bp:name","IL1BC"],["bp:name","p45"],["bp:name","CASP-1"],["bp:name","Caspase-1 subunit p20"],["bp:name","ICE"],["bp:name","IL1BCE"],["bp:name","Interleukin-1 beta convertase"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_NCBI_Gene_834_gene_product"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWX_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-175N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2H48_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_2FQQ_see-also"],["bp:comment","CASP1_HUMAN Reviewed; 404 AA."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWV_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1IBC_see-also"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_834"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC3_see-also"],["bp:comment","FUNCTION: Thiol protease that cleaves IL-1 beta between an Asp andan Ala, releasing the mature cytokine which is involved in avariety of inflammatory processes. Important for defense againstpathogens. Cleaves and activates sterol regulatory element bindingproteins (SREBPs). Can also promote apoptosis. Upon inflammasomeactivation, during DNA virus infection but not RNA viruschallenge, controls antiviral immunity through the cleavage ofMB21D1/cGAS, rendering it inactive (PubMed:28314590).{ECO:0000269|PubMed:15498465, ECO:0000269|PubMed:1574116,ECO:0000269|PubMed:28314590, ECO:0000269|PubMed:7876192}.CATALYTIC ACTIVITY: Strict requirement for an Asp residue atposition P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-.ENZYME REGULATION: Specifically inhibited by the cowpox virus Crmaprotein.SUBUNIT: Heterotetramer that consists of two anti-parallelarranged heterodimers, each one formed by a 20 kDa (p20) and a 10kDa (p10) subunit. The p20 subunit can also form a heterodimerwith the epsilon isoform which then has an inhibitory effect. Maybe a component of the inflammasome, a protein complex which alsoincludes PYCARD, CARD8 and NALP2 and whose function would be theactivation of proinflammatory caspases. Both the p10 and p20subunits interact with MEFV. Interacts with CARD17/INCA andCARD18. {ECO:0000269|PubMed:11051551, ECO:0000269|PubMed:15383541,ECO:0000269|PubMed:16785446, ECO:0000269|PubMed:8044845,ECO:0000269|PubMed:9987822}.SUBCELLULAR LOCATION: Cytoplasm.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=5;Comment=Additional isoforms seem to exist.;Name=Alpha;IsoId=P29466-1; Sequence=Displayed;Name=Beta;IsoId=P29466-2; Sequence=VSP_000798;Name=Gamma;IsoId=P29466-3; Sequence=VSP_000799;Name=Delta;IsoId=P29466-4; Sequence=VSP_000799, VSP_000800;Note=Apoptosis inactive.;Name=Epsilon;IsoId=P29466-5; Sequence=VSP_000797;Note=Apoptosis inactive.;TISSUE SPECIFICITY: Expressed in larger amounts in spleen andlung. Detected in liver, heart, small intestine, colon, thymus,prostate, skeletal muscle, peripheral blood leukocytes, kidney andtestis. No expression in the brain. {ECO:0000269|PubMed:15498465}.INDUCTION: Transcription and translation induced by M.tuberculosisand a number of different M.tuberculosis components; EsxA is themost potent activator tested (at protein level) (PubMed:20148899).{ECO:0000269|PubMed:20148899}.PTM: The two subunits are derived from the precursor sequence byan autocatalytic mechanism.SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.SEQUENCE CAUTION:Sequence=AAT72297.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};Sequence=AAT72297.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncologyand Haematology;URL=\"http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC1_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1RWW_see-also"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_00977_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1BMQ_see-also"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150635"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_150634"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_001214"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1SC4_see-also"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P29466-3"],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_834"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72689"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72692"],["bp:stoichiometricCoefficient","2.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_72688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89768"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89766"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89766"]]}},{"data":{"id":"Protein_fa3f6f083ad30072e326e2b74e117221","class":"macromolecule","label":"IL18","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_fa3f6f083ad30072e326e2b74e117221.info.1","class":"state variable","state":{"variable":"","value":"x[37 - 193]"}},{"id":"Protein_fa3f6f083ad30072e326e2b74e117221.state.2","class":"state variable","state":{"variable":"","value":"Act"}}],"unitsOfInformation":[],"bbox":{"x":332.17065,"y":855.69305,"w":48,"h":25},"metadata":[["bp:displayName","IL18 fragment"],["bp:feature",[["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89753"],["bp:featureLocation",[["bp:sequenceIntervalEnd",[["bp:sequencePosition","193"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_85501"]]],["bp:sequenceIntervalBegin",[["bp:sequencePosition","37"],["bp:positionStatus","EQUAL"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_6505"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89754"]]]]],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, active"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89752"]]],["bp:entityReference_http://identifiers.org/uniprot/Q14116",[["bp:standardName","Interleukin-18"],["bp:xref",[["bp:id","Q14116"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","IL18"],["bp:db","hgnc symbol"]]],["bp:organism",[["bp:relationshipType",null],["bp:id","IL18"],["bp:db","hgnc symbol"]]],["bp:displayName","IL18_HUMAN"],["bp:name","Interleukin-1 gamma"],["bp:name","IL-18"],["bp:name","Interferon gamma-inducing factor"],["bp:name","IL18"],["bp:name","IFN-gamma-inducing factor"],["bp:name","IL-1 gamma"],["bp:name","Iboctadekin"],["bp:name","IGIF"],["bp:name","IL1F4"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_011541107"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-3785N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_HPRD_02976_identity"],["bp:comment","FUNCTION: Augments natural killer cell activity in spleen cellsand stimulates interferon gamma production in T-helper type Icells.SUBCELLULAR LOCATION: Secreted.ALTERNATIVE PRODUCTS:Event=Alternative splicing; Named isoforms=2;Name=1;IsoId=Q14116-1; Sequence=Displayed;Name=2; Synonyms=Delta3pro-IL-18;IsoId=Q14116-2; Sequence=VSP_044934;Note=Expressed in ovarian carcinoma but undetectable in normalovarian epithelial cells. Resistant to proteolytic activation bycaspase-1 and -4.;PTM: The pro-IL-18 precursor is processed by CASP1 or CASP4 toyield the active form. {ECO:0000269|PubMed:15326478}.SIMILARITY: Belongs to the IL-1 family. {ECO:0000305}.WEB RESOURCE: Name=Wikipedia; Note=Interleukin-1 entry;URL=\"https://en.wikipedia.org/wiki/Interleukin_1\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_3606"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_3606"],["bp:comment","REPLACED http://www.inoh.org/biopax/memberPR_UniProt_Q14116"],["bp:comment","IL18_HUMAN Reviewed; 193 AA."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89750"],["bp:dataSource",[["bp:standardName","NCI Pathway Interaction Database: Pathway"],["bp:displayName","pid"],["bp:comment","Source type: BIOPAX, NCI Curated Human Pathways from PID (final); 27-Jul-2015"]]]]}},{"data":{"id":"Protein_0e0ebbab4043a0bc0a123f449a5f7c29","class":"macromolecule","label":"Lethal factor (3 molecules)","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":428.51154,"y":305.72073,"w":48,"h":25},"metadata":[["bp:displayName","Lethal factor (3 molecules)"],["bp:entityReference_http://identifiers.org/uniprot/P15917",[["bp:entityFeature",[["bp:modificationType",[["bp:term","inactive"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_inactive_P15917"]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","active"]]],["bp:comment","REPLACED http://www.drugbank.ca/#mod_active_P15917"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1888703417"],["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_33798663"],["bp:id","M29081"],["bp:db","genbank gene database"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1582770902"],["bp:id","143144"],["bp:db","genbank protein database"]]],["bp:xref",[["bp:id","P15917"],["bp:db","uniprot knowledgebase"]]],["bp:xref",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1774533490"],["bp:id","LEF_BACAN"],["bp:db","uniprot accession"]]],["bp:organism",[["bp:comment","REPLACED http://www.drugbank.ca/#rxref_1774533490"],["bp:id","LEF_BACAN"],["bp:db","uniprot accession"]]],["bp:displayName","lef"],["bp:name","Lethal factor (3 molecules)"],["bp:name","Anthrax lethal toxin endopeptidase component"],["bp:name","3.4.24.83"],["bp:name","LF"],["bp:name","Lethal factor"],["bp:name","pXO1-107"],["bp:name","UniProt:P15917 lef"],["bp:name","BXA0172"],["bp:name","GBAA_pXO1_0172"],["bp:comment","CATALYTIC ACTIVITY Preferred amino acids around the cleavage site can be denoted BBBBxHx-|-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases.INDUCTION Positively transcriptionally regulated by AtxA, which, in turn, is induced by bicarbonate and high temperatures (37 degrees Celsius).DOMAIN It comprises four domains: domain I binds the membrane-translocating component (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK before cleavage. Domain IV contains the catalytic center.DOMAIN The PA-binding region is found in both B.anthracis EF and LF.MISCELLANEOUS LF binds to the heptamer formed by cleaved PA on the host cell membrane. This step is followed by internalization of the heterooligomeric complex by receptor-mediated endocytosis. LeTx requires passage through an acidic vesicle for activity; at acidic pH, as the pore is inserted into the membrane, LF is translocated and reaches its cytosolic targets. LF is probably directly involved in its routing, by interacting with the lipid membrane. This interaction could involve a conformational change of LF and/or an oligomerization of the protein. LF may have the capability of partially unfolding in order to cross the membrane."]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89508"]]}},{"data":{"id":"SmallMolecule_ee06536974bc5ab74caf99fbfc82981b","class":"simple chemical","label":"NO","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":982.1936,"y":1397.215,"w":48,"h":20},"metadata":[["bp:displayName","NO"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16480",[["bp:standardName","oxidonitrogen(.)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25546"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62764"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25512"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:16480"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35620"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:48578"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35196"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:77746"],["bp:db","chebi"]]],["bp:chemicalFormula","NO"],["bp:displayName","nitric oxide"],["bp:name","Stickstoffmonoxid"],["bp:name","oxido de nitrogeno(II)"],["bp:name","[N]=O"],["bp:name","oxoazanyl"],["bp:name","oxido nitrico"],["bp:name","Nitric oxide"],["bp:name","monoxido de nitrogeno"],["bp:name","Nitrogen monoxide"],["bp:name","NO"],["bp:name","nitrosyl"],["bp:name","nitrogen monoxide"],["bp:name","Stickstoff(II)-oxid"],["bp:name","monoxyde d'azote"],["bp:name","(NO)(.)"],["bp:name","NO(.)"],["bp:name","[NO]"],["bp:name","nitrogen monooxide"],["bp:name","mononitrogen monoxide"],["bp:name","EDRF"],["bp:name","oxyde azotique"],["bp:name","CHEBI:16480"],["bp:name","endothelium-derived relaxing factor"],["bp:name","(.)NO"],["bp:name","oxyde nitrique"],["bp:molecularWeight","30.00614"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7689"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:26523"],["bp:comment","has_role CHEBI:35620"],["bp:comment","has_role CHEBI:48578"],["bp:comment","A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom."],["bp:comment","has_role CHEBI:62488"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d009569"],["bp:comment","is_a CHEBI:36871"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/3001380"],["bp:comment","has_role CHEBI:35523"],["bp:comment","has_role CHEBI:25512"],["bp:comment","is_a CHEBI:62764"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00533.eref"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB00435"],["bp:comment","is_a CHEBI:35196"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100128_nitric_oxide"],["bp:comment","has_role CHEBI:77746"],["bp:structure","has_role CHEBI:77746"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"]]}},{"data":{"id":"Protein_d25452f7e59b6b0725ad1eb090d30ccc","class":"macromolecule","label":"NR3C1","parent":"","clonemarker":false,"stateVariables":[{"id":"Protein_d25452f7e59b6b0725ad1eb090d30ccc.info.1","class":"state variable","state":{"variable":"","value":"Ina"}}],"unitsOfInformation":[],"bbox":{"x":685.2951,"y":839.1182,"w":48,"h":25},"metadata":[["bp:displayName","Glucocorticoid Receptor"],["bp:feature",[["bp:modificationType",[["bp:term","residue modification, inactive"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89470"]]],["bp:entityReference_http://identifiers.org/uniprot/P04150",[["bp:entityFeature",[["bp:modificationType",[["bp:term","N6-acetyllysine"],["bp:term","MOD_RES N6-acetyllysine"]]],["bp:comment","MOD_RES 492 492 N6-acetyllysine."],["bp:featureLocation",[["bp:sequencePosition","492"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",[["bp:term","Phosphoserine"],["bp:term","MOD_RES Phosphoserine"]]],["bp:comment","MOD_RES 134 134 Phosphoserine."],["bp:featureLocation",[["bp:sequencePosition","134"],["bp:positionStatus","EQUAL"]]]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:entityFeature",[["bp:modificationType",null],["bp:comment","MOD_RES 45 45 Phosphoserine."],["bp:featureLocation","MOD_RES 45 45 Phosphoserine."]]],["bp:standardName","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:xref","Glucocorticoid receptor"],["bp:organism","Glucocorticoid receptor"],["bp:displayName","GCR_HUMAN"],["bp:name","NR3C1"],["bp:name","Nuclear receptor subfamily 3 group C member 1"],["bp:name","GRL"],["bp:name","GR"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_protein_gene_2908"],["bp:comment","REPLACED http://www.gene-regulation.com/#proteinref_gene_2908"],["bp:comment","REPLACED http://identifiers.org/refseq/XP_005268477"],["bp:comment","REPLACED http://identifiers.org/uniprot/Q3MSN4"],["bp:comment","FUNCTION: Receptor for glucocorticoids (GC) (PubMed:27120390). Hasa dual mode of action: as a transcription factor that binds toglucocorticoid response elements (GRE), both for nuclear andmitochondrial DNA, and as a modulator of other transcriptionfactors. Affects inflammatory responses, cellular proliferationand differentiation in target tissues. Involved in chromatinremodeling (PubMed:9590696). Plays a role in rapid mRNAdegradation by binding to the 5' UTR of target mRNAs andinteracting with PNRC2 in a ligand-dependent manner which recruitsthe RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leadingto RNA decay (PubMed:25775514). Could act as a coactivator forSTAT5-dependent transcription upon growth hormone (GH) stimulationand could reveal an essential role of hepatic GR in the control ofbody growth (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:25775514, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:9590696}.FUNCTION: Isoform Alpha: Has transcriptional activation andrepression activity (PubMed:15866175, PubMed:19248771,PubMed:20484466, PubMed:23820903, PubMed:11435610,PubMed:15769988, PubMed:17635946, PubMed:19141540,PubMed:21664385). Mediates glucocorticoid-induced apoptosis(PubMed:23303127). Promotes accurate chromosome segregation duringmitosis (PubMed:25847991). May act as a tumor suppressor(PubMed:25847991). May play a negative role in adipogenesisthrough the regulation of lipolytic and antilipogenic geneexpression (By similarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:20484466, ECO:0000269|PubMed:21664385,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903,ECO:0000269|PubMed:25847991}.FUNCTION: Isoform Beta: Acts as a dominant negative inhibitor ofisoform Alpha (PubMed:7769088, PubMed:8621628, PubMed:20484466).Has intrinsic transcriptional activity independent of isoformAlpha when both isoforms are coexpressed (PubMed:19248771,PubMed:26711253). Loses this transcription modulator function onits own (PubMed:20484466). Has no hormone-binding activity(PubMed:8621628). May play a role in controlling glucosemetabolism by maintaining insulin sensitivity (By similarity).Reduces hepatic gluconeogenesis through down-regulation of PEPCKin an isoform Alpha-dependent manner (PubMed:26711253). Directlyregulates STAT1 expression in isoform Alpha-independent manner(PubMed:26711253). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:20484466,ECO:0000269|PubMed:26711253, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.FUNCTION: Isoform Alpha-2: Has lower transcriptional activationactivity than isoform Alpha. Exerts a dominant negative effect onisoform Alpha trans-repression mechanism (PubMed:20484466).FUNCTION: Isoform GR-P: Increases activity of isoform Alpha.{ECO:0000269|PubMed:11358809}.FUNCTION: Isoform Alpha-B: More effective than isoform Alpha intranscriptional activation, but not repression activity.{ECO:0000269|PubMed:11435610, ECO:0000269|PubMed:15866175}.FUNCTION: Isoform 10: Has transcriptional activation activity.{ECO:0000269|PubMed:20484466}.FUNCTION: Isoform Alpha-C1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-C3: Has highest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). Mediates glucocorticoid-inducedapoptosis (PubMed:23303127, PubMed:23820903).{ECO:0000269|PubMed:15866175, ECO:0000269|PubMed:23303127,ECO:0000269|PubMed:23820903}.FUNCTION: Isoform Alpha-D1: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D2: Has transcriptional activationactivity. {ECO:0000269|PubMed:15866175}.FUNCTION: Isoform Alpha-D3: Has lowest transcriptional activationactivity of all isoforms created by alternative initiation(PubMed:15866175, PubMed:23820903). Has transcriptional repressionactivity (PubMed:23303127). {ECO:0000269|PubMed:15866175,ECO:0000269|PubMed:23303127, ECO:0000269|PubMed:23820903}.SUBUNIT: Heteromultimeric cytoplasmic complex with HSP90AA1,HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID,STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Uponligand binding FKBP5 dissociates from the complex and FKBP4 takesits place, thereby linking the complex to dynein and mediatingtransport to the nucleus, where the complex dissociates (Bysimilarity). Directly interacts with UNC45A (PubMed:16478993).Binds to DNA as a homodimer, and as heterodimer with NR3C2 or theretinoid X receptor. Binds STAT5A and STAT5B homodimers andheterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2and TRIM28 (By similarity). Interacts with several coactivatorcomplexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L(Ada complex) and p160 coactivators such as NCOA2 and NCOA6(PubMed:10866662, PubMed:12151000, PubMed:12686538,PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibitstransactivation (PubMed:10477749). Interacts with HEXIM1, PELP1and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832).Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3,SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interactswith CLOCK, CRY1 and CRY2 in a ligand-dependent fashion(PubMed:19141540, PubMed:21980503, PubMed:22170608). Interactswith CIART (By similarity). Interacts with RWDD3 (By similarity).Interacts with UBE2I/UBC9 and this interaction is enhanced in thepresence of RWDD3 (By similarity). Interacts with GRIP1(PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (vianuclear receptor DNA-binding domain), represses transcriptionactivity of NR4A3 on the POMC promoter Nur response element(NurRE) (PubMed:15591535). Directly interacts with PNRC2 toattract and form a complex with UPF1 and DCP1A; the interactionleads to rapid mRNA degradation (PubMed:25775514). Interacts withGSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2(PubMed:27353360). {ECO:0000250|UniProtKB:P06536,ECO:0000250|UniProtKB:P06537, ECO:0000269|PubMed:10477749,ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:12151000,ECO:0000269|PubMed:12415108, ECO:0000269|PubMed:12686538,ECO:0000269|PubMed:15211577, ECO:0000269|PubMed:15591535,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:15941832,ECO:0000269|PubMed:16478993, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:19141540,ECO:0000269|PubMed:21730050, ECO:0000269|PubMed:21980503,ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:25775514,ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:9154805,ECO:0000269|PubMed:9590696}.SUBCELLULAR LOCATION: Isoform Alpha: Cytoplasm{ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:17635946,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}. Nucleus {ECO:0000269|PubMed:15769988,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:18838540,ECO:0000269|PubMed:27120390, ECO:0000269|PubMed:8621628}.Mitochondrion {ECO:0000269|PubMed:21664385}. Cytoplasm,cytoskeleton, spindle {ECO:0000269|PubMed:25847991}. Cytoplasm,cytoskeleton, microtubule organizing center, centrosome{ECO:0000269|PubMed:25847991}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:8621628}.SUBCELLULAR LOCATION: Isoform Beta: Nucleus{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253,ECO:0000269|PubMed:8621628}. Cytoplasm{ECO:0000269|PubMed:19248771, ECO:0000269|PubMed:26711253}.Note=Expressed predominantly in the nucleus with some expressionalso detected in the cytoplasm. {ECO:0000269|PubMed:19248771,ECO:0000269|PubMed:26711253}.SUBCELLULAR LOCATION: Isoform Alpha-B: Nucleus{ECO:0000269|PubMed:15866175}. Cytoplasm{ECO:0000269|PubMed:15866175}. Note=After ligand activation,translocates from the cytoplasm to the nucleus.{ECO:0000269|PubMed:15866175}.ALTERNATIVE PRODUCTS:Event=Alternative splicing, Alternative initiation; Named isoforms=16;Name=Alpha; Synonyms=Alpha-A, GR-alphaA;IsoId=P04150-1; Sequence=Displayed;Note=Predominant physiological form.{ECO:0000269|PubMed:15866175};Name=Beta; Synonyms=Beta-A;IsoId=P04150-2; Sequence=VSP_003703;Name=Alpha-2; Synonyms=Gamma;IsoId=P04150-3; Sequence=VSP_007363;Note=Due to a partial intron retention.;Name=Beta-2;IsoId=P04150-6; Sequence=VSP_007363, VSP_003703;Note=Due to a partial intron retention.;Name=GR-A alpha;IsoId=P04150-5; Sequence=VSP_013340;Note=Lacks exons 5, 6 and 7. Found in glucocorticoid-resistantmyeloma patients. {ECO:0000269|PubMed:8358712};Name=GR-A beta;IsoId=P04150-7; Sequence=VSP_013340, VSP_003703;Note=Lacks exons 5, 6 and 7. {ECO:0000269|PubMed:8358712};Name=GR-P;IsoId=P04150-4; Sequence=Not described;Note=Encoded by exons 2-7 plus several basepairs from thesubsequent intron region. Lacks the ligand binding domain.Accounts for up to 10-20% of mRNAs.{ECO:0000269|PubMed:8358712};Name=Alpha-B; Synonyms=GR-alphaB;IsoId=P04150-8; Sequence=VSP_018773;Note=Produced by alternative initiation at Met-27 of isoformAlpha. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378};Name=Beta-B;IsoId=P04150-9; Sequence=VSP_018773, VSP_003703;Note=Produced by alternative initiation at Met-27 of isoformBeta. Contains a N-acetylmethionine at position 1.{ECO:0000244|PubMed:22814378, ECO:0000269|PubMed:15866175};Name=10; Synonyms=hGRDelta313-338;IsoId=P04150-10; Sequence=VSP_043908;Name=Alpha-C1; Synonyms=GR-alphaC1;IsoId=P04150-11; Sequence=VSP_058317;Note=Produced by alternative initiation at Met-86 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C2; Synonyms=GR-alphaC2;IsoId=P04150-12; Sequence=VSP_058316;Note=Produced by alternative initiation at Met-90 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-C3; Synonyms=GR-alphaC3;IsoId=P04150-13; Sequence=VSP_058315;Note=Produced by alternative initiation at Met-98 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D1; Synonyms=GR-alphaD1;IsoId=P04150-14; Sequence=VSP_058314;Note=Produced by alternative initiation at Met-316 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D2; Synonyms=GR-alphaD2;IsoId=P04150-15; Sequence=VSP_058313;Note=Produced by alternative initiation at Met-331 of isoformAlpha. {ECO:0000269|PubMed:15866175};Name=Alpha-D3; Synonyms=GR-alphaD3;IsoId=P04150-16; Sequence=VSP_058312;Note=Produced by alternative initiation at Met-336 of isoformAlpha. {ECO:0000269|PubMed:15866175};TISSUE SPECIFICITY: Widely expressed including bone, stomach,lung, liver, colon, breast, ovary, pancreas and kidney(PubMed:25847991). In the heart, detected in left and right atria,left and right ventricles, aorta, apex, intraventricular septum,and atrioventricular node as well as whole adult and fetal heart(PubMed:10902803). Isoform Beta: Widely expressed including brain,bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat,skeletal muscle, heart, placenta and blood leukocytes(PubMed:7769088, PubMed:8621628). Isoform Alpha-2: Expressed atlow level. {ECO:0000269|PubMed:10902803,ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:7769088,ECO:0000269|PubMed:8621628}.INDUCTION: Isoform Alpha: Up-regulated by TNF (at protein level).Isoform Beta: Up-regulated by TNF and becomes the predominantisoform which may lead to glucocorticoid resistance (at proteinlevel). {ECO:0000269|PubMed:11381138}.DOMAIN: Composed of three domains: a modulating N-terminal domain,a DNA-binding domain and a C-terminal ligand-binding domain(PubMed:3841189). The ligand-binding domain is required forcorrect chromosome segregation during mitosis although ligandbinding is not required (PubMed:25847991).{ECO:0000269|PubMed:25847991, ECO:0000269|PubMed:3841189}.PTM: Acetylation by CLOCK reduces its binding to glucocorticoidresponse elements and its transcriptional activity.{ECO:0000269|PubMed:19141540, ECO:0000269|PubMed:21980503}.PTM: Increased proteasome-mediated degradation in response toglucocorticoids (PubMed:11555652). Isoform Alpha-B appears to bemore susceptible to proteolytic degradation than isoform Alpha(PubMed:11435610). {ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:11555652}.PTM: Phosphorylated in the absence of hormone; becomeshyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainlycytoplasmic, and the Ser-211-phosphorylated form is nuclear(PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211increases transcriptional activity (PubMed:12000743,PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404decreases signaling capacity (PubMed:12000743, PubMed:18483179,PubMed:18838540). Phosphorylation at Ser-404 may protect fromglucocorticoid-induced apoptosis (PubMed:18838540).Phosphorylation at Ser-203 and Ser-211 is not required inregulation of chromosome segregation (PubMed:25847991). May bedephosphorylated by PPP5C, attenuates NR3C1 action (Bysimilarity). {ECO:0000250|UniProtKB:P06537,ECO:0000269|PubMed:12000743, ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:18838540, ECO:0000269|PubMed:25847991}.PTM: Sumoylation at Lys-277 and Lys-293 negatively regulates itstranscriptional activity (PubMed:12144530). Sumoylation at Lys-703positively regulates its transcriptional activity in the presenceof RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 isdispensable whereas sumoylation at Lys-703 is critical for thestimulatory effect of RWDD3 on its transcriptional activity (Bysimilarity). Heat shock increases sumoylation in a RWDD3-dependentmanner (By similarity). {ECO:0000250|UniProtKB:P06536,ECO:0000269|PubMed:12144530}.PTM: Ubiquitinated; restricts glucocorticoid-mediatedtranscriptional signaling. {ECO:0000250|UniProtKB:P06537}.POLYMORPHISM: Carriers of the 22-Glu-Lys-23 allele are relativelymore resistant to the effects of GCs with respect to thesensitivity of the adrenal feedback mechanism than non-carriers,resulting in a better metabolic health profile. Carriers have abetter survival than non-carriers, as well as lower serum CRPlevels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as wellas greater muscle strength in males.DISEASE: Glucocorticoid resistance, generalized (GCCR)[MIM:615962]: An autosomal dominant disease characterized byincreased plasma cortisol concentration and high urinary freecortisol, resistance to adrenal suppression by dexamethasone, andthe absence of Cushing syndrome typical signs. Clinical featuresinclude hypoglycemia, hypertension, metabolic alkalosis, chronicfatigue and profound anxiety. {ECO:0000269|PubMed:11589680,ECO:0000269|PubMed:11701741, ECO:0000269|PubMed:12050230,ECO:0000269|PubMed:15769988, ECO:0000269|PubMed:1704018,ECO:0000269|PubMed:17635946, ECO:0000269|PubMed:20335448,ECO:0000269|PubMed:21362280, ECO:0000269|PubMed:23426617,ECO:0000269|PubMed:24483153, ECO:0000269|PubMed:26031419,ECO:0000269|PubMed:26541474, ECO:0000269|PubMed:27120390,ECO:0000269|PubMed:7683692}. Note=The disease is caused bymutations affecting the gene represented in this entry.MISCELLANEOUS: Isoform Beta: High constitutive expression byneutrophils may provide a mechanism by which these cells escapeglucocorticoid-induced cell death and up-regulation byproinflammatory cytokines such as IL8 further enhances theirsurvival in the presence of glucocorticoids during inflammation.{ECO:0000269|PubMed:11238589}.MISCELLANEOUS: Can up- or down-modulate aggregation and nuclearlocalization of expanded polyglutamine polypeptides derived fromAR and HD through specific regulation of gene expression.Aggregation and nuclear localization of expanded polyglutamineproteins are regulated cellular processes that can be modulated bythis receptor, a well-characterized transcriptional regulator.{ECO:0000269|PubMed:10639135}.SIMILARITY: Belongs to the nuclear hormone receptor family. NR3subfamily. {ECO:0000305}.WEB RESOURCE: Name=NIEHS-SNPs;URL=\"http://egp.gs.washington.edu/data/nr3c1/\";WEB RESOURCE: Name=Wikipedia; Note=Glucocorticoid receptor entry;URL=\"https://en.wikipedia.org/wiki/Glucocorticoid_receptor\"; COPYRIGHT: UniProt Consortium (www.uniprot.org). Distributed under the Creative Commons Attribution-NoDerivs License."],["bp:comment","REPLACED http://mirtarbase.mbc.nctu.edu.tw/#ref_2908"],["bp:comment","GCR_HUMAN Reviewed; 777 AA."],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-9"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-8"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-7"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-6"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-5"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-4"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-3"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-2"],["bp:comment","REPLACED http://identifiers.org/uniprot.isoform/P04150-1"],["bp:comment","REPLACED http://identifiers.org/refseq/NP_000167"],["bp:comment","REPLACED http://www.phosphosite.org/phosphosite.owl#po_1310"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_dip_DIP-576N_identity"],["bp:comment","REPLACED http://pathwaycommons.org/pc2/ProteinReference_rcsb_pdb_1NHZ_see-also"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89469"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89469"]]}},{"data":{"id":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","class":"process","label":"","parent":"","clonemarker":false,"stateVariables":[],"unitsOfInformation":[],"bbox":{"x":1078.4379,"y":1404.4822,"w":15,"h":15},"metadata":[["bp:participantStoichiometry",[["bp:physicalEntity",[["bp:displayName","NO"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16480",[["bp:standardName","oxidonitrogen(.)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25546"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62764"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25512"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:16480"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35620"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:48578"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:chemicalFormula","NO"],["bp:displayName","nitric oxide"],["bp:name","Stickstoffmonoxid"],["bp:name","oxido de nitrogeno(II)"],["bp:name","[N]=O"],["bp:name","oxoazanyl"],["bp:name","oxido nitrico"],["bp:name","Nitric oxide"],["bp:name","monoxido de nitrogeno"],["bp:name","Nitrogen monoxide"],["bp:name","NO"],["bp:name","nitrosyl"],["bp:name","nitrogen monoxide"],["bp:name","Stickstoff(II)-oxid"],["bp:name","monoxyde d'azote"],["bp:name","(NO)(.)"],["bp:name","NO(.)"],["bp:name","[NO]"],["bp:name","nitrogen monooxide"],["bp:name","mononitrogen monoxide"],["bp:name","EDRF"],["bp:name","oxyde azotique"],["bp:name","CHEBI:16480"],["bp:name","endothelium-derived relaxing factor"],["bp:name","(.)NO"],["bp:name","oxyde nitrique"],["bp:molecularWeight","30.00614"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7689"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:26523"],["bp:comment","has_role CHEBI:35620"],["bp:comment","has_role CHEBI:48578"],["bp:comment","A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom."],["bp:comment","has_role CHEBI:62488"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d009569"],["bp:comment","is_a CHEBI:36871"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/3001380"],["bp:comment","has_role CHEBI:35523"],["bp:comment","has_role CHEBI:25512"],["bp:comment","is_a CHEBI:62764"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00533.eref"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB00435"],["bp:comment","is_a CHEBI:35196"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100128_nitric_oxide"],["bp:comment","has_role CHEBI:77746"],["bp:structure","has_role CHEBI:77746"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89496"],["bp:stoichiometricCoefficient","1.0"]]],["bp:right",[["bp:physicalEntity",[["bp:displayName","NO"],["bp:entityReference_http://identifiers.org/chebi/CHEBI:16480",[["bp:standardName","oxidonitrogen(.)"],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25546"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:62764"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:25512"],["bp:db","chebi"]]],["bp:xref",[["bp:id","CHEBI:16480"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35620"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:48578"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:xref",[["bp:relationshipType",null],["bp:id","CHEBI:35523"],["bp:db","chebi"]]],["bp:chemicalFormula","NO"],["bp:displayName","nitric oxide"],["bp:name","Stickstoffmonoxid"],["bp:name","oxido de nitrogeno(II)"],["bp:name","[N]=O"],["bp:name","oxoazanyl"],["bp:name","oxido nitrico"],["bp:name","Nitric oxide"],["bp:name","monoxido de nitrogeno"],["bp:name","Nitrogen monoxide"],["bp:name","NO"],["bp:name","nitrosyl"],["bp:name","nitrogen monoxide"],["bp:name","Stickstoff(II)-oxid"],["bp:name","monoxyde d'azote"],["bp:name","(NO)(.)"],["bp:name","NO(.)"],["bp:name","[NO]"],["bp:name","nitrogen monooxide"],["bp:name","mononitrogen monoxide"],["bp:name","EDRF"],["bp:name","oxyde azotique"],["bp:name","CHEBI:16480"],["bp:name","endothelium-derived relaxing factor"],["bp:name","(.)NO"],["bp:name","oxyde nitrique"],["bp:molecularWeight","30.00614"],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7689"],["bp:comment","has_role CHEBI:76971"],["bp:comment","is_a CHEBI:26523"],["bp:comment","has_role CHEBI:35620"],["bp:comment","has_role CHEBI:48578"],["bp:comment","A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom."],["bp:comment","has_role CHEBI:62488"],["bp:comment","REPLACED http://www.ctdbase.org/#ref_chemical_mesh_d009569"],["bp:comment","is_a CHEBI:36871"],["bp:comment","REPLACED http://identifiers.org/pubchem.substance/3001380"],["bp:comment","has_role CHEBI:35523"],["bp:comment","has_role CHEBI:25512"],["bp:comment","is_a CHEBI:62764"],["bp:comment","REPLACED http://www.ra.cs.uni-tuebingen.de/software/KEGGtranslator/cpdC00533.eref"],["bp:comment","has_role CHEBI:75771"],["bp:comment","REPLACED http://www.drugbank.ca/#ref_DB00435"],["bp:comment","is_a CHEBI:35196"],["bp:comment","REPLACED http://www.inoh.org/biopax/IMR_0100128_nitric_oxide"],["bp:comment","has_role CHEBI:77746"],["bp:structure","has_role CHEBI:77746"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_7688"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89496"],["bp:stoichiometricCoefficient","1.0"]]],["bp:comment","REPLACED http://pid.nci.nih.gov/biopax#pid_89495"],["bp:dataSource","REPLACED http://pid.nci.nih.gov/biopax#pid_89495"]]}}],"edges":[{"data":{"id":"Protein_113b3c0be2b4ceabd30a4319c1400208--to--BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_113b3c0be2b4ceabd30a4319c1400208","target":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_113b3c0be2b4ceabd30a4319c1400208","portTarget":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_9b22836354cdf8aea3eff63fd02770a2--to--BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_9b22836354cdf8aea3eff63fd02770a2","target":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_9b22836354cdf8aea3eff63fd02770a2","portTarget":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-output--to--Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","class":"production","cardinality":0,"source":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","target":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","portTarget":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_9ad1fe91c68525293ccc9fa8cd5986e0--to--BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_9ad1fe91c68525293ccc9fa8cd5986e0","target":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_9ad1fe91c68525293ccc9fa8cd5986e0","portTarget":"InputPort_BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_bf52215c50aa3837652ce37f0f7a1963--to--BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_bf52215c50aa3837652ce37f0f7a1963","target":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_bf52215c50aa3837652ce37f0f7a1963","portTarget":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64--to--ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","target":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_5c5ea046aba3d8f59f4aa35ec1f57a64","portTarget":"InputPort_ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a3645b1d8f86749ea253214e3ae4efc3--to--ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_a3645b1d8f86749ea253214e3ae4efc3","target":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a3645b1d8f86749ea253214e3ae4efc3","portTarget":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8--to--ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_23ab286f772424a61df373a8ae77d4c8","target":"ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_23ab286f772424a61df373a8ae77d4c8","portTarget":"InputPort_ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT-output--to--Protein_1046951e1eaf0edd57f635b05d7518a9","class":"production","cardinality":0,"source":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","target":"Protein_1046951e1eaf0edd57f635b05d7518a9","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","portTarget":"Protein_1046951e1eaf0edd57f635b05d7518a9"}},{"data":{"id":"Protein_23ab286f772424a61df373a8ae77d4c8--to--ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_23ab286f772424a61df373a8ae77d4c8","target":"ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_23ab286f772424a61df373a8ae77d4c8","portTarget":"InputPort_ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT-output--to--Protein_113b3c0be2b4ceabd30a4319c1400208","class":"production","cardinality":0,"source":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","target":"Protein_113b3c0be2b4ceabd30a4319c1400208","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","portTarget":"Protein_113b3c0be2b4ceabd30a4319c1400208"}},{"data":{"id":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT-output--to--Complex_0cc29c9365910b581e2d7970e350a3f4","class":"production","cardinality":0,"source":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","target":"Complex_0cc29c9365910b581e2d7970e350a3f4","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","portTarget":"Complex_0cc29c9365910b581e2d7970e350a3f4"}},{"data":{"id":"Protein_d3215672be20c65a36ae88c23f249383--to--BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_d3215672be20c65a36ae88c23f249383","target":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_d3215672be20c65a36ae88c23f249383","portTarget":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac--to--BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","target":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","portTarget":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_0cc29c9365910b581e2d7970e350a3f4--to--BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_0cc29c9365910b581e2d7970e350a3f4","target":"BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_0cc29c9365910b581e2d7970e350a3f4","portTarget":"InputPort_BiochemicalReaction_3c88878d94ebbe3749039b0300a46fc6_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_a56ed666236bbdbf9bd991c41754204f--to--BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_a56ed666236bbdbf9bd991c41754204f","target":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a56ed666236bbdbf9bd991c41754204f","portTarget":"InputPort_BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2--to--BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","target":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_b54ed7eb0d63a83fb04431a4f179ecf2","portTarget":"InputPort_BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_8c42f97fd80a86c01161722db974a062--to--ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT-input","class":"consumption","cardinality":2,"source":"Protein_8c42f97fd80a86c01161722db974a062","target":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_8c42f97fd80a86c01161722db974a062","portTarget":"InputPort_ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT-output--to--Complex_0cc29c9365910b581e2d7970e350a3f4","class":"production","cardinality":0,"source":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","target":"Complex_0cc29c9365910b581e2d7970e350a3f4","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","portTarget":"Complex_0cc29c9365910b581e2d7970e350a3f4"}},{"data":{"id":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT-output--to--Protein_865edebf87abc1177735ccdb3359403a","class":"production","cardinality":0,"source":"BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","target":"Protein_865edebf87abc1177735ccdb3359403a","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_451e2cbee979e3c064fcb1b49cf912fa_LEFT_TO_RIGHT","portTarget":"Protein_865edebf87abc1177735ccdb3359403a"}},{"data":{"id":"Protein_e65f555bf88d9d6eeb4334997011203b--to--ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e65f555bf88d9d6eeb4334997011203b","target":"ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e65f555bf88d9d6eeb4334997011203b","portTarget":"InputPort_ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e65f555bf88d9d6eeb4334997011203b--to--BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e65f555bf88d9d6eeb4334997011203b","target":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e65f555bf88d9d6eeb4334997011203b","portTarget":"InputPort_BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_d99e6918542cbd099f5826a654d9b43b--to--ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_d99e6918542cbd099f5826a654d9b43b","target":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_d99e6918542cbd099f5826a654d9b43b","portTarget":"InputPort_ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT-output--to--SmallMolecule_e251e68f3321c5cb807aa97132bcfba7","class":"production","cardinality":0,"source":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","target":"SmallMolecule_e251e68f3321c5cb807aa97132bcfba7","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","portTarget":"SmallMolecule_e251e68f3321c5cb807aa97132bcfba7"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"InputPort_BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1--to--BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","target":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","portTarget":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_67c8de75d5dc723dda616b98126413cb--to--BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_67c8de75d5dc723dda616b98126413cb","target":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_67c8de75d5dc723dda616b98126413cb","portTarget":"InputPort_BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT-output--to--Protein_19dbfbf992345d3d84b48e37dfd392aa","class":"production","cardinality":0,"source":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","target":"Protein_19dbfbf992345d3d84b48e37dfd392aa","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","portTarget":"Protein_19dbfbf992345d3d84b48e37dfd392aa"}},{"data":{"id":"Complex_0cc29c9365910b581e2d7970e350a3f4--to--ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_0cc29c9365910b581e2d7970e350a3f4","target":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_0cc29c9365910b581e2d7970e350a3f4","portTarget":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT-output--to--Protein_e84bfd1cc1eaa853e592d66921c21aa6","class":"production","cardinality":0,"source":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","target":"Protein_e84bfd1cc1eaa853e592d66921c21aa6","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","portTarget":"Protein_e84bfd1cc1eaa853e592d66921c21aa6"}},{"data":{"id":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT-output--to--Protein_113b3c0be2b4ceabd30a4319c1400208","class":"production","cardinality":0,"source":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","target":"Protein_113b3c0be2b4ceabd30a4319c1400208","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","portTarget":"Protein_113b3c0be2b4ceabd30a4319c1400208"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT-output--to--Protein_eb6f6aef8a7a0f98e551795882bdc3d1","class":"production","cardinality":0,"source":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","target":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","portTarget":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1"}},{"data":{"id":"Protein_3de48755180a4a3529a499c370317030--to--BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_3de48755180a4a3529a499c370317030","target":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_3de48755180a4a3529a499c370317030","portTarget":"InputPort_BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-output--to--Complex_d99e6918542cbd099f5826a654d9b43b","class":"production","cardinality":0,"source":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","target":"Complex_d99e6918542cbd099f5826a654d9b43b","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","portTarget":"Complex_d99e6918542cbd099f5826a654d9b43b"}},{"data":{"id":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT-output--to--Protein_fa3f6f083ad30072e326e2b74e117221","class":"production","cardinality":0,"source":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","target":"Protein_fa3f6f083ad30072e326e2b74e117221","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","portTarget":"Protein_fa3f6f083ad30072e326e2b74e117221"}},{"data":{"id":"Protein_cbb94d6b16ea77d0d4e3333573c48654--to--BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_cbb94d6b16ea77d0d4e3333573c48654","target":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_cbb94d6b16ea77d0d4e3333573c48654","portTarget":"InputPort_BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2--to--BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","target":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","portTarget":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_0e1cdb16881e89a3a864b018959a0b1b--to--BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_0e1cdb16881e89a3a864b018959a0b1b","target":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_0e1cdb16881e89a3a864b018959a0b1b","portTarget":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1--to--BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","target":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_eb6f6aef8a7a0f98e551795882bdc3d1","portTarget":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT-output--to--Protein_d3215672be20c65a36ae88c23f249383","class":"production","cardinality":0,"source":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","target":"Protein_d3215672be20c65a36ae88c23f249383","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","portTarget":"Protein_d3215672be20c65a36ae88c23f249383"}},{"data":{"id":"ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT-output--to--Complex_0cc29c9365910b581e2d7970e350a3f4","class":"production","cardinality":0,"source":"ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT","target":"Complex_0cc29c9365910b581e2d7970e350a3f4","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT","portTarget":"Complex_0cc29c9365910b581e2d7970e350a3f4"}},{"data":{"id":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT-output--to--Protein_12ce91dd41f0737ffb0898c71af2f854","class":"production","cardinality":0,"source":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","target":"Protein_12ce91dd41f0737ffb0898c71af2f854","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","portTarget":"Protein_12ce91dd41f0737ffb0898c71af2f854"}},{"data":{"id":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT-output--to--Protein_ff50293a626a43a3575e3ef26dc20da3","class":"production","cardinality":0,"source":"ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","target":"Protein_ff50293a626a43a3575e3ef26dc20da3","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_0b6688775fdee68f93f2d7cb105d5e6e_LEFT_TO_RIGHT","portTarget":"Protein_ff50293a626a43a3575e3ef26dc20da3"}},{"data":{"id":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT-output--to--Protein_80b38565780a9a6cbd4b39d8b614b11e","class":"production","cardinality":0,"source":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","target":"Protein_80b38565780a9a6cbd4b39d8b614b11e","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","portTarget":"Protein_80b38565780a9a6cbd4b39d8b614b11e"}},{"data":{"id":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT-output--to--Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","class":"production","cardinality":0,"source":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","target":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","portTarget":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac"}},{"data":{"id":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT-output--to--Protein_8c314e71e98ca454f68a0ba5c351e6ff","class":"production","cardinality":0,"source":"BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","target":"Protein_8c314e71e98ca454f68a0ba5c351e6ff","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_867ce4e3e26b1ebc79fb81f7dfe941be_LEFT_TO_RIGHT","portTarget":"Protein_8c314e71e98ca454f68a0ba5c351e6ff"}},{"data":{"id":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7--to--BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7","target":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7","portTarget":"BiochemicalReaction_c077b4641916cac60f26e9418e4903d4_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_0e0ebbab4043a0bc0a123f449a5f7c29--to--ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_0e0ebbab4043a0bc0a123f449a5f7c29","target":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_0e0ebbab4043a0bc0a123f449a5f7c29","portTarget":"InputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_10658ad17aa0266d361c96bf2a9c7d68--to--BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_10658ad17aa0266d361c96bf2a9c7d68","target":"BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_10658ad17aa0266d361c96bf2a9c7d68","portTarget":"InputPort_BiochemicalReaction_bd5980024bd3da35241c5b5853c86f81_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7--to--BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7","target":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_a26f9391e06843a776c46ce4ebb390b7","portTarget":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT-output--to--Protein_ae18bb0c7fb20e92441b843d6a51f500","class":"production","cardinality":0,"source":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","target":"Protein_ae18bb0c7fb20e92441b843d6a51f500","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","portTarget":"Protein_ae18bb0c7fb20e92441b843d6a51f500"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-output--to--Complex_0cc29c9365910b581e2d7970e350a3f4","class":"production","cardinality":0,"source":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","target":"Complex_0cc29c9365910b581e2d7970e350a3f4","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","portTarget":"Complex_0cc29c9365910b581e2d7970e350a3f4"}},{"data":{"id":"Complex_0cc29c9365910b581e2d7970e350a3f4--to--ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_0cc29c9365910b581e2d7970e350a3f4","target":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_0cc29c9365910b581e2d7970e350a3f4","portTarget":"InputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2--to--BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","target":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","portTarget":"BiochemicalReaction_0baf56f9fd813157f60b9face7329339_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e2861ae7a61f3469a6509614275092e7--to--BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e2861ae7a61f3469a6509614275092e7","target":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e2861ae7a61f3469a6509614275092e7","portTarget":"InputPort_BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2--to--BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","class":"inhibition","cardinality":0,"source":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","target":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_dd8177568a93f2348dfa1e4ef6f664c2","portTarget":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_84cb6c5d91a711aa1319723c8904c751--to--ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_84cb6c5d91a711aa1319723c8904c751","target":"ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_84cb6c5d91a711aa1319723c8904c751","portTarget":"InputPort_ComplexAssembly_00490b60a4eb6c6753e2266ca09f936b_LEFT_TO_RIGHT"}},{"data":{"id":"ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT-output--to--Complex_d9db3aaef19689040cd2291a442db6a4","class":"production","cardinality":0,"source":"ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT","target":"Complex_d9db3aaef19689040cd2291a442db6a4","bendPointPositions":[],"portSource":"OutputPort_ComplexAssembly_2dd541bfd1a8bf01ee7311bc7a14daf4_LEFT_TO_RIGHT","portTarget":"Complex_d9db3aaef19689040cd2291a442db6a4"}},{"data":{"id":"Protein_f1a4eab3c776c0a7d0ff066569d2dbca--to--BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f1a4eab3c776c0a7d0ff066569d2dbca","target":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f1a4eab3c776c0a7d0ff066569d2dbca","portTarget":"InputPort_BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e47df6e9143abd56f0359798973ea35e--to--BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e47df6e9143abd56f0359798973ea35e","target":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e47df6e9143abd56f0359798973ea35e","portTarget":"InputPort_BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_8adbefbdca410e46634689879c5aaddb_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_611f13ead06fd476d39022ff0937dff1--to--BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_611f13ead06fd476d39022ff0937dff1","target":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_611f13ead06fd476d39022ff0937dff1","portTarget":"InputPort_BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT-output--to--SmallMolecule_ee06536974bc5ab74caf99fbfc82981b","class":"production","cardinality":0,"source":"BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","target":"SmallMolecule_ee06536974bc5ab74caf99fbfc82981b","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_a4a5f7bf4b6ea4b0e22fb478bec554e3_LEFT_TO_RIGHT","portTarget":"SmallMolecule_ee06536974bc5ab74caf99fbfc82981b"}},{"data":{"id":"Protein_ef80db43845677b1e05acc7880705290--to--ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_ef80db43845677b1e05acc7880705290","target":"ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ef80db43845677b1e05acc7880705290","portTarget":"InputPort_ComplexAssembly_864f36bab575d70fd72134d82e744c0f_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT-output--to--Protein_84cb6c5d91a711aa1319723c8904c751","class":"production","cardinality":0,"source":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","target":"Protein_84cb6c5d91a711aa1319723c8904c751","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","portTarget":"Protein_84cb6c5d91a711aa1319723c8904c751"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_f38b90b2aa4ee2682f8e635c4e6c71e7_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_f770be719c3769a43a5ae41343066e13--to--BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_f770be719c3769a43a5ae41343066e13","target":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_f770be719c3769a43a5ae41343066e13","portTarget":"InputPort_BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_4b54a396195a7afb2d66e2623aef4725--to--BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_4b54a396195a7afb2d66e2623aef4725","target":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_4b54a396195a7afb2d66e2623aef4725","portTarget":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT"}},{"data":{"id":"Complex_d9db3aaef19689040cd2291a442db6a4--to--ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Complex_d9db3aaef19689040cd2291a442db6a4","target":"ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_d9db3aaef19689040cd2291a442db6a4","portTarget":"InputPort_ComplexAssembly_8761ac5a17357073ec3e05289e9d4fcf_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT-output--to--Protein_1480a71b5fcb5ed92442219cdf2c803d","class":"production","cardinality":0,"source":"BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","target":"Protein_1480a71b5fcb5ed92442219cdf2c803d","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_6238be776e6554403b6dbabf98dee165_LEFT_TO_RIGHT","portTarget":"Protein_1480a71b5fcb5ed92442219cdf2c803d"}},{"data":{"id":"Protein_a3645b1d8f86749ea253214e3ae4efc3--to--BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_a3645b1d8f86749ea253214e3ae4efc3","target":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_a3645b1d8f86749ea253214e3ae4efc3","portTarget":"BiochemicalReaction_cc97853e2dc26df74b669c8cb24e0905_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_e137e9a54322e34881c467efeb070fa6--to--BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_e137e9a54322e34881c467efeb070fa6","target":"BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_e137e9a54322e34881c467efeb070fa6","portTarget":"InputPort_BiochemicalReaction_f44f491bb0439a50d37ffaeab702ec85_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT-output--to--Protein_3dae87e8b2d131ac77af80ab21758406","class":"production","cardinality":0,"source":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","target":"Protein_3dae87e8b2d131ac77af80ab21758406","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","portTarget":"Protein_3dae87e8b2d131ac77af80ab21758406"}},{"data":{"id":"Protein_7b5bedaf1d5cfe7f0ada582e5773c6b1--to--BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"Protein_7b5bedaf1d5cfe7f0ada582e5773c6b1","target":"BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_7b5bedaf1d5cfe7f0ada582e5773c6b1","portTarget":"InputPort_BiochemicalReaction_99df83e902f8a6e2fa69b06866d64a72_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT-output--to--Protein_0d32fa56842fc6735647a989fc43bd18","class":"production","cardinality":0,"source":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","target":"Protein_0d32fa56842fc6735647a989fc43bd18","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","portTarget":"Protein_0d32fa56842fc6735647a989fc43bd18"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_5c736702ad08f7f0c99371d1f859c8ca_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT-output--to--Protein_df684cdcf919e347d3ad85620a83c969","class":"production","cardinality":0,"source":"BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","target":"Protein_df684cdcf919e347d3ad85620a83c969","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_b3887017432ad0566205e5b60a22d510_LEFT_TO_RIGHT","portTarget":"Protein_df684cdcf919e347d3ad85620a83c969"}},{"data":{"id":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT-output--to--Protein_2cd29b54b96adac86239030097504aab","class":"production","cardinality":0,"source":"BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","target":"Protein_2cd29b54b96adac86239030097504aab","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_2116d248caa737385e94ac25e7b27226_LEFT_TO_RIGHT","portTarget":"Protein_2cd29b54b96adac86239030097504aab"}},{"data":{"id":"Protein_ff50293a626a43a3575e3ef26dc20da3--to--BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_ff50293a626a43a3575e3ef26dc20da3","target":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_ff50293a626a43a3575e3ef26dc20da3","portTarget":"BiochemicalReaction_cfdcdb539b3a41df2e9c3035b522df77_LEFT_TO_RIGHT"}},{"data":{"id":"SmallMolecule_bccee74407d2f7a76e0e86b318622e2b_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT--to--BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT-input","class":"consumption","cardinality":0,"source":"SmallMolecule_bccee74407d2f7a76e0e86b318622e2b_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","target":"BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"SmallMolecule_bccee74407d2f7a76e0e86b318622e2b_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT","portTarget":"InputPort_BiochemicalReaction_7ffdee6cb430f3c6548cd91812341afa_LEFT_TO_RIGHT"}},{"data":{"id":"Protein_80b38565780a9a6cbd4b39d8b614b11e--to--ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Protein_80b38565780a9a6cbd4b39d8b614b11e","target":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Protein_80b38565780a9a6cbd4b39d8b614b11e","portTarget":"ComplexAssembly_0ec8d14f4fdaf04a9648a2c77e0df001_LEFT_TO_RIGHT"}},{"data":{"id":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT-output--to--Protein_d25452f7e59b6b0725ad1eb090d30ccc","class":"production","cardinality":0,"source":"BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","target":"Protein_d25452f7e59b6b0725ad1eb090d30ccc","bendPointPositions":[],"portSource":"OutputPort_BiochemicalReaction_6427d2f4c9476f3ff03808470958a175_LEFT_TO_RIGHT","portTarget":"Protein_d25452f7e59b6b0725ad1eb090d30ccc"}},{"data":{"id":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac--to--BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","class":"catalysis","cardinality":0,"source":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","target":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT","bendPointPositions":[],"portSource":"Complex_b1ae6006620d93cbf0ccb97c7be5f9ac","portTarget":"BiochemicalReaction_1acc1c7fbfd3f910f5f0fa9a926d4207_LEFT_TO_RIGHT"}}],"pathwayMetadata":{"comments":["REPLACED http://pid.nci.nih.gov/biopax#pid_89416"],"dataSource":["pid"],"title":["Cellular roles of Anthrax toxin"]}}